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Summary 
Obesity has become a global health concern not only in the general population but also 
among liver transplant (Tx) recipients. For more than 2 decades, rates of obesity in 
liver Tx candidates have been rising;1 and post-Tx weight gain is contributing to a rising 
prevalence of post-Tx obesity in this group compared to pre-Tx measurements.2-4 
While obesity predicts morbidity and mortality in the general population,5-8 this 
relationship has not been reported consistently in liver Tx recipients. Regarding the 
impact of pre- and post-Tx obesity on metabolic or cardiovascular comorbidities, cur-
rent evidence is mixed.9-11 However, the few studies examining post-Tx weight gain 
found that it increased the burden of disease and predicted both nonalcoholic fatty liver 
disease12,13 and metabolic syndrome.12,14 
Metabolic syndrome occurs in 44% to 58% of liver Tx recipients,12 contributing 
to an increased risk of cardiovascular disease and mortality.12 Indeed, cardiovascular 
events (CVEs) are a leading cause of mortality after liver Tx.15-18 And while first-year 
post-Tx patient and graft survival rates have been increasing steadily for decades, 
long-term outcomes have not echoed these improvements.19 This progress gap is at-
tributed partly to the post-Tx development of comorbidities such as hypertension, dia-
betes, and dyslipidemia–due largely to the side effects of long-term immunosuppres-
sive medication intake accompanied by lifestyle factors (e.g., physical inactivity, un-
healthy eating).12,14,20-22 
To reduce post-Tx morbidity risks, the Tx community has called for action to 
tackle weight gain and obesity via lifestyle interventions.22-25 Expressed as a deceptive-
ly simple equation, weight gain most commonly results from an energy imbalance 
whereby energy intake surpasses energy expenditure.26 Although a web of intercon-
nected variables are involved, behavioral factors related to energy balance, such as 
physical activity and diet, are among the most influential and can be targeted via inter-
ventions. Intervention research on this topic is rare regarding the liver Tx population. 
To date, only one study has tested an intervention using individual counseling on exer-
cise and diet after liver Tx;27 however, its authors did not examine the intervention’s 
impact in relation to weight gain prevention. 
The systematic development of a behavioral weight management intervention is 
no easy task: such interventions are typically complex, and should be informed by a 
theoretical model.28,29 However, the crucial first step in developing any behavioral inter-
vention is to build a sound understanding and definition of the problem in behavioral 
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terms. Also, in the context of weight gain after liver Tx, two clinical questions remain 
unanswered: “How important is the prevention of weight gain after Tx?” and “Which 
factors are related to weight gain and obesity after Tx?” 
The overall aim of this dissertation was to generate evidence to answer these 
questions and facilitate the development of a behavioral intervention focusing on phys-
ical activity and diet to support effective post-Tx weight management. To achieve this 
aim, this dissertation was designed as a multiphase mixed method research project 
including three data analyses of the prospective nationwide Swiss Transplant Cohort 
Study (STCS), and one systematic review with meta-analysis. The results (summarized 
below) promise to facilitate evidence-based decision-making towards the development 
of a behavioral intervention to prevent post-Tx weight gain. 
Body weight parameters vary considerably among solid organ Tx populations 
and geographical regions. However, a rigorous comparison of these parameters’ evolu-
tion between organ groups and throughout the course of Tx is limited due to methodo-
logical and terminological differences between the relevant studies (e.g., single center 
versus database studies, different timeframes for follow up measures, diverse opera-
tional definitions). Therefore, to compare all solid organ Tx populations concurrently, 
we conducted a descriptive longitudinal study (Chapter 3) using data from the STCS, a 
prospective nationwide cohort study. The STCS’s long-term prospective design al-
lowed comparison of weight change patterns among organ groups and among patients 
in different body mass index (BMI) categories to assess weight parameters in relation 
to settings and patient groups. Changes in weight and BMI category were compared to 
the reference values at 6 months post-Tx. 
We included 1359 adult kidney (58.3%), liver (21.7%), lung (11.6%), and heart 
(8.4%) recipients. Compared to data on international Tx groups, the majority of our 
Swiss Tx recipients had lower post-Tx weight gain. However, their cumulative inci-
dence of obesity at 3 years after kidney, liver, lung, and heart Tx was 18.1%, 38.1%, 
15.3%, and 13.3%, respectively. At 3 years post-Tx, in relation to their BMI categories 
at 6 months, normal weight and obese liver Tx patients, followed by underweight kid-
ney, lung and heart Tx patients, showed the greatest weight gains. Compared to all 
other organ groups, liver Tx recipients showed both the greatest weight gain (mean 4.8 
± 10.4 kg), with 57.4% gaining >5% of their body weight, and the highest incidence of 
obesity (38.1%). Although weight gain patterns varied both within and across organ Tx 
groups, long-term monitoring of weight is indicated in all solid organ Tx populations to 
prevent weight gain leading to obesity. 
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Weight gain and obesity are the result of complex interactions between genetic, 
sociodemographic, behavioral, biomedical, psychological, and environmental factors. 
Therefore, a clear knowledge of factors influencing weight gain and other body weight 
parameters in Tx is important in view of tailoring interventions to avoid or modify these 
factors. As weight gain in this group has never been the subject of a systematic review, 
though, evidence on risk factors in the liver Tx population remains non-explicit. In our 
systematic review (Chapter 4), then, we summarized the available evidence in view of 
factors associated with post-liver Tx BMI, obesity, and weight gain. Meta-analysis 
techniques were applied to relationships investigated at least 5 times. Of the 16495 
articles retrieved, 43 assessed risk factors for body weight parameters. These identi-
fied a total of 82 separate factors, most of which either biomedical (e.g., etiology of liver 
disease, metabolic comorbidities before liver Tx) or sociodemographic (e.g., age, gen-
der, pre- and post-Tx education). 
In view of energy balance-related behaviors, not one of the 43 retrieved studies 
examined eating behavior; but 4 examined physical activity in relation to BMI or obesity 
after liver Tx. Overall, extensive variation in risk factor definitions limited the combina-
tion of factors to groups of at least 5 studies. The final meta-analyses focused on two 
risk factors–tacrolimus and cyclosporine–in 6 studies (median sample size: n = 171 
(range: 63–455); 3 from Europe, 3 from the United States; publication era: 1997 – 
2015). Post-Tx obesity was neither significantly associated with tacrolimus (odds ratio 
(OR), 0.75; 95% confidence interval (CI), 0.47-1.21; p = 0.24) nor cyclosporine (OR, 
1.40; 95% CI, 0.89-2.18; p = 0.14). Evidence on factors related to post-liver Tx body 
weight parameters is still limited and warrants further investigation. It is recommended 
that future research be guided by theoretical frameworks to facilitate a systematic ex-
amination of interrelationships among selected factors. 
Genetic factors also interact with clinical and psychosocial variables. To exam-
ine associations between weighted genetic risk scores and BMI up to 1 year after Tx 
(Chapter 5), we studied 2 patient samples. Sample A (n = 995) consisted of kidney, 
liver, heart, lung and multi-organ Tx patients from the STCS; sample B (n = 156) in-
cluded only kidney, liver and lung Tx patients enrolled between 2003 and 2005 from 
the Tx center of the University Hospital of Lausanne. Calculation of genetic risk scores 
used data on Tx candidate genes and single nucleotide polymorphisms (SNPs) asso-
ciated with BMI in genome-wide association studies. Classified by the number of BMI 
risk alleles identified (range: 0 – 2), the genotypes were coded as 0, 1 or 2. Based on 
the assumption that each SNP effects BMI separately, SNPs were then weighted by 
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allele effect (β-coefficient), leading to the calculation of the final weighted genetic risk 
score. 
The weighted genetic risk scores were associated with BMI increase for each 
additional risk allele in both samples (p-values < 0.008). Additionally, compared to the 
models incorporating no genetic factors, those using genetic risk scores better predict-
ed weight gain at 1 year post-Tx. This result highlights the complexity of weight gain 
and the importance of incorporating a range of factors that influence post-Tx weight 
gain. Further research will be necessary to examine the genetic risk score and post-Tx 
body weight parameters in relation to patient outcomes. 
In addition to studying weight gain per se, we examined the impact of new-onset 
obesity on cardiovascular events (CVEs) and patient survival to identify related post-
liver Tx sociodemographic, behavioral, biomedical, psychological and genetic risk fac-
tors (Chapter 6). Based on STCS data on 253 liver Tx patients, the cumulative inci-
dence of new-onset obesity was 21.3%, while that of CVE was 28.1%. Independent of 
the CVE status at liver Tx, risk factors for post-Tx CVEs were new-onset obesity (Haz-
ard Ratio (HR) 2.95; 95% CI, 1.47-5.95; p = 0.002) and higher age at liver Tx (HR, 
1.05; 95% CI, 1.02-1.08; p < 0.001). In patients without pre-Tx CVEs (n = 214), risk 
factors for post-Tx CVEs also included new-onset obesity (HR, 2.59; 95% CI, 1.21-
5.53; p = 0.014) and higher age (HR, 1.04; 95% CI, 1.02-1.07; p = 0.001). However, 
survival itself was not associated with new-onset obesity (HR, 0.84; 95% CI, 0.34-2.04; 
p = 0.696). Independent predictors of new-onset obesity were male gender (HR, 0.39; 
95% CI, 0.16-0.93; p = 0.034) and alcoholic liver disease (HR, 3.37; 95% CI, 1.17-9.71; 
p = 0.025). The genetic risk score was available in a subsample of 114 patients. In this 
analysis, male gender (HR, 0.26; 95% CI, 0.076-0.889; p = 0.032) and the genetic risk 
score (HR, 21.83; 95% CI, 1.50-317.64; p = 0.024) predicted new-onset obesity. Given 
the link between new-onset obesity and CVEs, the prevention of new-onset obesity by 
effective early weight management programs could probably lead to improved post-Tx 
cardiovascular outcomes. 
In conjunction with the existing evidence, the findings of this dissertation con-
tributed to the development of a behavioral weight management intervention. The 
COM-B model and the behavior change wheel served as theoretical guidance.28,29 
While COM-B is an explanatory model, characterizing the sources of behavior (i.e., 
capability, opportunity, and motivation), the behavior change wheel informed the inter-
vention’s systematic development and evaluation. Beginning with a theoretical intro-
duction, Chapter 7 follows the three stages of the behavior change wheel, leading to 
the suggestion of the BALANCE intervention in the liver Tx population. 
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In conclusion, this dissertation contributed to the evidence base regarding 
weight gain and obesity after solid organ Tx. For the first time, we simultaneously com-
pared the evolution of body weight parameters up to 3 years after kidney, liver, heart 
and lung Tx to identify patterns of interest among these four populations. By studying 
the impact of new-onset obesity on cardiovascular morbidity and patient survival after 
liver Tx, we increased the limited evidence on the impact of post-Tx body weight pa-
rameters on patient health outcomes. In 3 studies, all guided by our theoretical frame-
work, we systematically examined biomedical, behavioral, sociodemographic, psycho-
logical and genetic risk factors leading to weight gain, obesity and new onset obesity 
after Tx, thereby highlighting the cross-category interplay of factors. These studies’ 
findings highlighted various implications for future research and clinical practice. Based 
on these findings, we recommend organizing post-Tx follow-up care based on a chron-
ic care model, supported by eHealth technology. Such a care model has the potential 
not only to support effective weight management, but also to improve long-term patient 
outcomes. 
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1.1 Obesity – a global epidemic 
The term globesity expresses the magnitude of obesity, which has become a global 
public health issue in recent decades.1,2 Based on age-standardized estimates for na-
tional and global obesity rates, between 1980 and 2013, Ng et al. reported that the 
number of overweight and obese adults (³20 years) increased from 857 million to 2.1 
billion over that 33-year period.3 
The geographic differences are particularly noteworthy. In 2013, about one-third 
of the population of the United States (US) (female: 33.9%; male: 31.6%) were obese, 
with a slightly higher prevalence among women. In Central, Western and Eastern Eu-
rope, obesity was also more prevalent in women (20.7% - 21%) compared to men 
(14.8% - 20.5%), while in Switzerland the estimates for women and men were 17% and 
18.4%, respectively. A 2017 report from the Organization for Economic Co-operation 
and Development (OECD) projected an increasing prevalence of obesity until at least 
2030.1 While obesity rates in Switzerland are low by global standards, they are ex-
pected to increase faster than other countries. 
As a simple and easily comparable classification of body weight, the World 
Health Organization (WHO) proposed the body mass index (BMI). This is calculated by 
dividing a person's weight in kilograms by the square of their height in meters, i.e., 
kg/m2. The WHO’s BMI categories are: underweight (<18.5 kg/m2), normal weight (18.5 
– 24.9 kg/m2), overweight (25 – 29.9 kg/m2), and obese (≥30 kg/m2). Obesity can be 
further differentiated into class I (30 – 34.9 kg/m2), class II (34.9 – 39.9 kg/m2), and 
class (III ≥40 kg/m2).4 As BMI is easy to determine, it is the most commonly used clas-
sification system for body weight not only in clinical practice but also in research. 
Accounting for age, sex and race-ethnicity, the BMI corresponds well to the per-
centage of body fat;5 however, certain shortcomings limit its use in severely ill people. 
E.g., its poor differentiation between fat and lean body mass hinders identification of 
ascites or edema.6 Therefore, BMI is recommended not as a diagnostic measure but 
for screening alongside complementary measures,7 e.g., bioelectrical impedance, to 
distinguish between total body water, fat-free body mass, body weight and body fat. 
Additionally, waist circumference and skin-fold thicknesses are easy assessable, while 
dual X-ray absorptiometry, magnetic resonance imaging, and computed tomography 
are among the more sophisticated (and expensive) techniques.8 Although a variety of 
measures are in use, practical and budgetary considerations make BMI the most popu-
lar for studies. 
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1.2 Obesity and weight gain in the course of transplantation 
The rising prevalence of obesity in the general population is mirrored in all solid organ 
transplant (Tx) populations. From 1990 to 2003, the proportion of obese (BMI >30 
kg/m2) candidates on the US liver Tx waiting list increased from 15% to 25% (National 
Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation data-
base);9 and a 2015 report identified 35.8% of candidates in the database of the Organ 
Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 
as obese at Tx.10 The same development has been reported separately in US kidney,11 
heart,12 and lung13 transplant patients. 
After Tx, weight gain is common, resulting in a higher prevalence of post-Tx 
obesity. In liver Tx, for example, excessive weight gain in the first year post-Tx (mean 
weight gain: 5 – 9 kg) leads to double the prevalence of pre-Tx obesity.14-16 Beyond 1 
year, body weight tends to increase less steadily; however, it has been reported that at 
2 and 3 years after liver Tx, 21.6% and 31%, respectively, of initially non-obese recipi-
ents became obese.15,16 Independent of BMI category at Tx, weight gain occurs in all 
patients after Tx. Still, it appears that those who were overweight or obese before Tx 
tend to gain more weight compared than those who were initially under- or normal 
weight.14 
Weight parameters vary considerably among geographic regions and organ 
groups. For example, at 1 year post-Tx, while kidney Tx recipients in France had a 
mean weight gain of 2.7 kg,17 their US counterparts had gained 10.3 kg18. Weight gain 
variations in the first year post-Tx have also been shown across organ groups in the 
US, e.g., 1.1 kg in heart19 versus 9.2 kg in liver recipients.20 The same differences ap-
ply to the prevalence of obesity. For example, in the US, approximately 30% of kidney21 
and liver22 Tx patients were obese at Tx, compared to, respectively, 22.7% and 15.2% 
of heart23 and lung recipients.24 
Comparison of body weight parameter evolution between organ groups is ham-
pered by variations among studies in view of design (e.g., single center versus data-
base related studies), sampling methods, operational definitions and measurement 
methods. 
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Chapter 3 describes and compares the evolution of weight parameters within and 
among adult kidney, liver, lung, and heart Tx recipients up to 3 years post-Tx. The 
analysis used data from the nationwide, open, and prospective Swiss Transplant 
Cohort Study (STCS). The standardized methodology of the STCS data collection 
allowed a substantiated comparison of all organ groups. 
1.3 Morbidity and mortality associated with weight gain and obesity 
The widely accepted health risks of weight gain and obesity relate to their association 
with comorbidities including cancer, musculoskeletal disorders, cardiovascular dysfunc-
tion and metabolic diseases.2,25-27 Figure 1 depicts obesity’s most important relation-
ships with medical complications. Further, Flegal et al.’s 2013 meta-analysis found a 
significant association between obesity (BMI ³30 kg/m2) and increased all-cause mor-
tality in the general adult population.28 However, when that study’s BMI categories were 
examined separately, only values ³35 kg/m2 remained associated with higher mortality; 
and BMIs of 25 – 29.9 kg/m2 were actually associated with significantly lower all-cause 
mortality than normal ones. 
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Figure 1. Obesity and its association with medical complications.  
Source: http://www.glsurgical.com.sg/weight-loss-procedure/why-weight-loss-
procedure/ 
Metabolic and cardiovascular diseases after liver transplantation 
Metabolic diseases such as hypertension, diabetes mellitus and dyslipidemia common-
ly occur after liver Tx.29,30 One of the most common post-Tx complications–affecting 
44% to 58% of liver Tx recipients29–is metabolic syndrome, i.e., the occurrence of ≥3 of 
the following symptoms: impaired glucose tolerance, hypertriglyceridemia, high blood 
pressure, low high density lipoprotein levels, or abdominal obesity.31-33 Still, although 
obesity is used as a diagnostic component of metabolic syndrome,34 the impacts of 
body weight parameters on its development are mixed. While pre- and post-Tx obesity 
rates were both significant in univariate analysis;35 multivariate analyses indicated that 
pre-Tx BMI35,36 and post-Tx weight gain29,30 were both independent predictors of meta-
bolic syndrome. Other factors consistently related to post-Tx metabolic syndrome are 
immunosuppressive drugs (which are required lifelong to prevent graft rejection epi-
sodes),37-39 lifestyle factors (e.g., physical inactivity, unhealthy dietary habits, and a 
history of smoking) and various non-modifiable factors including higher age, gene pol-
ymorphisms or end-stage organ disease.29,30 
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The clinical impact of metabolic syndrome is substantial: it contributes to overall and 
cardiovascular mortality after liver Tx, and to an increased risk of cardiovascular dis-
ease.29,39,40 Among liver graft recipients, cardiovascular events (CVEs) such as myo-
cardial infarction, cerebrovascular accidents, cardiac arrests, atrial fibrillation, pulmo-
nary embolism, heart failure, and/or stroke have been reported as leading causes of 
mortality.41-44 A recent systematic review of 29 studies summarized the incidence rates 
of CVEs in relation to time after liver Tx.45 In the first 6 months post-Tx, the average 
incidence was 22% (range: 1.1% – 50%); after 6 months, that figure fell to 11.8% 
(range 0 to 31.4%). The wide range of incidence rates reflected variations in outcome 
definitions applied in the individual studies. Although obesity is a well-described risk 
factor for cardiovascular disease in the general population,46 this relationship has not 
yet been verified in liver Tx, as only one study identified obesity at Tx as a predictor for 
CVE.47 In fact, few studies have corroborated this or various other apparent relation-
ships, i.e., in most studies, multivariate analyses have indicated no associations be-
tween CVE and obesity at Tx, BMI before or after Tx,45or post-Tx weight gain.48 
One possible explanation for this lack of corroboration is that researchers focus 
predominantly on pre-Tx body weight parameters, but may not adjust for fluid-altering 
conditions. For example, given that ascites and edema are common in patients with 
end-stage liver disease, unless measurements are corrected for abnormal fluid levels, 
pre-Tx body weight parameters as outcome-predictive factors are limited.40 Therefore, 
it may be more appropriate to measure CVE in relation not to BMI at Tx but to accu-
rately measured obesity or new-onset obesity after Tx. To date, no such relationship 
has been examined. 
Nonalcoholic fatty liver disease before and after liver transplantation 
Raising additional concerns, obesity also contributes to another epidemic: nonalcoholic 
fatty liver disease (NAFLD), i.e., macrovesicular hepatic steatosis with >5% fat in the 
liver in the absence of significant alcohol intake (20 g/day in men, 10 g/day in women), 
viral infection, or any other specific etiology of liver disease.49 NAFLD is the hepatic 
manifestation of metabolic syndrome, often occurring simultaneously with obesity, 
dyslipidemia and insulin resistance.50 Obese people have 3.5 times the risk of develop-
ing NAFLD compared to normal weight people.51 Along with rates of obesity increasing 
worldwide, NAFLD has become the most common liver disease, with a global preva-
lence of 25.2%.52 The progressive version of NAFLD is nonalcoholic steatohepatitis 
(NASH). NASH is associated with hepatocellular carcinoma development and in-
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creased mortality, liver-related disease, cardiovascular disease and malignancy in the 
general population.53-55 
NASH-related cirrhosis is now the fastest increasing indication for liver Tx in Eu-
rope and the US, where it is expected to overtake Hepatitis C as the leading cause in 
10 – 15 years.56-58 Liver graft recipients transplanted because of NASH have either 
similar58 or better long-term patient survival compared to those transplanted for other 
reasons.59 However, diagnosis of NAFLD after Tx–either the recurrence of liver steato-
sis or the development of de novo NAFLD–is a new health issue, affecting 25% – 60% 
of liver Tx recipients.60 Its underlying mechanisms are complex, and its pathogenesis in 
transplanted grafts is not yet fully understood. Still, along with genetic factors, NASH 
cirrhosis as the primary indicator for Tx is associated with post-Tx NAFLD.60 Of note, 
one of the most consistent predictors of NAFLD is post-Tx weight gain,29,60 which is 
congruent with evidence in the general population.27 
Post-operative outcomes and survival after liver transplantation 
Pre-Tx obesity has been associated with increased risk for post-operative complica-
tions (i.e., operative complications, infections), and increased length of intensive care 
unit and hospital stays.61 However, a recent meta-analysis found no association–even 
after adjustment for ascites or severity of liver disease–between patient survival and 
pre-Tx BMI, noting similar survival rates across BMI categories and obesity classes.62 
To date, to the best of our knowledge, no study examined the impact of post-Tx body 
weight parameters on patient survival. 
In conclusion, the discord between the research results noted above might be 
explained by methodological differences among the studies, e.g., variations in meas-
urement points (e.g., short- or long-term outcomes after Tx), the dominant use of cross-
sectional study design, the diversity of diagnostic criteria (e.g., for metabolic syndrome, 
cardiovascular disease, NAFLD) and the measurement of body weight parameters. 
Especially before Tx, the measurement of body weight (and the further calculation of 
the BMI) may be skewed by the presence of ascites and edema. While the impact of 
pre-Tx BMI and obesity have been examined extensively in the literature, post-Tx body 
weight parameters such as weight gain and subsequent obesity are not well under-
stood. Finally, evidence is either scant or contradictory regarding how post-Tx weight 
gain and new-onset obesity impact patient outcomes such as metabolic and cardiovas-
cular diseases or patient and graft survival. 
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Chapter 6 presents the results of an STCS analysis aimed at and examining the 
impact of new-onset obesity on CVE and patient survival, and determining risk fac-
tors for the development of new-onset obesity after liver Tx. Longitudinal data from 
the Swiss cohort allowed a time-dependent analysis of outcomes and predictors. 
1.4 Factors influencing weight gain and energy balance 
The regulation of body weight follows the first law of thermodynamics, i.e., the principle 
that energy can be transformed from one form to another, but cannot be created or 
destroyed. This leads to the energy balance equation: energy storage = energy intake - 
energy expenditure.63 In physiology, weight change results from an imbalance between 
energy intake (calories consumed) and expenditure (calories expended) over time.64 
Therefore, maintaining a stable weight, i.e., balancing energy intake with expenditure, 
may appear a simple matter of adherence to energy balance related behaviors, e.g., 
healthy eating (energy intake) and physical activity (energy expenditure). In fact, effec-
tive weight management is extremely complex: the etiology of weight gain, leading to 
overweight and obesity, depends on a multitude of interconnected factors. 
One of the most comprehensive overviews of weight-influencing factors and 
their interrelationships is presented in the 2007 United Kingdom (UK) Foresight report’s 
obesity system map (Figure 2, the interactive version is available on 
http://www.shiftn.com/obesity/Full-Map.html.).65 The center of the diagram is energy 
balance, embedded in a dense tangle of 108 variables from 10 source types: media, 
social, psychological, economic, food, activity, infrastructure, developmental, biological 
and medical. Among the variables, positive or negative influences are depicted via 304 
causal linkages. Finally, the variables are grouped into 8 superior clusters: social psy-
chology, individual psychology, individual physical activity, physical activity environ-
ment, food production food consumption, physiology and individual physiology. 
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Figure 2. Obesity system map in the UK Foresight report. To highlight the different variable 
clusters, the system map was redesigned by ShiftN 
 Source: (http://www.shiftn.com) 
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Based on the Foresight report and current literature, we developed a simplified frame-
work (Figure 3) to guide the design and research of the studies conducted within this 
PhD project and described in chapters 4 and 6 below. This framework covers 6 catego-
ries of variables related to weight gain: genetic, sociodemographic, behavioral, biomed-
ical, psychological, and environmental.66-69 The framework is intended for use as a 
working model, and should be adapted according to the most compelling available evi-
dence. 
To date, few studies have examined factors influencing post-liver Tx weight gain 
in ways that would add information to our framework. The examination of genetic fac-
tors in relation to weight gain is only beginning in Tx populations. One genomic study in 
liver Tx found that recipients carrying at least one D allele of the ACE gene had a near-
ly 4 times the risk of weight gain compared to those with no D allele.70 This study also 
found a gene-age effect, as weight gain was particularly prevalent in patients aged 
>55. These results call for further research to test findings such as in kidney Tx popula-
tions. E.g., when Cashion et al. examined gene expression profiles in subcutaneous 
adipose tissue, they found 4 genes positively (CPE, LEP, NPY1R, NPY5R), and 2 
genes negatively (APOM, CRP) correlated with post-Tx weight gain.71 
Regarding sociodemographic influences, evidence of major factors’ impact on 
post-Tx weight gain can be contradictory. For example, the impacts of age and gender 
remain controversial;14-16,20 however, other factors, such as BMI before liver disease 
onset, higher weight/BMI before Tx, family history of overweight and being married 
have been consistently associated with weight gain.14,15,20,72 
Surprisingly few studies have examined behavioral factors, and especially en-
ergy balance-related behaviors; and some of those few have made counter-intuitive 
findings. Perhaps most notably, in Anastacio et al.’s cross-sectional study, neither die-
tary intake nor daily physical activity could be related to post-liver Tx overweight or 
obesity.72 In another case, Ferreira et al. prospectively assessed energy intake and 
expenditure in 17 recipients before liver Tx and during the first year after.73 Compared 
to the pre-Tx measurement, energy intake increased post-Tx, while expenditure re-
mained rather stable. This resulted in a positive energy balance and by 12 months 
post-Tx, mean weight had increased from 69.6 ± 17.2 kg to 74.2 ± 17.7 kg. Unfortu-
nately, the relationship between energy balance and weight gain was not analyzed. 
Another behavioral factor examined with weight gain was current and former smoking; 
however the results remain inconclusive.14,15,72 
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Most studies have examined biomedical factors, especially immunosuppres-
sive medication use. In general, one side effect commonly attributed to prednisone is a 
craving for sweets and increasing weight, especially when prescribed at >5 mg/day.74 
However, little evidence in liver Tx supports this relationship. While a number of studies 
have reported that the cumulative prednisone dose at 1 year post-Tx predicts obesity, 
weight gain, weight change or a decrease of fat-free body mass,15,75 others have found 
no such association.14,16,20,76,77 Results for other immunosuppressive drugs such as 
cyclosporine tend to be similarly inconsistent.14,20,72 Only tacrolimus is generally agreed 
to have no impact on post-Tx weight gain.14,15,20,72,77 
Our literature study uncovered no studies that examined post-liver Tx weight 
gain in relation to psychological or environmental factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Theoretical framework of factors influencing weight gain in the BALANCE project. 
The variables assigned to the 6 main categories are examples from the liver Tx pop-
ulation and selected variables from the general population (in grey color and italics). 
Source: Own Illustration. 
Overall, the evidence regarding weight gain influencing factors remains scarce; and it 
is not yet clear which variables predict weight gain after Tx as the few existing results 
are partly conflicting. This might be explained by methodological reasons, e.g., most 
studies used cross-sectional designs, which precludes the detection or inference of 
causal relationships. In view of the content gaps, most single center and also data-
base-related studies are limited regarding data collection to mainly sociodemographic 
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and biomedical variables. As such limitations obscure the complexity of weight gain, 
they limit any examination of predictive factors and their interrelationships. Additionally, 
to the best of our knowledge, no study has yet examined associations between post-Tx 
weight gain and energy balance-related behavior, psychological or environmental fac-
tors. 
Chapter 4 describes the results of our systematic literature review and meta-
analysis investigating the risk factors regarding post-liver Tx changes in BMI, weight 
gain and obesity. This is the first summary and synthesis of the current evidence 
regarding risk factors in liver Tx. Guided by our theoretical framework, the data 
were extracted according to the 6 main categories. The results guided the adaption 
of the framework according to the evidence provided by the meta-analysis. 
Chapter 5 provides the results of a study using data from the STCS to examine as-
sociations between genetic factors and weight gain after Tx. This study shows the 
importance of including genetic factors in risk factor models in order to strengthen 
predictive power. 
Chapter 6 presents a study about outcomes and risk factors of new-onset obesity 
after liver Tx. This study identified patients at risk for weight gain and subsequent 
new-onset obesity. The results highlight the importance of preventing weight gain 
and the development of new-onset obesity as it was associated with post-Tx CVE. 
1.5 Energy balance-related behaviors 
Although the multiplicity of factors influencing weight gain has been acknowledged, 
energy balance-related behaviors such as dietary intake and physical activity are still 
perceived as the most important dynamics related to energy balance and weight man-
agement.2,78 So far, though, no evidence indicates that any specific diet can effectively 
prevent weight gain.79,80 The general recommendations to maintain a stable weight are 
to adjust caloric intake to match one’s expenditures (i.e., decreased intake during peri-
ods of reduced physical activity), adhere to a well-balanced diet (i.e., including vegeta-
bles, fruits, beans and pulses, whole grains and fish), and limit intake of energy-dense 
foods (e.g., fats and sugars).81 Following a particular diet such as Mediterranean style, 
low-fat, low-carbohydrate, or low glycemic index is important for overweight and obese 
people who aim to lose weight.7 Regarding physical activity, guidelines recommend for 
healthy adults a minimum of 150 min of moderate-intensity physical activity with per 
week78,82–an activity level associated with healthy normal weight and general health 
benefits such as reduced risk for cardiovascular disease.81,83 
CHAPTER 1. INTRODUCTION 
25 
In the liver Tx population, factors including immunosuppressive medication in-
crease the risk for metabolic and cardiovascular comorbidities. Therefore, to maintain 
normal weight and prevent comorbidities, graft recipients need to adopt a particularly 
healthy post-Tx lifestyle, adhering to energy balance-related behaviors such as a 
healthy diet and physical activity.84 Despite the known benefits of healthy eating and 
physical activity after Tx, non-adherence with recommendations is well documented.85 
A small number of small studies have examined healthy eating over the course 
of liver Tx, measured by short-term self-reported dietary intake, i.e., 3-day food intake 
records. In one study with 31 participants, the total number of calories consumed re-
mained stable from pre-Tx to 6 months post-Tx;86 however, two others reported in-
creases in energy intake at 9 months (n=23)87 and 1 year post-Tx (n=17).73 While car-
bohydrate and protein consumption remained rather stable, fat intake increased. As a 
result, body weight and fat mass increased in both study samples.73,87 Similarly, a 
German cross-sectional study examined 42 liver Tx recipients’ total energy intake and 
macronutrients compared to the general population’s consumption patterns and the 
recommendations of the German Nutrition Society.76 Tx recipients (median time after 
Tx: 50 months; range: 17.7 – 100.6) consumed more total energy than national rec-
ommendations (2389 kcal/d versus 2200 kcal/d), with higher proportional fat intake 
(41%) than either the recommendations (30%) or the general population (36%). 
Regarding physical activity, roughly half of US liver Tx recipients engage in reg-
ular physical activity; however, activity levels still remain below those recommended in 
US public health guidelines.88,89 A subgroup analysis in liver recipients more than 1 
year after Tx showed very similar results, suggesting that decreased post-liver Tx phys-
ical activity levels are independent of physical limitations in the early recovery phase.88 
These results are worrisome: low physical activity has been associated with metabolic 
syndrome after liver Tx,88 as well as cardiovascular and all-cause mortality after kidney 
Tx.90 Conversely, post-Tx physical activity has been associated with beneficial effects 
such as increased health-related quality of life, self-efficacy, personal fitness, muscle 
strength and functional performance.89,91-94 Few studies have linked increased physical 
activity to reductions in the incidence of hepatic steatosis in individuals with NAFLD;95-
97 however, this has not been examined in the Tx population. 
1.6 Behavioral interventions in weight management 
Three approaches drive weight management: (1) the prevention of weight gain; (2) 
short-term weight loss due to a temporary negative energy balance; and (3) long-term 
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weight loss maintenance due to re-achieving continuous energy balance at a reduced 
level. Experts and guidelines consistently advise a focus on weight gain 
prevention.25,78,81,98 This strategy is based on physiological mechanisms, which com-
pensate during phases of energy shortage. I.e., while reduced energy intake by food 
restriction leads to short-term weight loss, homoeostatic factors drive a feedback loop 
by changing body energy requirements and increasing appetite.99-101 Behavioral factors 
(e.g., challenges to retain changes, especially with regard to diet and physical activity), 
as well as environmental variables (e.g., availability of energy-dense foods, increased 
portion sizes, epigenetic modifications such as higher risk for obesity and metabolic 
diseases after intrauterine exposure to very low or very high maternal nutrition102) add 
to the complexity of the underlying physiology.100 
Based on these mechanisms, weight loss is commonly followed by weight re-
gain.103,104 Even in behavioral intervention studies applying state-of-the-art recommen-
dations, sustainable weight loss maintenance remains a major problem.101,105 Middleton 
et al.’s 2012 meta-analysis synthesized 11 randomized-controlled trials examining the 
effects of extended care (i.e., continued therapist contact to prevent weight regain fol-
lowing initial loss) on weight loss maintenance.106The trials’ follow-up lengths varied; 
however, the 5 that used 18 months of follow-up reported lower mean weight regain in 
their intervention groups (from 1.2 kg to 4.5 kg) compared to their controls (from 3.3 kg 
to 7.2 kg). 
Comprehensive lifestyle interventions have become a cornerstone of weight 
gain and obesity prevention.7 To tackle individual, environmental and systemic drivers, 
a multilevel approach has been recommended.67 On the individual level, interventions 
focusing on health behaviors are suggested.67 Three systematic reviews examined 
effective patient-level interventions and their key components to prevent weight gain in 
adults.80,107,108 Their findings indicated that multicomponent interventions (combining 
dietary advice, physical activity and promotion of behavior change) are more effective 
than single component interventions. However, few of the included behavior change 
interventions were based on underlying theories,107 nor was their development com-
prehensively described. 
Studies focusing on energy balance-related interventions in the liver Tx popula-
tion are scarce. Still, even while the Tx community calls for assistance in weight gain 
and obesity management to prevent comorbidities,39,84,96,109 the development and im-
plementation of structured, noninvasive, multidisciplinary weight management pro-
grams has virtually stalled. Since 2006, only one randomized controlled trial (in 119 
liver Tx recipients) has examined the effects of a combined dietary and physical activity 
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intervention on exercise capacity, muscle strength, body composition, nutritional intake 
and health-related quality of life.110 That intervention included individual counseling on 
exercise prescription (e.g., walking or cycling for 30 min per session with increasing 
intensity, at least three times per week), and nutrition recommendations (caloric bal-
ance, fat intake ≤30% of total caloric intake, and additional dietary recommendations). 
The 10-month follow-up was based on home-based exercise and dietary modification. 
Although exercise capacity increased only in the intervention group, body weight, BMI 
and fat mass significantly increased in both groups. However, even though the trial was 
not powered to detect changes in body composition, the intervention group’s increase 
of fat mass was slower than that of the usual care group, suggesting a favorable inter-
vention effect. And while the authors did not explicitly address behavior change within 
the intervention, the counseling session comprised several components that could be 
assigned and coded to behavior change techniques: short and long-term goal setting, 
self-monitoring with exercise logs and 3-day food diaries, review of current behaviors, 
recommendations for program progression, discussion of problems and barriers, sug-
gestions for changes and encouragement for continued participation, and a newsletter 
offering information and tips for adherence. 
The overall aim of this dissertation was to generate evidence that would facilitate 
the development of a behavioral intervention based on physical activity and diet to 
support effective weight management and a healthy lifestyle after liver Tx. 
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The overall aim of this dissertation was to generate evidence that would facilitate the 
development of a behavioral intervention focusing on physical activity and diet to sup-
port effective weight management and a healthy lifestyle after liver Tx. 
Based on the gaps described in the introduction regarding body weight parame-
ter evolution among solid organ Tx populations, the complex mechanisms leading to 
post-Tx weight gain and obesity, and body weight parameter’s impacts on patient out-
comes, the specific aims were as follows: 
1) To examine the evolution of body weight parameters up to 3 years after Tx within 
and among adult kidney, liver, lung, and heart Tx patients in the STCS (Chapter 3). 
2) To summarize and synthesize the current literature in view of risk factors for post-
Tx BMI, weight gain and obesity in the liver Tx population (Chapter 4). 
3) To examine weight gain in the first year after solid organ Tx in the STCS from a 
genomic perspective (Chapter 5). 
4) To determine clinical and psychosocial risk factors for post-liver Tx new-onset obe-
sity and examine its impact on outcomes including patient survival and CVEs in the 
STCS (Chapter 6). 
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3.1 Abstract 
Obesity and weight gain are serious concerns after solid organ transplantation (Tx); 
however, no unbiased comparison regarding body weight parameter evolution across 
organ groups has yet been performed. Using data from the prospective nationwide 
Swiss Transplant Cohort Study, we compared the evolution of weight parameters up to 
3 years post-Tx in 1359 adult kidney (58.3%), liver (21.7%), lung (11.6%), and heart 
(8.4%) recipients transplanted between May 2008 and May 2012. Changes in mean 
weight and body mass index (BMI) category were compared to reference values from 6 
months post-Tx. At 3 years post-Tx, compared to other organ groups, liver Tx recipi-
ents showed the greatest weight gain (mean 4.8 ± 10.4 kg), 57.4% gained >5% body 
weight, and they had the highest incidence of obesity (38.1%). After 3 years, based on 
their BMI categories at 6 months, normal weight and obese liver Tx patients, as well as 
underweight kidney, lung and heart Tx patients had the highest weight gains. Judged 
against international Tx patient data, the majority of our Swiss Tx recipients’ experi-
enced lower post-Tx weight gain. However, our findings show weight gain pattern dif-
ferences, both within and across organ Tx groups that call for preventive measures. 
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3.2 Background 
As the number of obese patients awaiting solid organ transplantation (Tx) has steadily 
increased over the past decades1-4 and considerable post-Tx weight gain has been 
described in all Tx populations,5 patient weight parameters (e.g., obesity and weight 
gain) are relevant factors to investigate over the Tx continuum. Moreover, obesity and 
weight gain have been associated with serious health issues across all solid organ Tx 
populations.6 Conclusive evidence links pre-Tx obesity with worse post-Tx outcomes, 
for example, increased risk of graft dysfunction and post-Tx surgical, cardiovascular or 
metabolic complications.6 Over the post-Tx course, obesity and weight gain at 1 year 
after kidney Tx are associated with increased risks of cardiovascular and all-cause 
mortality,7-9 as well as graft failure.7-10 
Weight parameters vary considerably among organ groups. In the United States 
(US), for example, approximately 30% of kidney11 and liver12 Tx patients are obese at 
the time of Tx, while the numbers in heart13 and lung Tx14 are 22.7% and 15.2%, re-
spectively. Also mean weight gain in the first year after Tx varies across organ groups, 
for example, 1.1 kg in heart15 versus 9.2 kg in liver Tx,16 and across geographic re-
gions, e.g., 2.7 kg weight gain in kidney Tx recipients in France8 versus 10.3 kg in the 
US.17 
Recent reviews highlight the challenges of comparing different studies’ results 
as definitions, measurements and sampling methods might vary.6,18 Body mass index 
(BMI in kg/m2) and weight change in kilogram or in percent are the weight parameters 
most often used. BMI categories applied in adults, according to the World Health Or-
ganization (WHO) are underweight (<18.5 kg/m2), normal weight (18.5 – 24.9 kg/m2), 
overweight (25 – 29.9 kg/m2), and obese (≥30 kg/m2).19 Although the BMI is easy to 
calculate, it has considerable limitation for example, it provides no information about 
the distribution of weight or fat, and it fails to differentiate between muscle mass, fat, or 
extracellular water.20 In a Tx candidate with ascites or edema, a high BMI may reflect 
fluid overload rather than increased fat mass. Especially in the liver Tx population the 
pre-Tx BMI should be corrected for ascites to avoid misclassification regarding BMI 
category.3 Still, flawed though it may be, BMI is certainly worth monitoring. In the kid-
ney Tx population, a BMI increase in >5%, independent of pre-Tx BMI, has been asso-
ciated with graft loss.8 
Another commonly used weight parameter in the Tx literature is post-Tx weight 
change, expressed as the calculated difference in kilogram over time. This is a rather 
crude measure, as it disregards differences in baseline weight (e.g., a 5 kg weight gain 
in an underweight patient is clinically dissimilar from a similar weight gain in an obese 
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patient). One useful weight parameter to consider would be weight change in percent 
related to baseline weight. In this regard, a weight gain of ≥5% functions well as a clini-
cally relevant cutoff, as it has been identified as a risk factor for cardiovascular and 
metabolic disorders in overweight or obese adults. In the same populations, losses of 5 
– 10% are associated with health benefits.21 In the literature, one limitation of percent-
age weight change related to baseline weight remains the limited consideration of 
baseline BMI category (e.g., 5 – 10% weight gain in underweight vs obese patients). 
Importantly, few studies addressing weight parameters in solid organ Tx have exam-
ined weight changes longer than 1-year post-Tx. Additionally, except for a small num-
ber of notable exceptions,5,15,22 the vast majority of studies focus on individual centers 
and on a solitary Tx population only. 
The absence of a standard methodology to assess the evolution of various post-
Tx weight parameters, including the longer-term post-Tx course, precludes firm conclu-
sions on the prevalence and evolution of relevant weight parameters between organ 
groups. Across solid organ Tx groups, identifying these patterns will allow researchers 
to determine how and in which groups to first invest their efforts for preventive 
measures. Using data from the nationwide, open, and prospective Swiss Transplant 
Cohort Study (STCS), including all patients transplanted in any of the six Swiss Tx cen-
ters since 2008, we aim to describe and compare the evolution of weight parameters 
within and among adult kidney, liver, lung, and heart Tx recipients up to 3 years post-
Tx. 
3.3 Methods 
Patients and Methods 
The STCS includes all patients transplanted in Switzerland since 2008. Data in the 
STCS are collected at Tx, at 6 and 12 months post-Tx, then yearly thereafter. Follow-
up ends with the patient’s death or dropout. The STCS was approved by all relevant 
cantonal ethic committees. More details about the design and methodology of the 
STCS are described elsewhere.23,24 Inclusion criteria for this analysis were as follows: 
age ≥18 years, data available about weight and height at Tx, and receiving a first kid-
ney, liver, lung, or heart Tx between May 5th 2008 and May 31st 2012, thus allowing a 
3-year follow-up in all participants. Patients who supplied no informed consent for fur-
ther data analysis, or who were receiving multiple grafts were excluded. 
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Variables and measurement 
Body weight parameters 
Height and weight at Tx, 6 months, 1, 2, and 3 years post-Tx were used to calculate 
patients’ BMIs (weight in kilogram divided by height in meters squared). BMI categories 
were determined according to the WHO definition.19 Changes in weight parameters 
over time (i.e., mean weight or BMI category) were examined in relation to the meas-
urements at 6 months post-Tx. Using these figures as reference values allowed an 
unbiased and comparative examination of changes between all four organ groups, as 
no correction for pre-Tx ascites or edema was possible using STCS data. 
Weight change in kilogram was calculated for each patient as the difference be-
tween the reference weight at 6 months post-Tx and the weight at Tx, 1, 2, and 3 years 
post-Tx. The means of weight changes were then calculated for each organ group and 
for the BMI subgroups, respectively, which were defined based on the reference BMI 
category at 6 months. 
Weight change in % was calculated for each patient as the difference between 
the weight at 3 years post-Tx multiplied by 100 and divided by the 6-month reference 
weight. Means were then calculated for each organ group and for the BMI subgroups, 
which were again based on the reference BMI category at 6 months, and categorized 
as follows: weight loss (loss of >5% weight), stable weight (weight change between   -
5% and 5%), and weight gain (gain of >5% weight). 
The evolution of BMI over time was examined using two analyses. First, as the 
proportion of patients in each of the BMI categories at Tx, 6 months, 1, 2, and 3 years 
post-Tx. As patients can shift from one BMI category to another at different measure-
ment points, this presentation does not necessarily represent individual changes. Con-
sequently, we examined the evolution of BMI on an individual level and analyzed at 3 
years post-Tx the proportions of patients who remained in their 6-month reference BMI 
categories versus those who shifted between categories. 
Clinical and socio-demographic variables 
To describe the sample at time of Tx, we extracted following variables from the STCS 
database: age, gender, length of follow-up, donor type (deceased or living, only in kid-
ney and liver Tx), and ethnicity (Caucasian, African, Asian, and other race) and end-
stage organ disease leading to Tx. Death, graft loss, and rejection were recorded from 
Tx until the end of the 3-year follow-up period. Rejection for each organ group was de-
fined according to the definition used by the STCS: kidney: acute humoral or cellular 
rejection; liver: clinically suspected and biopsy-proven rejection; lung: bronchoalveolar 
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lavage or clinically suspected and biopsy-proven rejection; and heart: biopsy-proven 
rejection from grade 1a to grade 4. 
Statistical analysis 
Based on measurement level and data distribution, descriptive statistics including fre-
quencies and percentages, means and standard deviations (SD) were used to describe 
both the sample and the evolution of BMI and weight. In the STCS dataset, the varia-
bles weight and height were missing in 4.3% and 3.0% of the cases, respectively. 
Missing variables were not imputed, nor were patients with missing values excluded 
from further analysis. All analyses were performed using SPSS Version 23.0 statistical 
software (IBM Corp., Armonk, NY, USA). 
3.4 Results 
In August 2015, the STCS database included 3315 patients. After the exclusion of    n 
= 1956 patients based on the application of our inclusion and exclusion criteria, a total 
of 1359 patients were eligible for the final analysis (kidney = 58.3%, liver = 21.7%, lung 
= 11.6%, and heart = 8.4%). The most common underlying end-stage organ diseases 
were as follows: in kidney patients, glomerulonephritis (22.9%), polycystic kidney dis-
ease (21.6%), and nephrosclerosis (13.8%); in liver patients, viral hepatitis (35.9%), 
alcoholic liver disease (22.7%), and hepatocellular carcinoma (8.5%); in lung patients, 
chronic obstructive pulmonary disease (30.4%), cystic fibrosis (24.1%), and idiopathic 
pulmonary fibrosis (20.3%); and in heart patients, cardiomyopathy (55.3%) and is-
chemic heart disease (28.9%). Further sample characteristics are summarized in Table 
1. 
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Variables 
Total group 
n = 1359 
Kidney Tx 
n = 792 
Liver Tx 
n = 295 
Lung Tx 
n = 158 
Heart Tx 
n = 114 
Age at Tx, mean ± 
SD 52.0 ± 13.3 52.5 ± 13.8 52.7 ± 11.3 49.7 ±13.8 49.1 ±14.5 
Male, n (%) 888 (65.3) 530 (66.9) 192 (65.1) 77 (48.7) 89 (78.1) 
Ethnicity      
  Caucasian, n (%) 1283 (94.4) 736 (92.9) 279 (94.6) 156 (98.7) 112 (98.2) 
  Black, n (%) 36 (2.6) 26 (3.3) 8 (2.7) 1 (0.6) 1 (0.9) 
  Asian, n (%) 34 (2.5) 24 (3.0) 8 (2.7) 1 (0.6) 1 (0.9) 
  Other, n (%) 6 (0.4) 6 (0.8) 0 0 0 
Death, n (%) 159 (11.7) 51 (6.4) 44 (14.9) 38 (24.1) 26 (22.8) 
Graft loss, n (%) 95 (7.0) 44 (5.6) 21 (7.1) 19 (12.0) 11 (9.6) 
Rejection, n (%) 613 (45.1) 288 (36.4) 138 (46.8) 97 (61.4) 90 (78.9) 
Deceased donor, n 
(%)  438 (55.3) 276 (93.6) 158 (100) 114 (100) 
Weight       
  at Tx, mean ± SD 73.8 ± 16 75.3 ± 15.5 74.9 ± 16.4 62.8 ± 15.3 75.5 ±14.2 
BMI       
  at Tx, mean ± SD 25.3 ± 4.7 25.8 ± 4.6 25.5 ± 4.5 22.3 ± 4.9 25.3 ± 4.1 
  at 6mo, mean ±  
  SD (n) 25.3±4.6 (1280) 26.3±4.7 (777) 23.8±4.0 (255) 22.9±4.2 (151) 25.5±3.9 (97) 
  at 1y, mean ± SD  
  (n) 25.7±4.8 (1209) 26.4±4.9 (738) 24.6±4.4 (238) 23.4±4.1 (143) 26.2±4.6 (90) 
  at 2y, mean ± SD  
  (n) 26.0±4.9 (1114) 26.5±4.9 (688) 25.5±4.9 (209) 23.7±4.0 (128) 26.2±4.8 (89) 
  at 3y, mean ± SD  
  (n) 26.1±5.0 (995) 26.6±5.0 (628) 25.7±4.9 (170) 23.9±4.5 (116) 25.9±5.0 (81) 
Tx, transplant; BMI, body mass index; SD, standard deviation; y, year 
Table 1. Demographic and clinical patient characteristics. 
Source: Own Illustration. 
Weight changes in kilogram compared to the reference weight at 6 months after kid-
ney, liver, lung, and heart Tx are shown in Figure 1. With regard to the period between 
Tx and 6 months, kidney, lung, and heart Tx patients were already gaining weight in 
the early post-Tx phase, while liver Tx patients showed a different pattern, with a mean 
weight loss of −5 kg (± 8.5 kg). From 6 months to 3 years post-Tx, all organ groups 
gained weight (overall mean weight gain: 2.0 ± 7.5 kg). However, the amount of weight 
gain differed between groups. Liver Tx recipients gained the most weight (4.8 ± 10.4 
kg), while kidney Tx patients gained the least (1.2 ± 6.3 kg). 
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 From Tx to       6 mo 
Reference 
at 6 mo  
From 6 mo to 
1 year  
From 6 mo to 
2 years  
From 6 mo to 3 
years 
Total sample 
weight change / kg 
mean ± SD, 
range, (n) 
0.03 ± 7.3 
-30 - 37.7, 
(1280) 
0 ± 0, 
(1280) 
1.2 ± 4.8 
-32 - 19, 
(1188) 
1.8 ± 6.3 
-30 - 37.1, 
(1095) 
2.0 ± 7.5 
-40.1 - 43.3, 
(983) 
Kidney 
weight change / kg 
mean ± SD, 
range, (n) 
-1.2 ± 5.8 
-27 - 17.7, 
(777) 
0 ± 0, 
(777) 
0.7 ± 4.6 
-32 - 19,  
(73) 
1.1 ± 5.5 
-30 - 21.5, 
(684) 
1.2 ± 6.3 
-40.1 - 21.6, (624) 
Liver 
weight change / kg 
mean ± SD, 
range, (n) 
5 ± 8.5 
-20 - 37.7, 
(255) 
0 ± 0, 
(255) 
2.1 ± 5.4 
-12.5 - 18.9, 
(225) 
3.6 ± 8.2 
-24.7 - 37.1, 
(197) 
4.8 ± 10.4 
-38 - 43.3, 
(162) 
Lung 
weight change / kg 
mean ± SD, 
range, (n) 
-1.7 ± 7.5 
-30 - 18.9, 
(151) 
0 ± 0, 
(151) 
1.2 ± 4.9 
-21 - 14.7, 
(140) 
2.2 ± 6.7 
23.1 - 25.7, 
(125) 
2.3 ± 8.0 
-27.9 - 25, 
(116) 
Heart 
weight change / kg 
mean ± SD, 
range, (n) 
-0.6 ± 8.2 
-19.4 - 20.4, 
(97) 
0 ± 0, 
(97) 
2.2 ± 4.6 
-11.5 - 14, 
(90) 
2.3 ± 6.5 
-11.5 - 22.1, 
(89) 
1.6 ± 7.5 
-16.5 - 27.1, 
(81) 
 
Tx, transplant; SD, standard deviation; y, year; mo, month 
Figure 1.  Mean weight changes in kg compared to the reference weight at 6 months after kid-
ney, liver, lung and heart Tx. 
Source: Own Illustration. 
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Mean weight changes in kilogram compared to the 6-month reference weight by BMI 
category at 6 months after kidney, liver, lung, and heart Tx are shown in Figure 2. In 
kidney, lung, and heart Tx, patients who were underweight at 6 months post-Tx subse-
quently gained the most weight compared to those in higher BMI categories. Obese 
liver Tx patients at 6 months post-Tx gained the most weight up to 2 years post-Tx, 
while at 3 years, patients who had normal weight at 6 months post-Tx showed the 
highest increase in weight. Lung Tx patients who were obese at 6 months post-Tx lost 
weight during the observation period. 
 Weight changes in percent categories by BMI category at 6 months after kid-
ney, liver, lung, and heart Tx are shown in Figure 3. From 6 months to 3 years post-Tx, 
55.3% of kidney Tx patients maintained a stable weight, compared with 45.7% of lung, 
33.3% of heart, and 30.2% of liver Tx patients. The liver Tx group had the largest pro-
portion of patients who gained >5% weight (57.4%) over the observation period, com-
pared with the lung (37.9%), heart (33.3%), and kidney Tx (29.8%) groups. A more 
detailed examination revealed that in kidney, lung, and heart Tx, the underweight pa-
tients were the largest fraction gaining >5% weight, while liver Tx, these were the recip-
ients who were normal weight or obese at 6 months. In lung and liver Tx, obese pa-
tients formed the largest proportion of the weight loss group. 
 The proportion of patients per BMI category at each measurement from Tx to 3 
years after kidney, liver, lung, and heart Tx is shown in Figure 4. The distribution of 
BMI categories at time of Tx among kidney, liver, and heart Tx candidates is compara-
ble, while in lung Tx, a higher proportion of underweight (28.5%) and a lower proportion 
of obese patients (5.7%) were observed. From Tx to 6 months post-Tx, the prevalence 
of obesity decreased in the liver and heart Tx groups (from 17.3% to 5.9% and from 
14.9% to 11.3%, respectively). However, during the entire observation period, the 
prevalence of overweight and obesity increased in all organ groups except heart Tx, 
where the prevalence of obesity peaked at 2 years post-Tx. 
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Kidney Tx Liver Tx 
  
 
 Tx 1 year post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 
(SD) 777 (5.8) 733 (4.6) 684 (5.5) 624 (6.3) 
Under-
weight, 
n (SD) 
19 (3.1) 19 (2.5) 17 (6.1) 17 (6.3) 
Normal 
weight, 
n (SD) 
309 (5.2) 299 (4.1) 277 (4.9) 246 (5.4) 
Over-
weight, 
n (SD) 
292 (5.7) 274 (4.2) 263 (4.7) 248 (5.4) 
Obesity, 
n (SD) 157 (6.7) 141 (6.3) 127 (7.6) 113 (9.0) 
 
 
 Tx 1 year post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 
(SD) 255 (8.5) 225 (5.4) 197 (8.2) 162 (10.4) 
Under-
weight, 
n (SD) 
18 (6.5) 16 (4.9) 12 (3.3) 11 (10.2) 
Normal 
weight, 
n (SD) 
150 (8.1) 131 (5.0) 109 (7.4) 93 (8.7) 
Over-
weight, 
n (SD) 
72 (9.1) 64 (6.1) 62 (9.0) 48 (10.6) 
Obesity, 
n (SD) 15 (11.4) 14 (6.3) 14 (12.5) 10 (21.0) 
 
Lung Tx Heart Tx 
  
 
 Tx 1 year post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 
(SD) 151(7.5) 140 (4.9) 125(6.7) 116 (8.0) 
Under-
weight, 
n (SD) 
22 (5.9) 20 (5.0) 18 (7.7) 13 (8.3) 
Normal 
weight, 
n (SD) 
81 (7.1) 76 (3.9) 68 (5.6) 67 (6.7) 
Over-
weight, 
n (SD) 
40 (8.0) 36 (5.3) 33 (7.3) 29 (9.1) 
Obesity, 
n (SD) 8 (10.9) 8 (6.6) 6 (7.1) 7 (11.4) 
 
 
 Tx 1 year post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 
(SD) 97 (8.2) 90 (4.6) 89 (6.5) 81 (7.5) 
Under-
weight, 
n (SD) 
2 (4.2) 2 (1.1) 2 (4.2) 2 (4.3) 
Normal 
weight, 
n (SD) 
48 (6.7) 44 (3.5) 45 (4.8) 41 (5.8) 
Over-
weight, 
n (SD) 
36 (8.1) 34 (4.6) 33 (7.1) 30 (8.1) 
Obesity, 
n (SD) 11 (11.0) 10 (6.7) 9 (8.9) 8 (11.1) 
 
Footnote: Mean weight changes in kg were calculated as the differences between each meas-
urement point and the reference weight at 6 months post-Tx, which is the initial value in the 
graph. At the time of Tx, the bars with positive values indicate a higher mean weight compared 
to the measure at 6-months post-Tx, corresponding to weight loss between Tx and 6 months 
thereafter. Bars with a negative value indicate a lower mean weight, corresponding to weight 
gain in this timeframe. After Tx, the bars with positive values indicate a higher mean weight 
compared to the measure at 6-months post-Tx, corresponding to weight gain beyond 6 months. 
Bars with a negative value indicate a lower mean weight, corresponding to weight loss. 
Tx, transplant; SD, standard deviation 
Figure 2.  Mean weight changes in kg compared to the 6-month reference weight by BMI cate-
gory at 6 months after kidney, liver, lung and heart Tx. 
Source: Own Illustration 
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Kidney Tx Liver Tx 
  
 
 >5% 
weight loss 
stable 
weight 
>5% 
weight gain 
Total, n 93 345 186 
Underweight, n 1 8 8 
Normal weight, n 33 129 84 
Overweight, n 35 148 65 
Obesity, n 24 60 29 
 
 
 >5% 
weight loss 
stable 
weight 
>5% 
weight gain 
Total, n 20 49 93 
Underweight, n 0 7 4 
Normal weight, n 10 20 63 
Overweight, n 8 20 20 
Obesity, n 2 2 6 
 
  
Lung Tx Heart Tx 
  
 
 
 >5% 
weight loss 
stable 
weight 
>5% 
weight gain 
Total, n 19 53 44 
Underweight, n 2 4 7 
Normal weight, n 9 31 27 
Overweight, n 4 16 9 
Obesity, n 4 2 1 
 
 
 
 >5% 
weight loss 
stable 
weight 
>5% 
weight gain 
Total, n 15 39 27 
Underweight, n 0 0 2 
Normal weight, n 9 21 11 
Overweight, n 5 12 13 
Obesity, n 1 6 1 
 
Footnote: Mean weight changes in % categories were calculated as differences between the 
measure at 6 months and 3 years post-Tx. Weight categories were defined as weight loss (los-
ing >5% weight), stable weight (weight change between -5% and 5%), and weight gain (gaining 
>5% weight). 
Figure 3.  Weight changes in % categories from 6 months to 3 years after kidney, liver, lung 
and heart Tx using 6 month BMI category as reference value. 
Source: Own Illustration 
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Kidney Tx Liver Tx 
  
 Tx 6 mo post-Tx 
1 year 
post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 792 777 738 688 628 
Underweight, n 25 19 17 16 15 
Normal weight, n 340 309 292 262 233 
Overweight, n 274 292 275 257 242 
Obesity, n 153 157 154 153 138 
 
 
Tx 6 mo post-Tx 
1 year 
post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 295 255 238 209 170 
Underweight, n 10 18 15 13 11 
Normal weight, n 151 149 129 91 71 
Overweight, n 83 73 65 68 56 
Obesity, n 51 15 29 37 32 
 
Lung Tx Heart Tx 
  
 Tx 6 mo post-Tx 
1 year 
post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 158 151 143 128 116 
Underweight, n 45 22 12 8 11 
Normal weight, n 65 81 80 68 58 
Overweight, n 39 40 44 44 39 
Obesity, n 9 8 7 8 8 
 
 Tx 6 mo post-Tx 
1 year 
post-Tx 
2 years 
post-Tx 
3 years 
post-Tx 
Total, n 114 97 90 89 81 
Underweight, n 3 2 1 2 3 
Normal weight, n 55 48 40 37 37 
Overweight, n 39 36 34 32 30 
Obesity, n 17 11 15 18 11 
 
Tx, transplant 
Figure 4. Proportion of patients per BMI category at each measurement from Tx to 3 years 
after kidney, liver, lung and heart Tx 
Source: Own Illustration. 
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The shift among BMI categories from 6 months to 3 years after kidney, liver, lung, and 
heart Tx is shown in Figure 5. Shifting upwards one or even two BMI categories over 
the observation period was common in all organ groups. In liver and lung Tx, 9.1% and 
7.7% of underweight patients became overweight, respectively. In kidney, liver, and 
lung Tx, 1.2%, 5.4%, and 1.5% of normal weight patients became obese, respectively. 
In all organ groups, the majority of patients who were obese at 6 months post-Tx re-
mained obese at 3 years post-Tx (i.e., kidney: 81.4%; liver: 90%; lung: 42.9%, and 
heart 87.5%). The cumulative incidence of obesity at 3 years after kidney, liver, lung, 
and heart Tx was 18.1%, 38.1%, 15.3%, and 13.3%, respectively. 
Kidney Tx Liver Tx 
  
Lung Tx Heart Tx 
  
Footnote: This analysis included only patients with data at 6 months and 3 years post-Tx. The 
bars reflect patients’ individual weight change trajectories between the two measurement points, 
leading to a possible subsequent shift to another BMI category. 
Figure 5. Shift among BMI categories from 6 months to 3 years after kidney, liver, lung and 
heart Tx. 
Source: Own Illustration. 
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3.5 Discussion 
In a nationwide prospective cohort, we simultaneously examined the evolution of dif-
ferent weight parameters such as weight in kg and % categories as well as BMI up to 3 
years after kidney, liver, lung, and heart Tx, thereby allowing a rigorous comparison of 
the results among all four Tx groups. Although post-Tx weight gain was common in all 
populations, our analysis revealed differing patterns among and within the specific or-
gan groups. 
Weight changes related to the reference weight at 6 months 
All organ Tx groups had a steep weight increase from 6 months to 1 year post-Tx that 
leveled off on average after 2 years post-Tx. Importantly, kidney and lung Tx patients 
had already gained a comparable amount of weight in the very early postoperative pe-
riod, that is, in the first 6 months following Tx. Liver Tx recipients showed a different 
pattern of weight loss, which might be explained by the loss of ascites and edema fol-
lowing Tx. Our results confirm previous findings of post-Tx weight gain, especially in 
the first year after Tx.7,15,25 However, with regard to the timeframe used in our analysis 
(from 6 months to 1 year), the mean weight gain in the Swiss Tx populations is still 
slightly lower than that of international studies in liver (means of 3 kg and 4 kg),16,25 
lung (mean 3.4 kg),15 and heart Tx patients (mean 2.3 kg).15 Studies in kidney Tx ex-
amined post-Tx weight gain only from time of Tx to 1 year post-Tx (means ranging from 
2.3 kg to 10.3 kg).7,8,17,26,27 Considering the era from Tx to 1 year after Tx, the kidney Tx 
patients in our study would have gained 2 ± 6.8 kg, which is lower compared to the 
European and US samples.7,8,17,26,27 The relatively low mean weight gain in our Swiss 
cohort is an encouraging result, as it may reflect a rather healthy lifestyle and high self-
perceived general state of health, as has been reported in the Swiss general popula-
tion.28 
While there is consensus that post-Tx weight gain occurs independently of pre-
Tx BMI, the analysis based on BMI categories provided a more detailed picture. Some 
studies in kidney, liver, lung, and heart Tx have reported the highest weight gain in pa-
tients who were under- or normal weight at the time of Tx.5,9,27,29 Our findings in kidney, 
lung, and heart Tx are congruent with those studies, although our analyses were based 
on weight change in relation to BMI category at 6 months post-Tx. In liver Tx, we found 
the highest post-Tx weight gain in those who were normal weight or obese at 6 months 
after Tx. This result was also reflected in the analysis of weight change by percentage 
category. Nearly 60% of the whole liver Tx population gained >5% weight between 6 
months and 3 years post-Tx. This group mainly consisted of patients who were normal 
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weight (67.7%) or obese (60%) at 6 months post-Tx, while the majority of underweight 
patients retained a stable weight. Again, this pattern differed from those of the other 
organ groups, in which by the majority the underweight patients were among those 
who gained >5% weight. 
Moderate weight gain, especially in underweight patients, can be desirable, as it 
reflects a state of recovery after severe illness or malnutrition. Therefore, weight gain at 
1 year post-Tx has been associated with increased 5-year patient and graft survival 
after liver Tx30 and with better patient survival in after lung Tx.31 However, independent 
of initial BMI, excessive weight gain carries also risks that may contradict such bene-
fits. A >5% BMI increase at 1 year post-kidney Tx increased the risk of graft loss three-
fold;8 and a ≥10% weight gain at 2 years post-Tx was associated with subsequent mor-
tality.7 As post-Tx weight gain is also associated with negative patient outcomes, our 
detailed results facilitate the premature identification of patients who might be at in-
creased risk of higher post-Tx weight gain. 
The evolution of BMI categories 
Our analysis of cross-category BMI shifts showed that 41.2% of underweight kidney Tx 
patients who gained weight between 6 months and 3 years post-Tx managed to 
achieve normal weight. Two underweight patients - from the liver and lung Tx groups - 
actually even became overweight. In non-underweight patients, weight gain contributed 
to an incidence of obesity between 13.3% and 18.1% at 3 years post-Tx, with liver Tx 
patients having the highest incidence, at 38.1%. This finding exceeds the results of a 
UK study (n = 597) that reported a 26.3% incidence of obesity at 3 years post-Tx 
among liver patients who were non-obese at the time of Tx.32 Interestingly, that study 
reported higher post-Tx weight gain than ours from 6 months to 3 years (median: 7.7 
versus 4 kg). 
Among all organ groups, the majority of patients who were overweight or obese 
at 6 months post-Tx remained so over time, which is in line with previous results.5 Con-
sidering that we calculated our patients’ reference BMI at 6 months post-Tx, this is par-
ticularly worrisome, as by that time they should have recovered from potential ascites 
and edema, and a BMI ≥30 kg/m2 could be considered as an unbiased measure of 
obesity. Given that Tx recipients with higher BMI values are already at increased risk of 
post-Tx metabolic and cardiovascular comorbidities6, these results call for interventions 
to reduce or prevent post-Tx obesity. However, we also found a promising result in 
lung Tx patients. Of that group’s obese patients, 57.2% shifted downwards to over-
weight or normal weight. Drivers for this development might include either close Tx 
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center follow-up care, which supports the implementation of weight loss behaviors, or 
the recipients’ renewed ability to engage in physical activity. Although exercise capacity 
remains limited after lung Tx,33 previous studies showed that the amount and intensity 
of post-Tx physical activity increased significantly compared to pre-Tx.34 
Still despite a small proportion of obese Tx recipients who lost weight over time, 
our overall prevalence of obesity increased after kidney, liver, and lung Tx. Although 
obesity has become a global public health issue, its prevalence varies tremendously 
across national populations35 and is reflected in national Tx populations.36 Due to these 
disparities and additional methodological challenges (e.g., operationalization of varia-
bles, study design, inclusion criteria), a reliable comparison to previous studies is nor-
mally difficult. However, a German study also examined the four solid organ Tx groups 
simultaneously up to 1 year post-Tx.5 In their graphs, they showed equal pre-Tx obesity 
rates in kidney and liver Tx, while their prevalence in lung and especially in heart Tx 
was clearly lower compared to our results. With regard to the evolution of BMI over the 
first year after Tx, the German Tx population showed the same pattern as our Swiss 
samples. 
In order to better classify the results of our study, we compared our patients’ 
BMI with the general Swiss population. The most recent rate for overweight in Swiss 
persons 16 or older is 30.8%.28 In liver and lung Tx groups, the rates were similar to 
that of the general population, while in kidney and heart Tx, the percentages of over-
weight patients were higher at all measurement points. With regard to obesity, the 
comparison between Tx patients and the general population was more alarming. As 
the national average is 10.3%, obesity in kidney Tx was roughly twice this value at all 
measurement points. Although the prevalence rates of obesity in liver and heart Tx 
were lower compared to the kidney Tx patients, their values later than 1 year post-Tx 
were still above the level of the Swiss general population. 
This study is subject to several limitations. First, BMI subgroup analyses are 
based on small sample sizes, especially in the heart and lung Tx groups. Second, the 
STCS dataset provides no measures on waist circumference or body composition. 
Third, an earlier measurement than 6 months post-Tx might have been a more appro-
priate proxy to adjust the weight and BMI for pre-Tx ascites and edema. The examina-
tion of long-term pre-Tx data, preferably dating to before the onset of end stage organ 
disease, would provide more accurate information about the evolution of patients’ body 
weight parameters. Despite these limitations, the STCS’s systematic and homogene-
ous methodology limited the risk of bias and offered a unique opportunity to study and 
compare all four solid organ groups simultaneously. Our recommendations for future 
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research would be to investigate the evolution of body weight parameters in the long-
term period after Tx and also examine predictors for weight gain in the specific organ 
groups such as pharmacological, behavioral, or genetic risk factors. Additionally, it 
would be important to incorporate the measurement of body composition and waist 
circumference, as this would allow a more detailed analysis regarding changes in the 
distribution of water, body fat, or muscle mass. 
Conclusion 
In our four Swiss solid organ Tx populations we found a relatively low mean post-Tx 
weight gain compared to international data. Nevertheless, the prevalence of obesity 
increased in all except the heart Tx group. The use of different weight parameters in 
our in-depth analyses revealed different patterns among the organ groups and BMI 
subgroups. Compared to kidney, lung, and heart Tx, the liver recipients had the highest 
post-Tx weight gain. They were the largest group of patients to increase their body 
weight by >5%, and had the highest incidence of obesity. Based on the BMI category 
at 6 months, underweight kidney, lung, and heart Tx patients gained more weight after 
Tx compared to those with a higher BMI category, while in liver Tx the obese and nor-
mal weight patients gained most weight. Except in lung Tx, the proportion of obese Tx 
patients was mostly higher compared to the Swiss general population. Our findings 
highlight the need for preventive interventions. Especially normal, overweight, and 
obese liver Tx should be targeted for interventions as they experience highest weight 
gain after Tx.  
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4.1 Abstract 
Background: Weight gain and obesity can increase liver transplant (LTx) recipients’ 
disease burden. We aimed to summarize and synthesize the evidence on pre- and 
post-transplant factors related to post-LTx BMI, weight gain, and obesity. 
Methods: For this systematic review and meta-analysis we searched Medline via 
PubMed, Cochrane library, CINAHL, PsycINFO, and EMBASE for original quantitative 
studies on 6 classes of factor (i.e., genetic, sociodemographic, behavioral, biomedical, 
psychological, and environmental) linked to body weight parameters in adult first-time 
LTx patients. A 19-item instrument was used for quality assessment. Effect sizes and 
odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for relationships 
investigated in ³5 studies. Factors investigated in <5 studies were summarized and 
described. 
Results: Of 16495 articles retrieved, 43 assessed factors in liver transplantation. The-
se examined 82 mainly biomedical and sociodemographic factors. However, variation 
between definitions allowed inclusion of only 2 factors (i.e., tacrolimus, cyclosporine) in 
our meta-analyses of 6 studies examining a shared parameter for body weight (median 
patient sample: 171 (range: 63 - 455); Europe n = 3; United States n = 3; publication 
years: 1997 - 2015). Neither tacrolimus (OR, 0.75; 95% CI, 0.47-1.21; p = 0.24) nor 
cyclosporine (OR, 1.40; 95% CI, 0.89-2.18; p = 0.14) were related significantly with 
post-LTx obesity. 
Conclusions: Evidence on factors, especially modifiable ones, related to post-LTx 
body weight parameters is still scarce, as heterogeneity among factor definitions limits 
data extraction and the performance of meta-analyses. To facilitate future research, 
studies should apply theoretical frameworks to guide their study design, select varia-
bles of interest and systematically examine interrelationships among selected factors. 
4.2 Background 
Obesity, defined as a body mass index (BMI) ³30 kg/m2, has become a major health 
issue in the liver transplant (LTx) population. An analysis of the Scientific Registry of 
Transplant Recipients in the United States (US) revealed that, from 2001 to 2011, re-
flecting a general worldwide trend towards rising BMI values,1 the prevalence of obesity 
in LTx candidates rose from 29% to 34.4%.2 Post-LTx weight gain increases this figure 
further in the recipients. Independent of geographical region or research era, obesity 
increased from pre-LTx to 1 year post-LTx in studies from the US (14.5% to 23.8%),3 
the United Kingdom (12.6% to 23.7%),4 and Poland (1.3% to 14.7%).5 However, these 
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values must be evaluated carefully, as their reported measurements do not necessarily 
account for pre-LTx fluid overload (e.g., edema), which biases measurement of BMI, 
i.e., body weight in kilograms divided by the square of height in meters (kg/m2). As this 
would falsely inflate the prevalence of obesity at LTx, the rise of its post-LTx preva-
lence may be even more pronounced. In fact, a recent Swiss prospective cohort study 
measuring weight gain between 6 months and 3 years post-LTx noted a mean weight 
gain of 4.8 kg, which increased the prevalence of obesity in their sample from 5.9% to 
18.8%.6 
In general, weight gain is the result of complex interactions between biological 
(including genetic), behavioral, social and environmental factors.7 Post-LTx weight gain 
is often attributed to immunosuppressive medication–especially prednisone, as its side 
effects include enhanced appetite, a craving for sweets and increased intake of high-fat 
foods.8,9 However, not all available evidence supports this relationship.10,11 Conflicting 
results have also been reported in view of other biomedical (cyclosporine),5,11,12 socio-
demographic (age and gender)3-5,11, and behavioral factors (current and former smok-
ing).3,11,12 However, a clear understanding of post-LTx body weight factors is important 
as both weight gain and obesity are associated with metabolic syndrome.13,14 As the 
LTx population is already exposed to a higher risk for metabolic and cardiovascular 
diseases because of the immunosuppressive medications,15-19 the possibility that obe-
sity might exacerbate their burden of disease, is worrisome. 
Examining risk factors for post-LTx body weight parameters offers three main 
advantages: it identifies patients at risk for weight gain and subsequent obesity; it facili-
tates understanding of pathways to weight gain; and it exposes modifiable risk factors. 
Together, these provide a firm basis upon which to develop preventive interventions 
against weight gain and obesity.20,21 Therefore, the primary aim of this systematic re-
view and meta-analysis was to summarize and synthesize the evidence regarding pre- 
and post-LTx risk factors influencing body weight parameters such as BMI, obesity, 
and weight gain. 
4.3 Methods 
The methodology of this systematic review and meta-analysis followed the recommen-
dations of the Cochrane Handbook for Systematic Reviews of Interventions.22 Report-
ing was structured according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: PRISMA statement.23 The review protocol was registered in the 
CHAPTER 4. PRE- AND POST-TRANSPLANT FACTORS ASSOCIATED WITH BODY WEIGHT… 
61 
international prospective register of systematic reviews (PROSPERO, registration 
number: CRD42014009151) and published.24 
Information sources and search strategy 
We searched the following electronic databases without limits: Medline via PubMed, 
Cochrane library, CINAHL, PsycINFO, and EMBASE. To identify relevant additional 
studies, we screened reference lists of studies in included in data extraction. The 
search string was developed according to PICOS criteria (Participants, Interven-
tions/Exposure, Comparisons, Outcomes/Topics, Study design). To allow a broad vari-
ety of search results, search strings were restricted to two concepts: ‘participants’ and 
‘exposure’. The first string was developed for PubMed (see Table 1) and later translat-
ed for the remaining databases in collaboration with a librarian. The first search was 
conducted March 17, 2014 and updated February 3, 2016. As the project aimed to ex-
amine risk factors related to body weight parameters in kidney, liver, heart and lung 
transplant populations, the search strategy included all solid organ groups.24 However, 
this article only reports the risk factors affecting the LTx population. 
(("Body Mass Index"[Mesh] OR "obesity"[Mesh] OR "overweight"[MeSH Terms] OR "Weight Gain"[Mesh] 
OR "Body Weight Changes"[Mesh:noexp] OR "Body Weight"[Mesh:noexp]) OR ("BMI"[Text Word] OR 
"Body Mass Index"[Text Word] OR "obesity"[Text Word] OR "overweight"[Text Word] OR "weight 
gain"[text word] OR "body weight change*"[Text Word] OR "body weight"[Text Word] OR "weight"[Text 
Word] OR "Ideal Body Weight"[Mesh] OR "weight management"[Text Word] OR "body size"[Text Word]) 
AND ("organ transplant*"[Text Word] OR "transplant*"[Text Word] OR "heart transplant*"[Text Word] OR 
"liver transplant*"[Text Word] OR "lung transplant*"[Text Word] OR "kidney transplant*"[Text Word]) OR 
("Kidney Transplantation"[Mesh] OR "Lung Transplantation"[Mesh] OR "Heart Transplantation"[Mesh] OR 
"Liver Transplantation"[Mesh] OR "Organ Transplantation"[Mesh:noexp] OR "Transplanta-
tion"[Mesh:noexp])) 
Table 1.  Detailed PubMed search string 
Source: Own Illustration. 
Inclusion and exclusion criteria 
Studies were included if they met following criteria: (1) original quantitative or mixed-
method study design; (2) first-time liver, heart, lung or kidney transplant candidates or 
recipients aged ≥18 years; (3) examination of risk factors or correlates associated with 
post-LTx body weight parameters; (4) study reported in English, German, Dutch or 
French; and (5) full text available. Studies with other than original quantitative or mixed-
method study design (e.g., case reports, reviews, editorials, letters to the editor, quali-
tative research), focusing on re-transplanted or multi-organ transplant recipients, or not 
examining any relationship between body weight parameters and other variables, were 
excluded. 
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Study selection 
In accordance with the inclusion and exclusion criteria, title and abstract screening 
(stage 1), then full text reading (stage 2) were performed by three researchers (SB, 
GD, NN) for the first search, and by two researchers for the 2016 search update (SB, 
GD). In both stages of the study selection process, the studies were divided into equal 
work packages. Each researcher independently evaluated the studies of the allocated 
work package. For feasibility reasons, as the first literature search retrieved 13367 hits, 
we deviated from the Cochrane Collaboration recommendation that at least two people 
should independently select studies and then verify all results.22 For quality monitoring, 
the study selection process was first pilot-tested and evaluated in 50 studies for stage 
1 and in 6 studies for stage 2. Researchers then cross-checked a random sample of 
10% of one another’s in- and exclusion decisions. Disagreements were resolved by 
discussions with a third researcher (SDG) until consensus was reached. 
Data extraction and management 
Data extraction was performed independently by two researchers (SB, GD). In case 
where an article provided either insufficient data for extraction or conflicting infor-
mation, the author was contacted for additional information at most twice via e-mail or 
research network platforms. The following general variables were extracted: general 
information (author, year, journal, continent, country, language, setting, database, 
study design, time of transplant), population (donor, etiology of liver disease, model of 
end-stage liver disease score, sample size, age, gender, race, follow-up time, correc-
tion for ascites, definition of BMI categories), details on statistical analysis, and body 
weight parameters (BMI and BMI category at LTx and post-LTx, as well as post-LTx 
weight gain). For the purposes of this study, we defined the most commonly used BMI 
classification–that proposed by the World Health Organization (WHO)–as an accurate 
outcome measure: underweight: <18.5 kg/m2; normal weight: 18.5-24.9 kg/m2; over-
weight: 25-29.9 kg/m2; and obesity ≥ 30 kg/m2.25 
As weight gain and obesity result from a complex interplay of factors,7 we used 
a previous extensive overview26 to develop a guiding framework, and categorized pre- 
and post-LTx factors as follows: genetic (e.g., single genes, family history of over-
weight), sociodemographic (e.g., age, gender, education, marital status, income level, 
working status), behavioral (e.g., energy intake, energy expenditure, physical activity, 
smoking), biomedical (e.g., BMI category, end-stage organ disease, hemodialysis, 
medication), psychological (e.g., stress, quality of life), and environmental (e.g., public 
transportation, availability of exercise areas). 
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Quality assessment 
Study quality was assessed independently by two researchers (SB, GD) via a 19-item 
instrument (see table 2), which was adapted from two other tools: the 27-item Downs 
and Black checklist27 and a quality assessment instrument used for Duerinckx et al.’s 
2016 systematic review.28 The results of the quality assessment were visualized via the 
Cochrane Risk of Bias summary figure provided by Cochrane Review Manager 5.3).29 
No Question  Definition  Rating 
Aim   
1 Is the hypothesis / 
aim / objective of the 
study clearly de-
scribed? 
   • Yes 
• No 
• Unable to de-
termine 
2 Does the study have 
a prospective de-
sign? 
 Yes: 
• Prospective data collection 
 • Yes 
• No 
• Unable to de-
termine 
Participants   
3 Are the characteris-
tics of the patients 
included in the study 
clearly described? 
 
 Yes: 
• Cohort studies and trials: inclusion and/or 
exclusion criteria given 
• Case-control studies: a case-definition and 
source for controls is given 
No: 
• No information about precise age, multi-
organ or re-transplant 
 • Yes 
• No 
• Partially 
4 Were the subjects 
asked / chosen to 
participate in the 
study representative 
of the entire popula-
tion from which they 
were recruited? 
Meaning: Identify the 
source population for 
patients and describe 
how the patients were 
selected 
 Yes: 
• Sample comprises the entire source popu-
lation 
• Unselected sample of consecutive pa-
tients 
• Random sample 
• Patients from more than one center or 
study setting included 
No: 
• Single center setting 
Unable to determine: 
• Study does not report the proportion of the 
source population from which the patients 
are derived 
 • Yes 
• No 
• Unable to de-
termine  
5 Were the patients in 
different intervention 
groups (trials and 
cohort studies) or 
 Yes: 
• Patients for all comparison groups were 
selected from the same hospital / popula-
 • Yes 
• No 
• Unable to de-
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No Question  Definition  Rating 
were the cases and 
controls (case-control 
studies) recruited 
from the same popu-
lation? 
tion / cohort 
Unable to determine: 
• In cohort and case-control studies: no 
information concerning the source of pa-
tients included  
termine  
6 Were study subjects 
in different interven-
tion groups (trials and 
cohort studies) or 
were the cases and 
controls (case-control 
studies) recruited 
over the same peri-
od of time? 
 Yes: 
• All patients recruited over the same period 
of time 
Unable to determine: 
• Time period over which patients were 
recruited for the study is not specified 
 • Yes 
• No 
• Unable to de-
termine  
7 Were losses of pa-
tients to follow-up 
taken into account? 
 Yes: 
• If the proportion lost to follow-up was too 
small to affect the main findings 
Unable to determine: 
• Numbers of patients lost to follow-up are 
not reported  
 • Yes 
• No 
• Unable to de-
termine  
Outcomes   
8 Are the main out-
comes to be meas-
ured clearly de-
scribed in the intro-
duction or methods 
section? 
 No: 
• If main outcomes are first mentioned in the 
results 
• No cutoffs for BMI categories given 
 • Yes 
• No 
• Partially 
9 Were the main out-
come measures 
used accurate (valid 
and reliable)? 
 Yes: 
• Outcome measures clearly described 
(psychometrics, values) 
• Studies referring to other work or demon-
strate the outcome measures are accurate 
(reference given) 
No: 
• Not WHO definition for BMI categories 
 • Yes 
• No 
• Unable to de-
termine 
10 Are the variables of 
interest clearly de-
scribed? 
 
 Yes: 
Clear description of content such as 
• Changes of weight, BMI 
• Risk factors 
• Consequences / outcomes 
 • Yes 
• No 
• Partially  
Results   
11 Are the main find-
ings of the study 
clearly described? 
 Yes: 
• Simple outcome data reported for all major 
findings 
 • Yes 
• No 
• Partially 
CHAPTER 4. PRE- AND POST-TRANSPLANT FACTORS ASSOCIATED WITH BODY WEIGHT… 
65 
No Question  Definition  Rating 
This question does not cover statistical tests. 
12 Have actual proba-
bility values been 
reported for the main 
outcomes except 
where the probability 
value is < 0.001? 
 Yes: 
• 0.035 rather than <0.05 
 • Yes 
• No 
• Partially 
13 Does the study pro-
vide estimates of the 
random variability in 
the data for the main 
outcomes? 
 Yes: 
• According distribution of data, results 
include: 
- Non-normal: IQR 
- Normal: SE, SD or CI 
• If distribution of data is not described, it 
must be assumed that the estimates were 
appropriate  
 • Yes 
• No 
• Partially 
14 Are principal con-
founders influencing 
the outcome clearly 
described? 
 Yes: 
• List of principal confounders is provided 
 • Yes 
• No 
• Partially 
Analysis   
15 In trials and cohort 
studies, do the anal-
yses adjust for 
different lengths of 
follow-up of patients, 
or in case-control 
studies, is the time 
period between the 
intervention and 
outcome the same for 
cases and controls? 
 Yes: 
• Follow-up was the same for all study 
patients 
• Different lengths of follow-up were adjust-
ed for (e.g. survival analysis) 
No: 
• Differences in follow-up are ignored 
 • Yes 
• No 
• Unable to de-
termine  
16 Were the statistical 
tests used to assess 
the main outcomes 
appropriate accord-
ing to the data and 
the aims? 
 Yes: 
• Analysis clearly described 
• Little statistical analysis but no evidence of 
bias 
• Risk factors: Multivariate analysis 
• Small sample size: nonparametric meth-
ods 
• If distribution of the data is not described it 
must be assumed that the estimates used 
were appropriate  
 • Yes 
• No 
• Partially 
17 Was there adequate 
adjustment for con-
founding in the anal-
yses from which the 
main findings were 
 Randomized studies: 
No: 
• Main conclusions of the study were based 
on analyses of treatment rather than inten-
 • Yes 
• No 
• Unable to de-
termine  
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No Question  Definition  Rating 
drawn? 
 
tion to treat 
• Distribution of known confounders in the 
different treatment groups was not de-
scribed or not taken into account in the 
analyses 
Non-randomized studies: 
No: 
• The effect of the main confounders was 
not investigated 
• Confounding was demonstrated but no 
adjustment was made in the final analyses  
18 Was the sample size 
appropriate? 
 Yes: 
• A priori sample size justification 
• At least 104+x if testing individual predic-
tors variables 
• At least 50+8x subjects 
x is the number of independent/ predictors 
variables for testing a multiple correlation  
 • Yes 
• No 
• Unable to de-
termine  
19 Reproducibility of 
the study on the basis 
of the description of 
methods and out-
comes 
 Yes: 
• Enough details described that the study 
could be repeated accurately 
• If yes in question: 18, 16, 10, 9, 8, 3 
 • Yes 
• No 
• Partially 
BMI, Body Mass Index; WHO, World Health Organization; IQR, interquartile range; SE, stand-
ard error; SD, standard deviation; CI, confidence interval 
Instrument adapted from the 27-item checklist by Downs SH, Black N. The feasibility of creating 
a checklist for the assessment of the methodological quality both of randomized and non-
randomized studies of health care interventions. J Epidemiol Community Health. 
1998;52(6):377-384. 
Table 2.  Quality assessment instrument 
Source: Own Illustration. 
Data analysis 
Study characteristics were presented using descriptive statistics. Where mean values 
for age or BMI were only provided for subgroups, a weighted mean was calculated for 
the total sample. Only risk factors assessed in ³5 studies were included in the meta-
analysis. Effect sizes were calculated to analyze the strengths and directions of rela-
tionships, and were expressed as odds ratios (OR) for associations between risk fac-
tors and post-LTx body weight parameters. All effect sizes were reported with the cor-
responding 95% confidence intervals (CIs). Because we expected sample heterogenei-
ty among the primary studies, estimated effects were pooled using a random-effects 
model. The included studies’ heterogeneity was assessed using both the Cochran Q 
test (with a p value <0.1 indicating significant heterogeneity) and I2 statistics, with val-
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ues of 25%, 50%, and 75% respectively indicating moderate low, moderate, and high 
heterogeneity.30 Subgroup analyses using year of publication and geographical location 
as moderators were conducted with meta-analytic versions of regression (for continu-
ous moderators) and ANOVA (for dichotomous moderators). Risk factors assessed in 
<5 studies were grouped within their categories and classed as significant or nonsignif-
icant based on their relationship with the body weight parameter. The results were 
summarized graphically. All analyses were conducted using Comprehensive Meta-
Analysis software (Biostat, Inc., Englewood, NJ, USA). 
4.4 Results 
Study selection and assignment to the categories 
The study selection process is shown in Figure 1. Of 16495 initial references, 43 stud-
ies in LTx met the inclusion criteria. These assessed 82 distinct pre-and post-LTx fac-
tors in relation to any of the 3 body weight parameters (i.e., post-LTx BMI, obesity and 
weight gain). Overall, factor definitions varied hugely, which limited pooling to groups of 
at least 5 studies examining the same factor in relation to the same body weight pa-
rameter of interest. Two factors (i.e., tacrolimus and cyclosporine) were examined in 6 
studies vis à vis post-LTx obesity, making them eligible for data extraction and meta-
analysis.13,31-35 
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Figure 1.  Flowchart according to PRISMA statement. 
Source: Own Illustration. 
Summary of factors examined in relation to post-LTx body weight parameters 
Figure 2 shows an overview of factors studied in fewer than 5 studies in relation to 
post-LTx BMI, obesity and weight gain. The majority of factors examined were catego-
rized as biomedical and sociodemographic. Within the pre-LTx biomedical factors, dia-
betes mellitus and BMI were studied 5 times in relation to either BMI, obesity or weight 
gain and represented the highest number of significant results relative to the total num-
ber of studies (respectively 3/5 and 5/5). Among the post-LTx biomedical factors of 
interest, 4 types of immunosuppressive medication were frequently examined in rela-
tion to the 3 body weight parameters, but generally yielded low proportions of signifi-
cant results: steroids (2/12), cyclosporine (2/8), tacrolimus (0/7), and sirolimus (2/3). In 
the group of pre-LTx sociodemographic factors, gender and age were studied most 
frequently, both with mixed results regarding their impact (2/7 and 2/5). Very few stud-
ies examined behavioral, genetic or psychological risk factors; none examined envi-
ronmental factors. 
Figure 1. Flowchart according to PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) statement 
Records identified through database searching  
(n = 16495) 
Sc
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g 
In
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de
d 
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ig
ib
ili
ty
 
Id
en
tif
ica
tio
n 
Additional records identified 
through reference screening 
(only liver) 
(n = 33) 
Records after duplicates removed 
(n = 15297) 
Records screened 
(n = 15297) 
Records excluded 
(n = 12961) 
Full-text articles assessed for eligibility 
(n = 2336) 
Full-text articles excluded, 
with reasons 
(n = 1351) 
No Full Text  n = 10 
Language  n = 25  
Design   n = 108 
Duplicate  n = 9  
Population n = 707 
Content  n = 492 
 Studies included in qualitative synthesis (n = 1018) 
 
Kidney  n= 617 
Liver  n= 224 
Heart  n= 136 
Lung  n= 52 
(7 studies examined >1 organ group) 
Liver studies eligible for meta-analysis (n = 224) 
Studies assessing risk factors  n = 43 
Studies assessing outcomes  n = 184 
 
Articles excluded from 
meta-analysis,  
with reasons 
(n = 31) 
Not enough data for 
extraction  n = 30 
Biased sample  n = 1 
Liver studies included in meta-analysis,  
risk factors assessed by t5 studies 
n = 6 
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NASH, nonalcoholic steatohepatitis; HCV, hepatitis C Virus; BMI, body mass index; UNOS, 
United Network for Organ Sharing; Tx, transplantation; HCC, hepatocellular carcinoma; Pred, pred-
nisone; Aza, Azathioprine, CsA, cyclosporine; Tac, Tacrolimus; CVD, cardiovascular disease 
Figure 2.  Pre- and post-LTx risk factors of post-LTx obesity, weight gain and BMI assessed by 
1 to 4 studies.         
 Source: Own Illustration 
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Characteristics of the studies included in meta-analysis 
The characteristics of the 6 studies examining tacrolimus and cyclosporine as possible 
factors of post-LTx obesity are summarized in Table 3. All 6 were single-center studies 
from either Europe (n = 3, 50%) or the US (n = 3, 50%), and were published between 
1997 and 2015. The median sample size was 171 patients (range, 63 – 455). Distribu-
tions of patients within BMI categories were not provided in all of the studies, nor were 
BMI category definitions used consistently. The final set of studies did not include 
companion papers. 
Risk factors for post-LTx obesity 
The 6 included studies, involving a total of 1177 participants, showed no association 
between tacrolimus and post-LTx obesity (OR, 0.75; 95% CI, 0.47-1.21; p = 0.24) (Fig-
ure 3). There was low but non-significant heterogeneity among the studies (Q, 7.12; I2 
= 29.75%; p = 0.21). Results of a subgroup analysis based on year of study publication 
was not significant (β = 0.05; p = 0.18); nor were those of a subgroup analysis based 
on where each study was conducted (Europe, including Turkey: mean OR, 0.56; 95% 
CI, 0.26-1.28; US: mean OR, 0.95; 95% CI, 0.506-1.791; p = 0.33). 
Further, no association was shown between cyclosporine use and post-LTx 
obesity (OR, 1.40; 95% CI, 0.89-2.18; p = 0.14). Heterogeneity among the studies was 
non-significant (Q = 4.67; I2 = 0.00%; p = 0.46). As with the tacrolimus analysis, cyclo-
sporine yielded no significant differences in study effect sizes based on year of publica-
tion (β = -0.03, p = 0.34); and no difference was shown due to study location (Europe, 
including Turkey: mean OR, 1.64 95% CI, 0.871-3.088); US: mean OR, 1.15 05% CI, 
0.59-2.25; p = 0.45). 
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Tacrolimus 
 
Cyclosporine 
 
CI, confidence interval 
Figure 3.  Forest plot of studies analyzing tacrolimus and cyclosporine in relation to post-LTx 
obesity in ≥5 studies. 
Source: Own Illustration 
Quality assessment 
The results of the quality assessment are shown in Figure 4. All studies had retrospec-
tive study designs (n = 6, 100%); 4 (66.6%) had sample sizes large enough to test indi-
vidual predictor variables. None used a theoretical framework to guide the research 
process or the selection of study variables; and none reported studying representative 
samples (selected via probability sampling). Three studies (50%) clearly described the 
patient characteristics needed to apply our systematic review’s inclusion and exclusion 
criteria. All 6 adequately described the results and the variables of interest, i.e., the 
factors analyzed in relation to body weight parameters. Although 2 (33.3%) took con-
founders into account, none adjusted adequately for them in the analysis. Based on the 
methods described in the articles, 3 studies (50%) met the criteria for reproducibility. 
Author (Year) ComparisonOutcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Akarsu et al. 2013 Tacrolimus Obesity 1.036 0.523 2.053 0.919
Bianchi et al. 2006 Tacrolimus Obesity 0.275 0.079 0.950 0.041
Canzanello et al. 1997 Tacrolimus Obesity 0.480 0.163 1.418 0.184
Fernandez-Miranda et al. 2002 Tacrolimus Obesity 0.453 0.156 1.318 0.146
Fussner et al. 2015 Tacrolimus Obesity 1.180 0.499 2.792 0.706
Rabkin et al. 2002 Tacrolimus Obesity 1.474 0.446 4.879 0.525
0.751 0.465 1.213 0.242
0.1 0.2 0.5 1 2 5 10
Less Obesity More Obesity
Meta Analysis
Author (Year) Comparison Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Akarsu et al. 2013 Cyclosporine Obesity 1.136 0.433 2.982 0.795
Bianchi et al. 2006 Cyclosporine Obesity 3.640 1.052 12.588 0.041
Canzanello et al. 1997 Cyclosporine Obesity 2.082 0.705 6.143 0.184
Fernandez-Miranda et al. 2002 Cyclosporine Obesity 1.426 0.541 3.760 0.473
Fussner et al. 2015 Cyclosporine Obesity 0.750 0.218 2.578 0.648
Rabkin et al. 2002 Cyclosporine Obesity 0.841 0.257 2.749 0.775
1.395 0.892 2.181 0.144
0.1 0.2 0.5 1 2 5 10
Less Obesity More Obesity
Meta Analysis
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4.5 Discussion 
This systematic literature review summarized pre- and post-LTx factors relating to post-
LTx BMI, obesity, and weight gain. In all, 82 factors were identified, mainly from the 
biomedical and sociodemographic categories. Behavioral, genetic or psychological 
factors were less frequently studied, while environmental factors were not examined in 
relation to any body weight parameter. As only tacrolimus and cyclosporine were ad-
dressed in more than 5 studies, they were the only factors eligible for meta-analysis. 
Neither tacrolimus nor cyclosporine was significantly associated with post-LTx obesity. 
Examination of factors associated with body weight parameters 
All factors were assigned to our predefined categories. As expected, the majori-
ty were biomedical or sociodemographic. Most are easily obtainable, as they are 
among the more common sample characteristics in single-center and database-related 
studies. In spite of a large initial search return, however, not enough articles were 
available to perform more meta-analyses, as the researchers’ factor definitions varied 
too greatly. E.g., steroid use was defined as use of cortisone (yes/no), cumulative ster-
oid dose, length of steroid use, or use of steroids in combination with other immuno-
suppressive drugs. This level of heterogeneity among definitions precluded meta-
analyses to test for relationships between immunosuppressive drugs and weight-gain 
parameters, which still warrant further investigation.9 
Following LTx, metabolic comorbidities such as diabetes, hypertension or 
dyslipidemia commonly occur as side-effects of immunosuppressive medication.17 Alt-
hough obesity is also classed as a metabolic disorder, few studies have examined 
possible relationships with it. Three out of 5 studies focusing on diabetes found that 
pre-LTx diabetes significantly related to post-LTx obesity and weight gain. Taking an-
other perspective, in a recent systematic review, Li et al. examined risk factors for new-
onset diabetes mellitus after LTx by meta-analyzing 7 studies with information on pre-
LTx BMI.36 The results suggest relationships between diabetes and body weight pa-
rameters, independent of when those parameters were measured; however, testing 
these relationships will require further investigation. 
Nevertheless, body weight influencing parameters include far more than bio-
medical or sociodemographic factors. As weight gain and subsequent obesity are driv-
en by multiple interrelated factors, a broader range of variables require consideration.26 
Evidence in the general population stresses the importance of socioeconomic (e.g., 
female gender with low income),37,38 psychological (e.g., depression),39 and genetic 
factors (e.g., BMI- and obesity-related genes such as FTO, MC4R, or BDNF).40 Yet, the 
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examination of those specific factors in large samples is often limited because they are 
not included per se in standardized database or registry data collection.  
Behavioral factors, e.g., healthy eating and physical activity, represent another 
important component in relation to body weight parameters. Still, while their value to 
prevent weight gain has been shown in the general population,41,42 evidence in the LTx 
population is lacking. Two quantitative studies asked LTx recipients their opinions re-
garding the causes of weight gain after LTx.16,43 Interestingly, increased food intake, 
constant hunger, and decreased daily physical activity where among the most common 
responses. Although these findings suggest that patients perceive behavioral factors 
as relevant to weight gain, this relationship needs further examination in both qualita-
tive and quantitative research. Examining barriers to physical activity after transplanta-
tion, a small study in kidney recipients found that, alongside fear of injuring the new 
kidney, health problems such as pain were limiting post-LTx activity levels, as well as 
time constraints after they returned to work.44 These findings not only provide prelimi-
nary insights regarding post-kidney transplant non-performance of physical activity, but 
also emphasizes behavior’s relationships with other, e.g., psychological (i.e., fear, anx-
iety), biomedical (i.e., pain), and sociodemographic factors (i.e., return to work). Given 
the complexity of factors related to body weight parameters, future research should 
incorporate theoretical frameworks guiding the choice of study design and selection of 
variables of interest. 
Overall, the alarming low amount of studies examining risk factors and body 
weight parameters in the LTx population indicates an urgent need for further investiga-
tion. Yet, methodological issues may be a barrier. Various genetic, sociodemographic, 
behavioral, biomedical, psychological, and environmental factors (e.g., epigenetic 
characteristics, monthly income, physical activity, immunosuppressive drugs, moving to 
another area) can change over the course of Tx: an adequately-sized prospective 
study cohort that can supply repeated measurements, thereby allowing multivariate 
analyses and the examination of interrelationships, would be optimal for this type of 
research. 
Examination of various body weight parameters 
Despite the broad choice of body weight parameters available for study, the majority of 
study authors chose to examine post-LTx obesity (BMI ³30 kg/m2). However, none 
differentiated between the WHO’s three obesity classes (class I: BMI ³30-34.9 kg/m2; 
class II: BMI 35-39.9 kg/m2; class III: ³40 kg/m2).25 As BMI values ³35 kg/m2 have been 
associated with lower patient survival,45 higher post-LTx morbidity and increased 
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healthcare utilization,45-47 risk factors associated with obesity classes II and III warrant 
far more attention. 
The small number of studies examining post-LTx weight gain–recognized as a 
health issue in LTx since the early 1990s43–was also somewhat surprising. Modifiable 
weight gain risk factors could be targeted by preventive interventions, which are widely 
accepted as the key strategy against weight gain and subsequent obesity.48-50 The rea-
son for this approach is the so-called yo-yo effect. In times of lower energy intake, e.g., 
during a diet, compensatory physiological mechanisms lead to reduced energy re-
quirements. Afterwards, when energy intake increases to a normal level, to have a re-
serve available for future shortages, the body takes up more energy than actually 
needed, resulting in weight re-gain.51 Based on the difficulty involved in overcoming 
these compensatory mechanisms, preventing weight gain should logically be easier 
than achieving and maintaining a target weight after weight loss.52 Therefore, we pro-
pose the identification of risk factors associated with post-LTx weight gain as an im-
portant area for future research. 
Risk factors for post-LTx obesity 
The use of neither tacrolimus nor cyclosporine–both calcineurin inhibitors–was associ-
ated with post-LTx obesity. Following LTx, tacrolimus has become the immunosup-
pressive treatment of choice, as it is associated with improved patient and graft survival 
and reduced rejection.53 Unfortunately, while functioning well as the major pathway of 
immunosuppression, calcineurin inhibition has also been associated with the develop-
ment of metabolic comorbidities such as diabetes mellitus, hypertension, and hyper-
lipidemia.54 However, our meta-analysis showed no association between either tacroli-
mus or cyclosporine and obesity as a metabolic disorder. Moreover, none of the other 
8 studies examining tacrolimus or cyclosporine with weight gain after LTx found a sig-
nificant association. Although heterogeneity was not statistically significant across our 
sample, the small number of studies included in the analysis (n = 6) might have con-
tributed to an inadequate statistical power to detect differences across studies. Sub-
group analyses considering year of study publication and geographical location found 
no differences. 
However, several inter-study methodological and clinical disparities may also 
have impacted our analyses. First, from a methodological perspective, obesity alone 
might not be accurate enough as an outcome measure. We did not distinguish in our 
review between obesity per se (which might have been present pre-LTx) and new-
onset obesity that developed post-LTx. Of the studies relevant to our meta-analyses, 
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only Akarsu et al. provided more detailed information about this differentiation, as they 
examined the factors related to obesity’s development.31 Second, the cutoff values de-
fining obesity differed across the 6 studies–one of which provided no BMI cutoff.35 
Third, 3 studies were cross-sectional, examining the relationship between immunosup-
pressive drugs and post-LTx obesity only at one specific time point, i.e., either 113,33 or 
3 years.35 The other 3 assessed post-LTx obesity longitudinally between 1 and 168 
months, weakening a precise definition of the outcome measured. Finally, as immuno-
suppressive medications are core treatment elements, preventing graft rejection after 
transplant, studies examining them often lack adequate control groups. 
From a clinical perspective, the amount of immunosuppressive medication ap-
plied likely varied across the 6 studies and over time. Dosing usually decreases in the 
post-LTx course to minimize long-term medication-related side effects and comorbidi-
ties.55 Also, in case of medication intolerance or other clinical, laboratory, or histological 
responses, a medication regimen might change radically.17 Finally, based on a growing 
body of research and clinical experience, since the first uses of cyclosporine and tacro-
limus–respectively in the late 1970s and late 1980s–, their application (i.e., amount of 
medication needed, combination of drugs) has improved continuously.55 Considering 
that the 6 studies included in our meta-analysis studied LTx over more than 2 decades 
(1986 – 2010), this long-term development process implies heterogeneity in the pre-
scription of both immunosuppressive agents. Neither of these clinical issues (e.g., pos-
sible changes of immunosuppressive regimen, dosing) was described explicitly in any 
of the 6 included studies. 
Limitations 
In addition to the shortcomings already mentioned in the discussion, this study has 
additional limitations. First, as noted, we could only include a small number of observa-
tional studies. Results should therefore be interpreted with caution. Second, the defini-
tions and reporting methods varied across all 43 articles examining risk factors. This 
hindered the extraction of variables needed for the final meta-analysis. Additionally, as 
we applied no time limit for the search. This limited the data extraction from studies 
performed more than 10 years ago with information missing from their reports or arti-
cles, as authors did not typically archive their data. Third, the inclusion criteria that all 
participants be aged ≥18 led to the exclusion of a number of papers, especially from 
the earlier transplantation era, when adults were often defined as aged ≥16 years. 
Fourth, we were not able to include data on body composition or waist circumference, 
both of which are important and informative body weight parameters. Finally, due to the 
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small number of eligible studies, we were unable to perform more comprehensive sub-
group analyses, examining moderators such as type of transplant, study setting, eth-
nicity, age, gender, adjustment for ascites or co-morbidities. 
Conclusion 
We identified 82 distinct pre- and post-LTx factors examined in relation to BMI, obesity 
and weight gain after LTx. The factors studied were mainly categorized as biomedical 
and sociodemographic. Unfortunately, strong variations in factor definitions limited the 
pooling to groups of at least 5 studies for meta-analysis. Only two factors were eligible 
for meta-analysis: tacrolimus and cyclosporine. Neither was significantly associated 
with post-LTx obesity. Subgroup analyses focusing on year of publication and geo-
graphical region yielded no significant results. Further research is necessary to identify 
modifiable factors associated with post-LTx weight gain and obesity, to facilitate devel-
opment of preventive interventions. Future studies should apply theoretical frameworks 
to select variables of interest and systematically examine interrelationships among dif-
ferent factors. 
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5.1 Abstract 
Background: Polygenic obesity in solid organ transplant (Tx) populations is consid-
ered a risk factor for the development of metabolic abnormalities and graft survival. 
Few studies to date have studied the genetics of weight gain in Tx recipients. We 
aimed to determine whether weighted genetic risk scores (w-GRS) integrating genetic 
polymorphisms from Genome Wide Association Studies (GWAS) (single nucleotide 
polymorphisms (SNP) group#1 and SNP group #2) and from Candidate Gene studies 
(SNP group#3) influence body mass index (BMI) in TX populations and if they pre-
dict ≥10% weight gain one year after Tx. To do so, two samples (nA = 995, nB = 156) 
were obtained from naturalistic studies and three w-GRS were constructed and tested 
for association with BMI over time. Prediction of 10% weight gain at one year after Tx 
was assessed with models containing genetic and clinical factors. 
Results: w-GRS were associated with BMI in sample A and B combined (BMI in-
creased by 0.14 and 0.11 units per additional risk allele in SNP group #1 and #2, re-
spectively, p-values<0.008). w-GRS of SNP group#3 showed an effect of 0.01 
kg/m2 per additional risk allele when combining sample A and B (p-value 0.04). Models 
with genetic factors performed better than models without in predicting 10% weight 
gain at one year after Tx. 
Conclusions: This is the first study in Tx evaluating extensively the association of w-
GRS with BMI and the influence of clinical and genetic factors on 10% of weight gain 
one year after Tx, showing the importance of integrating genetic factors in the final 
model. Genetics of obesity among Tx recipients remains an important issue and can 
contribute to treatment personalization and prediction of weight gain after Tx. 
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5.2 Background 
Obesity has become a worldwide major concern since it has more than doubled in the 
last decades. In 2014, 39% of adults were overweight (Body Mass Index (BMI) 25 - 
29.9 kg/m2) and 13% were obese (BMI ≥30 kg/m2).1 Obesity is a risk factor leading to 
other comorbidities such as diabetes, cardiovascular diseases and certain type of can-
cers.1 Among solid organ transplant (Tx) recipients, the rate of overweight and obesity 
has increased over the past years. By 2011, 34% of liver Tx candidates were obese, 
compared to 29% in 2001.2 Similar results have been found for kidney, heart and lung 
Tx recipients.3-5 Although overweight and obesity prevalence are similar to those 
measured in general population studies, in Tx recipients the consequences are more 
serious. Indeed, obesity in Tx is an important risk factor for the development of New 
Onset Diabetes after Transplant (NODAT)6 which has a deleterious effect on graft sur-
vival.7,8 Moreover, it can be often associated with delayed graft function related to sur-
gical and post-operative complications.9 
Few longitudinal studies examining weight gain among Tx recipients have been 
conducted to date, most of them focusing on weight gain during the first year post-Tx. a 
weight gain ranging from 3.5 kg to 10 kg has been reported in heart, liver and kidney 
Tx recipients10-14 and a mean of 10% weight gain during the first year after Tx was de-
scribed in kidney Tx recipients.15 A threshold of 10% increase of ideal body weight, 
defined as the metropolitan relative weight criteria,16 has been related to a risk of de-
veloping cardiovascular disease in general populations followed for more than 25 
years.16,17 Ethnicity, sex, age in addition to specific factors such as transplanted organ, 
glucocorticoids and immunosuppressive treatments are some of the described factors 
influencing weight gain following Tx and NODAT,18 as well as genetic factors. Most 
studies on Tx populations focused mainly on the NODAT rather than weight gain.19,20 
Regarding BMI-related phenotypes, a protocol for the first systematic literature review 
has been published. The aim is to condense and compare the current state of evidence 
on weight gain, overweight and obesity in Tx individuals including genetic and non-
genetic factors.21 
Regarding candidate gene approach, two single nucleotide polymorphisms 
(SNPs) and one insertion/deletion have previously been associated with BMI-related 
phenotypes.22-24 These studies were conducted in three heterogeneous populations 
with small or moderate sample sizes (n<270), with different obesity-related outcomes 
and type of Tx organ. Furthermore, different polymorphisms were analyzed. To our 
knowledge, no Genome Wide Association Studies (GWAS) investigating BMI variants 
within Tx recipients have yet been published. Recently, a microarray study examining 
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gene expression in subcutaneous adipose tissue in kidney Tx recipients found that the 
expression of obesity-related genes was correlated with weight change.25 The top 41 
ranked genes were further associated with obesity through a text mining approach,26 
including genes related to diabetes, obesity and neurological concepts such as dopa-
mine, nicotine, and cognition.25 Interestingly, two of these genes (i.e., MTCH2 and 
TFAP2B) were also found in the largest BMI GWAS meta-analysis conducted to date in 
the general population.27 This meta-analysis was conducted in more than 300 000 indi-
viduals and reported 97 SNPs associated with BMI, also including 32 previously repli-
cated BMI SNPs.28-31 All 97 polymorphisms explained up to 2.7% of BMI variability 
within these individuals.27 Since polygenic or common obesity is influenced by many 
genetic polymorphisms, genetic risk scores provide a useful tool summarizing risk-
associated variations across the genome by aggregating information from multiple-risk 
SNPs, and they may improve the consistency and the power to determine genetic risk 
in polygenic diseases.32,33 
In the present study, we aimed to study the association of three weighted genet-
ic risk scores (w-GRS), integrating previously published SNPs, with BMI in two cohorts 
of Swiss transplanted individuals. In addition, we assessed whether these genetic pol-
ymorphisms could predict a ≥10% weight gain during the first year post-Tx. 
5.3 Methods 
Sample A 
The Swiss transplant cohort study (STCS) is an ongoing prospective multicenter study 
(Basel, Bern, Geneva, Lausanne, St. Gallen and Zurich) started in May 2008 which 
enrolls Tx recipients with no particular eligibility or exclusion criteria other than having 
received an allotransplant and having signed the informed consent.34 The present 
study (May 2008 - May 2011) included Tx recipients (i.e., kidney, liver, lung, heart, or 
multi-organ) with a functional graft for at least 12 months after Tx in order to have a 
sufficient period of follow-up. A total of 1294 patients were followed up in their respec-
tive Tx centers at baseline and at 6, 12, 24, 36 and 48 months after Tx. Lipid profile, 
BMI, blood pressure and patient characteristics were collected at the different time-
points of the follow up. Further details have been published elsewhere.34,35 Only Cau-
casians and recipients of 18 years or older were retained. If an individual was subject-
ed to more than one Tx, only the first Tx was considered. A total of 995 patients were 
considered for analysis. 
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Sample B 
A total of 197 Tx recipients (i.e., lung, liver and kidney) were enrolled between 2003 
and 2005 from the outpatient clinic of the Tx center of the University Hospital of Lau-
sanne, Switzerland. Only patients with a functional graft for more than 12 months were 
eligible to participate in the study. Further details can be found elsewhere.35-37 Briefly, 
data regarding patients’ age, gender, BMI, ethnicity, immunosuppressive treatments 
among others were collected retrospectively from the medical files. Additionally, data 
concerning weight, at baseline, at 1, 3, 6, 9, 12 and at the yearly follow-up during the 5 
years after Tx were collected retrospectively from the medical files between October 
2011 and April 2012. Blood samples were collected for further genotyping analysis. 
156 individuals of 18 years or older for whom Caucasian ethnicity was reported and 
had clinical data available, were included in the analysis. This sample was considered 
as a replication sample. All patients gave their written informed consent and the studies 
were approved by the ethics committee of the Lausanne and Geneva University Hospi-
tals. 
Genotype selection and genotyping 
SNP selection was done according to large Meta analyses of GWAS published on BMI. 
SNP group #1 included 32 BMI associated polymorphisms in general adult popula-
tions.28 A second group consisted of 97 SNPs (SNP group #2) recently associated with 
BMI in general populations and which included the previous 32 SNPs (or its proxies).27 
Only SNPs significant at GWAS levels (i.e. p < 5x10-8) were retained for the analysis. 
Additionally, 41 genes whose expression in subcutaneous adipose tissue has been 
previously associated with weight change in kidney Tx recipients25 were included. A 
selection of tagging SNPs of these genes was obtained using HapMap Genome 
Browser (release 28). In order to avoid over representation of a particular gene, one 
tagging SNP per gene was selected based on the number of SNPs tagged and on the 
genotype availability in our samples. Six genes were excluded since no tagging SNPs 
were found in HapMap. Of note, two genes (i.e., MTCH2, TFAP2B) were also present 
in the GWAS mentioned previously (SNP group #1). Finally, 19 SNPs, for which geno-
type was available in both samples A and B, were retained in the SNP group#3. 
For the sample A, genotypes were analyzed with the Human OmniExpress-24 
BeadChip Kit as described by the manufacturer’s protocol (Illumina, San Diego, CA). 
For the sample B, genotyping was performed using the Illumina 200K Cardiometabo-
chip (Illumina, San Diego, CA). Briefly, the CardioMetabochip is a custom Illumina iSe-
lect genotyping array designed to test DNA variation of 200’000 SNPs from regions 
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identified by large scale meta-analyses of GWAS for metabolic and cardiovascular 
traits.38 Polymorphisms or proxies were chosen based on genotype availability. A Qual-
ity Control was done for the genotyped SNPs. Samples were excluded from the analy-
sis if sex was inconsistent with genetic data from X-linked markers, and when genotype 
call rate was <0.96 and gene call score <0.15. GenomeStudio Data Analysis Software 
was used to export results generated by Illumina CardiometaboChip. 
Construction of Genetic Risk Scores 
Three genetic risk scores were built following a w-GRS method as previously de-
scribed28 with 32 SNPs (SNP group #1) and 97 SNPs (SNP group #2) both from 
GWAS, and 19 SNPs (SNP group#3) from candidate genes. Briefly, genotypes from 
each SNP were coded as 0, 1 or 2 according to the number of BMI risk alleles and 
each polymorphism was then weighted by its β-coefficient (allele effect) based on the 
assumption that all SNP of interest have independent effects and contribute in an addi-
tive manner on BMI. In order to facilitate interpretation, the genetic risk score was sub-
sequently rescaled as previously described.39 Thus, each unit increase in the genetic 
risk score corresponded approximately to one additional risk allele. Allele effects on 
BMI were obtained from those published in the literature for the SNPs group#1 and 
#2.27,28 For the SNP group#3 allele effects were calculated from a large population 
based sample, GIANT, which consisted in a meta-analysis of GWAS with a discovery 
set of 123,865 individuals of European ancestry from 46 studies for height,40 BMI28 and 
waist-to-hip ratio.41 
Statistical analysis 
Descriptive analysis of quantitative data is presented as median and range unless oth-
erwise specified whereas qualitative data is expressed as percentages. Chi-squared 
test or rank sum test were used for association studies within categorical data or non-
parametric continuous variables, respectively. Hardy-Weinberg Equilibrium was deter-
mined for each polymorphism by a chi-square test. P-value threshold was set at <0.05 
and Bonferroni multiple test correction was applied when necessary (i.e., 0.05/6; 2 
tests of w-GRS in the whole sample A and 2 tests of w-GRS in two different sub-
groups). Due to the exploratory nature of the analysis conducted for the third GRS, in 
the present work we did not consider multiple test correction for this GRS. 
For multivariate analysis, a Generalized Additive Mixed Model was used to deal 
with complex and non-linear BMI evolution at different time points and presence of mul-
tiple observations per individual introducing interdependence among observations. A 
CHAPTER 5. WEIGHTED GENETIC RISK SCORES AND PREDICTION OF WEIGHT GAIN IN SOLID… 
89 
random effect at the subject level was also introduced to take the dependence struc-
ture of observed data into account. The models were fitted using the mgcv package of 
R (settings were fixed at package defaults). To be more conservative, the uncertainty 
of estimated parameters was assessed by 1’000 bootstraps on individuals.42 Multivari-
ate models were adjusted by gender, type of treatment, organ, living donor and CMV 
as previously described in the literature,18 as well as genetic factors and time of follow-
up. Because sex and age have been described as factors influencing weight gain,15 
further analyses were conducted stratifying by gender and the median age when the 
interactions with w-GRS were significant. 
Prediction of ≥10% weight gain one year after transplantation in the sample A 
A binary logistic regression model at 12 months after Tx was used to determine wheth-
er clinical and genetic factors influence a ≥10% weight gain one year after Tx for those 
cases where genetic components were significantly associated with BMI. The ability to 
discriminate between gainers of 10% weight versus those who did not gain 10% one 
year after Tx was assessed with the Area Under the Receiver Operating Characteristic 
Curve (AUROC) for a model containing only clinical covariates (i.e., age, sex, Tx organ, 
BMI at baseline, immunosuppressant treatment) and another model integrating clinical 
and genetic factors. For each pair of models compared (i.e., the non-genetic nested in 
its corresponding genetic model) the same number of individuals must be tested in 
order to be comparable. In addition, sensitivity (percentage of correctly predicted indi-
viduals with ≥10% weight gain among all individuals with ≥10% weight gain), specificity 
(percentage of correctly predicted individuals with <10% weight gain among all truly 
individuals with <10% weight gain) and accuracy (percentage of correctly classified 
gainers of ≥10% weight among all subjects) were obtained for each model using 
“pROC” R package.43 An AUROC lower than 0.70 indicates low discriminative accura-
cy.44 As previously described,45,46 in order to assess the added value of selected SNPs 
in predicting a ≥10% weight gain one year after Tx (i.e. comparison of genetic and non-
genetic models), likelihood ratio tests and Integrated Discrimination Improvement esti-
mates with their respective p-values were calculated. Finally, the number needed to 
genotype (i.e. the average number of patients who need to be genotyped to detect one 
misclassified case of ≥10% weight gain one year after transplantation if using only clin-
ical covariates) was calculated based on the inverse of the difference between the ac-
curacy of clinical and genetic models.47 
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5.4 Results 
Population description 
The characteristics of sample A are presented in Table 1. Sixty-six percent were men, 
17.0% were obese one year after Tx and 27.1% were diagnosed of NODAT. Similar 
patterns (p > 0.05) were observed in sample B (60.9%, 18.5% and 28.8%, respectively, 
Table 2). Twenty three percent of individuals in sample A gained ≥10% of weight the 
first year after Tx and 35% of individuals in sample B (p < 0.001). The mean of weight 
gain one year after Tx was 3.5% and 6.3% for samples A and B, respectively. Sample 
A included also heart and multi-organ Tx, individuals were older than in sample B (me-
dian age: 54 years compared to 48, p < 0.001) and there was a high prevalence of liv-
ing donors (27.1% and 11.5%, respectively, p < 0.001). Tacrolimus (TAC) was more 
frequently prescribed in sample A, whereas cyclosporine (CSA) was more used in 
sample B (45.1% versus 34.6%, respectively for TAC and 19.6% versus 65.4%, re-
spectively for CSA; p < 0.05). For sample A, individuals with at least 3 immunosup-
pressive treatments (i.e. CSA, TAC, glucocorticoids, azathioprine and/or mycopheno-
late) gained significantly more weight at one year after Tx compared to the others (p = 
0.01). Of note, 99% of those with at least 3 immunosuppressants had a glucocorticoid 
treatment prescribed, possibly contributing to this weight gain. No significant results 
were found in sample B. Among those individuals with less than 3 immunosuppressant 
drugs, sample A had lower prescription of glucocorticoids than sample B, probably con-
tributing to explain the differences of weight gain observed between both samples. 
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Characteristic All 
n=995 
Weight gain ≥10%* 
n=204 
Weight gain <10%* 
n=673 
p-value 
# 
Recipient age at Tx (y), median 
(range) 54 (18 - 79) 51 (18 - 73) 55 (18 - 79) 0.0001 
Recipient men, (%) 66.0 56.8 68.9 0.001 
Period of follow up (mo), median 
(range) 12 (0 - 48) 12 (0 - 48) 12 (0 - 48) 0.55 
Living donor (%) 27.1 27.9 29.6 0.6 
Donor age (y), median (range) 53 (1 - 86) 50 (1 - 80) 53 (1 - 86) 0.04 
Tx organ (%)     
Kidney 62.4 61.3 67.2 
<0.001 
Liver 15.9 10.3 14.7 
Lung 9.5 14.7 7.8 
Heart 6.5 11.3 4.6 
Multi-organ Tx 4.1 2.5 4.5 
Before Tx     
BMI (kg/m2), median (range) 24.6 (13.7 - 41.2) 
23.1 
(14.9 - 37.4) 
24.9 
(14.3 - 41.2) 0.0001 
Overweight 
(BMI 25 - 29.9 kg/m2), % 30.7 23.0 32.5 <0.001 
Obese (BMI ≥30 kg/m2), % 15.3 9.3 16.8 
High-density lipoprotein (mmol/L), 
median (range) 1.2 (0.01 - 8) 1.2 (0.1 - 4.1) 1.2 (0.09 - 8) 0.7 
Low-density lipoprotein (mmol/L), 
median (range) 
2.2 
(0.06 - 10.02) 
2.2 
(0.1 - 7.1) 
2.2 
(0.08 - 10) 0.3 
Cholesterol (mmol/L), 
median (range) 4.2 (0.3 - 11.7) 4.0 (0.3 - 9.9) 4.2 (0.8 - 11.7) 0.2 
At 12 months after Tx     
BMI (kg/m2), median (range) 25.2 (15.3 - 44.6) 
27.1 
(18.8 - 44.6) 
24.7 
(15.3 - 44.3) 0.0001 
Overweight 
(BMI 25 - 29.9 kg/m2), % 34.7 39.0 33.0 <0.001 
Obese (BMI ≥30 kg/m2), % 17.0 27.0 14.0 
High-density lipoprotein (mmol/L), 
median (range) 3.5 1.3 (0.5 - 4.1) 1.3 (0.2 - 7.0) 0.08 
Low-density lipoprotein (mmol/L), 
median (range) 1.3 (0.21 - 7) 2.6 (0.8 - 5.8) 2.6 (0.3 - 8.7) 0.8 
Cholesterol (mmol/L), median 
(range) 2.6 (0.3 - 8.7) 5.0 (2.3 - 9.2) 4.8 (1.7 - 12.0) 0.01 
Incidence of NODAT, (%)$ 27.1 25.9 28.1 0.6 
Cytomegalovirus serostatus (%)     
Recipient cytomegalovirus infec-
tion (R+) 57.1 21.8 23.7 
0.9 Donor cytomegalovirus infection (D+) 53.0 20.8 20.6 
Recipient and Donor cytomegalo-
virus infection (R+D+) 32.6 33.2 33.1 
Calcineurin inhibitors (%)     
TAC 45.1 42.2 48.6 
0.3 CSA 19.6 21.1 19.6 
None 35.2 36.8 31.8 
Tx, transplantation; BMI, body mass index; NODAT, new onset diabetes after transplant; y, year; mo, months; # com-
parison between weight gain ≥10% and weight gain <10%; *at 12 months after Tx, missing n=118; $ NODAT was diag-
nosed if patients were taking an antidiabetic treatment after Tx or if diabetes was reported in their case report forms. 
NODAT excluded those patients with diabetes previous to Tx 
Table 1.  Characteristics of Sample A (all and by 10% weight gain one year after Tx). 
Source: Own Illustration 
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Characteristic All 
n = 156 
Weight gain ≥10%* 
n = 42 
Weight gain 
<10%* 
n = 78 
p-value # 
Recipient age at Tx (years), 
median (range) 48 (22 - 68) 47 (26 - 66) 49 (22 - 68) 0.4 
Recipient men (%) 60.9 59.5 61.5 0.8 
Period of follow up (months), 
median (range) 12 (1 - 60) 12 (1 - 60) 12 (1 - 60) 1 
Living donor (%) 11.5 11.9 7.7 0.4 
Donor age (years), median 
(range) 43.5 (10 - 73) 45 (10 - 65) 43 (11 - 69) 0.7 
Tx organ (%)     
Kidney 65.4 76.2 60.3 
0.03 Liver 23.7 7.1 26.9 
Lung 10.9 16.7 12.8 
Before Tx     
BMI (kg/m2), median (range) 23.4 (15.8 - 37.3) 
22.9 
(18.7 - 33.5) 
24.2 
(15.8 - 37.3) 0.06 
Overweight 
(BMI 25 - 29.9 kg/m2), % 24.1 14.3 30.8 0.08 
Obese (BMI ≥30 kg/m2), % 10.9 9.5 12.8 
At 12 months after Tx     
BMI (kg/m2), median (range) 25.2 (16.5 - 39.3) 
26.8 
(20.9 - 39.3) 
24.3 
(16.5 - 35.4) 0.0006 
Overweight 
(BMI 25 - 29.9 kg/m2), % 35.1 45.2 28.2 0.004 
Obese (BMI ≥30 kg/m2), % 18.5 28.6 14.1 
Incidence of NODAT, (%) 28.8 30.9 35.9 0.6 
Cytomegalovirus serostatus (%)     
Recipient cytomegalovirus infec-
tion (R+) 49.3 30.8 36.1 
0.6 Donor cytomegalovirus infection (D+) 61.5 23.1 15.3 
Recipient and Donor cytomeg-
alovirus infection (R+D+) 27.6 30.8 27.8 
Calcineurin inhibitors (%)     
TAC 34.6 26.2 47.4 
0.02 
CSA 65.4 73.8 52.7 
Tx, transplantation; BMI, body mass index; NODAT, new onset diabetes after transplant; y, 
year; mo, months 
# comparison between weight gain ≥10% and weight gain <10% 
* at 12 months after Tx, missing n = 36 
Table 2.  Characteristics of Sample B (all and by 10% weight gain one year after Tx). 
Source: Own Illustration 
10% weight gain one year after Tx. 
In both samples A and B, those gaining ≥10% of weight had lower BMI at baseline and 
higher BMI 12 months after Tx compared to those gaining <10% (Tables 1 and 2). The 
prevalence of overweight and obese was lower at baseline and higher at one year after 
Tx for ≥10% when compared to <10% weight gain. The Tx organ differed between 
≥10% and <10% for both A and B samples. The kidney was the most prevalent Tx or-
gan in both groups. The second most prevalent Tx organ in the ≥10% weight gain 
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group was the lung while the heart and the liver were the third most frequently Tx or-
gans. In the <10% weight gain group, the liver and the lung were among the second 
and the third most frequently Tx organs. Additionally, in sample A donors were younger 
and individuals had higher cholesterol levels at 12 months in the ≥10% weight gain 
group (median: 50 years and 5.0 cholesterol mmol/L, p = 0.04 and p = 0.01, respec-
tively). In sample B, significant differences were found in the prescribed immunosup-
pressive treatments; CSA was highly prescribed in the ≥10% weight gain when com-
pared to the <10% weight gain group (73.8% versus 52.7%, respectively; p = 0.02). 
Genetic Risk Score analysis 
Weighted genetic risk score with GWAS polymorphisms. 
In samples A and B, w-GRS ranged from 16 to 40 (SNP group #1) and from 63 to 107 
(SNP group #2), respectively. The association between w-GRS and BMI over time for 
sample A is shown in Table 3. w-GRS built from the SNP group #1 was significantly 
associated with BMI, showing a 0.16 BMI units increase per additional risk allele and 
an explained variability of 1.46%. When stratified by the median of age (w-GRS*age p 
= 0.001 and p = 0.02 for SNP group #1 and #2, respectively) individuals older than 54 
years old had 0.23 BMI unit increase per additional risk allele and an explained BMI 
variability of 2.74% whereas those at 54 years or younger showed a trend of 0.10 units 
increase and 0.56% of explained BMI variability after multiple test correction (p = 0.08). 
For SNP group #2, the effect was slightly lower (0.11 units of BMI per risk allele in-
crease, explained variability of 2.08%). These results could be partially replicated in 
sample B (Table 4) for SNP group #1 with an effect of 0.20 BMI units per risk allele 
increase and explained variability of 2.40%. Analysis stratified by sex (w-GRS*sex, p = 
0.03 for SNP group #1) showed no significant associations after multiple test correction 
(Table 4). Additionally, a significant interaction between w-GRS and organ (i.e. kid-
ney/non-kidney) was found for sample B and SNP group #1 (n = 83, p = 0.04) showing 
a slightly higher effect (0.30 units of BMI per risk allele increase) in kidney Tx individu-
als when compared to the overall 0.20 units. When combining samples A and B, BMI 
increased by 0.14 [0.09–0.19] and 0.11 [0.07–0.15] units per additional risk allele in 
SNP group #1 and #2, respectively, p-values < 0.001). 
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n Effect on BMI 
per additional risk allele 
[CI 95%] 
p-value* Explained Vari-
ability 
(%) 
SNP group #1 
All population 881 0.16 [0.11 - 0.23] p<0.008 1.46 
Age 18 – 54 years 444 0.10 [0.01 - 0.17] 0.08 0.56 
Age > 54 years 437 0.23 [0.14 - 0.32] p<0.008 2.74 
SNP group #2 
All population 854 0.11 [0.07 - 0.15] p<0.008 2.08 
Age 18 – 54 years 452 0.08 [0.03 - 0.13] p<0.008 1.10 
Age > 54 years 426 0.13 [0.07 - 0.19] p<0.008 2.90 
BMI, body mass index; SNP, single nucleotide polymorphisms; CI, confidence interval 
* p-value corrected by multiple test 
Table 3.  Weighted Genetic Risk Scores from GWAS SNPs and their associations with BMI in 
Sample A. 
Source: Own Illustration 
 
n Effect on BMI 
per additional risk allele 
[CI 95%] 
p-value* Explained 
Variability 
(%) 
SNP group #1 
All population 124 0.20 [0.07 - 0.35] 0.02 2.40 
Men 82 0.14 [-0.01 - 0.31] 0.05* ° 
Women 61 0.28 [-0.05 - 0.63] 0.05 ° 
SNP group #2 
All population 117 0.02 [-0.08 - 0.11] 0.28 ° 
Men 69 -0.03 [-0.18 - 0.07] 0.33 ° 
Women 53 0.04 [-0.16 - 0.25] 0.34 ° 
BMI, body mass index; SNP, single nucleotide polymorphisms; CI, confidence interval 
° not calculated because of non-significant association and/or low sample size 
* p-value corrected by multiple test 
Table 4.  Weighted Genetic Risk Scores from GWAS SNPs and their associations with BMI in 
Sample B. 
Source: Own Illustration. 
Weighted genetic risk score in Candidate Gene polymorphisms (SNP group#3). 
No association of w-GRS from SNP group#3 and BMI was found in sample A whereas 
an increase of 0.05 units of BMI per additional risk allele was found in sample B (p = 
0.048) with an explained BMI variability of 1.72%. In addition, in sample B, when SNPs 
group#3 and #1 were combined (49 SNPs excluding repeated SNPs) a significant as-
sociation with BMI was found with an increase of 0.16 BMI units per additional risk al-
lele and an explained BMI variability of 4.1% (p = 0.001). The w-GRS from group 
SNP#3 in the combined A and B sample showed an effect of 0.01 kg/m2 per additional 
risk allele (p = 0.04). 
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Prediction of 10% weight gain one year after Tx. 
For the models in which the w-GRS was significantly associated with BMI, we evaluat-
ed the ability of the model to discriminate between gainers of ≥10% of weight and 
those who gained <10% the first year after Tx. In sample A, a model adjusted by clini-
cal covariates (i.e., age, sex, immunosuppressant treatment (TAC and/or CSA), base-
line BMI and Tx organ) as well as genetic factors (i.e., SNP group #1) performed better 
than a model adjusted only by clinical covariates (Likelihood Ratio Test p = 0.0004). 
The predictive value for gaining 10% or more weight when including SNP group #1 in 
the model resulted in an AUROC of 0.74, a specificity of 0.61, a sensitivity of 0.77 and 
an accuracy of 0.65, whereas the model without genetic components had 0.66, 0.59, 
0.66 and 0.61 of AUROC, specificity, sensitivity and accuracy, respectively (Table 5). 
Similarly, the genetic model including SNP group #2, performed better (Likelihood Ra-
tio Test p = 0.008) and had higher AUROC (0.80) than the non-genetic model (AUROC 
non-genetic: 0.66). Similarly, for sample B, the genetic model including clinical covari-
ates and SNP group #1 was significantly different from the clinical model, (Likelihood 
Ratio Test p = 0.04) had an AUROC of 0.89 and a specificity, sensitivity and accuracy 
of 0.78, 0.88 and 0.81, respectively (Table 5). The prediction performance of the genet-
ic model compared to the non-genetic one was significantly improved as shown by the 
Integrated Discrimination Improvement score. A statistically significant Integrated Dis-
crimination Improvement (p < 0.01, sample A, SNP group #2, Table 5) means a signifi-
cant improvement of the genetic model prediction, by increasing the average of sensi-
tivity and one minus specificity of the model. The lowest Number Needed to Genotype 
in order to detect one misclassified case of ≥10% weight increase one year after Tx 
(Table 5) was 6 (obtained for sample B, SNP group #1). In sample A, the Number 
Needed to Genotype was 13 for SNP group #2 and 24 for SNP group #1. 
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SNP group #1   
Non-genetic model 0.66 [0.58 - 0.72] 0.59 0.66 0.61 
0.0004 0.08 [0.06 - 0.10] 24 
Genetic model 0.74 [0.70 - 0.83] 0.61 0.77 0.65 
SNP group #2   
Non-genetic model 0.66 [0.54 - 0.69] 0.65 0.62 0.64 0.008 0.17 [0.14 - 0.20] 13 
Genetic model 0.80 [0.71 - 0.84] 0.70 0.77 0.72 
Sa
m
pl
e 
B
 SNP group #1        
Non-genetic model 0.67 [0.61 - 0.88] 0.55 0.76 0.63 0.04 0.36 [0.28 - 0.45] 6 
Genetic model 0.89 [0.79 - 0.97] 0.78 0.88 0.81 
SNP, single nucleotide polymorphisms; CI, confidence interval; AUROC, area under the receiv-
er operating characteristic curve 
Table 5.  Comparison of genetic versus non-genetic model for 10% weight gain prediction at 
one year after Tx. *p < 0.01 
Source: Own Illustration. 
5.5 Discussion 
To our knowledge, this is the first study examining the association of clinical and genet-
ic risk scores with weight gain in Tx patients. Our results showed that, in Tx popula-
tions, previously GWAS-BMI related SNPs in general populations, were associated 
with BMI when combined in w-GRS. These results could be partly replicated in a se-
cond sample (i.e., sample B). 
The influence of weighted score including SNP group #1 on BMI has been ex-
tensively replicated in several general populations from different ethnicities.29-32 This is 
the first study evaluating the effect of these polymorphisms on BMI in Tx recipients 
(kidney, liver, lung, heart, or multi-organ) and weight gain, with positive results being 
found in both samples. SNPs group#2 was recently published27 and contained a higher 
number of SNPs (including those from SNP group# 1 except of 2 SNPs). However, 
significant results were found only in sample A. The non-replication using SNPs 
group#2 in sample B could be attributed either to no effect at all or to the low number of 
patients in the latter sample and the large number of polymorphisms in group#2, each 
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one of small effect size, thus necessitating large sample sizes in order to observe an 
effect.48 
In addition, an exploratory analysis of 19 polymorphisms combined in a w-GRS 
(SNP group#3) showed an association with BMI in sample B. These variants were se-
lected from a microarray study examining subcutaneous gene expression which was 
correlated with weight change in kidney Tx recipients.25 These findings should be con-
sidered as preliminary as they were not further replicated nor corrected for multiple 
test. In sample B individuals were younger, had lower percentage of living donors and 
gained more weight after the first year of Tx compared to sample A. Young age, low 
BMI at baseline and deceased donors increase the risk of gaining weight, as previously 
described in the literature.15,49 Adding SNP group#3 to SNP group #1 resulted in an 
increased explained BMI variability of 4.1%. However, when all SNPs were combined 
(i.e., SNP group #2 and SNP group#3), no significant results were found, probably due 
to the low effect and sample size. 
In a second step, we showed that a combination of extensive genetic factors 
and clinical data predicts better a 10% weight gain after the first year of treatment than 
considering the model with clinical data alone, increasing AUROC and accuracy. When 
examining genetic factors in sample A, several polymorphisms were significantly asso-
ciated with 10% weight gain one year post-Tx. Interestingly, when looking at SNPs in-
dividually, only MC4R (rs571312, rs6567160) and SEC16B (rs543874) remained signif-
icant in both SNP group #1 and #2 analyses. MC4R is one of the most common genet-
ic causes of obesity and this gene participates in appetite regulation and energy bal-
ance.50 SEC16B has been associated with obesity-related phenotypes but the mecha-
nism behind remains unknown. In sample B, 4 SNPs in or near MTIF3, ETV5, 
GNPDA2 and FAIM2 gene regions (rs1006353, rs7647305, rs10938397 and 
rs7138803) were associated with 10% weight gain one year post-Tx (data not shown). 
Most of these gene functions are not clear yet. ETV5 modulates circulating glucocorti-
coids levels51 and GNPDA2 regulates metabolic pathways leading to insulin re-
sistance.52 Interestingly, the best group of polymorphisms predicting 10% weight gain 
at 12 months post-Tx was SNP group #2 (n = 97 SNPs) for sample A and SNP group 
#1 (n = 32 SNPs) for sample B. This could be tentatively explained by the fact that a 
higher sample size (i.e., sample A) is necessary to demonstrate the association with 
larger set of SNPs (i.e., SNP group #2). Finally, only the SNP group #1 was associated 
with BMI change over time in both samples A and B. 
In samples A and B, the mean of weight gain after one year post-Tx is 3.5% and 
6.3%, respectively, i.e. much lower than the 10% mean value described in the litera-
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ture.15 It should be noted that a solid consensus does not exist yet regarding weight 
gain after the first year post-Tx; a mean of 10% has been described but a range from 
3.5 kg to 10 kg as well. A weight gain of 10 kg over the first year following kidney12,13,53 
liver14 and cardiac10 Tx as described in some studies would correspond to an increase 
of 14% of weight in our samples (considering a mean baseline weight in sample A and 
B of 71 kg and 69.5 kg, respectively) which would be much higher than the weight gain 
mean in our samples. 
Some limitations of the present study should be acknowledged. These results 
can only be extrapolated to Caucasians. We could not obtain all genotypes, in particu-
lar those from the SNP group#3 and possible co-medications influencing weight in ad-
dition to the immunosuppressant treatment were not reported and/or considered. Final-
ly, sample B size was small and other replication in larger cohorts should be tested. 
However, both samples were obtained from naturalistic setting studies, which should 
represent the real cases in clinical practice. Further studies should analyze whether 
graft rejection in less than one year would influence weight gain (out of the scope of the 
present study). Also, further analysis stratified by type of Tx organ should be conduct-
ed, as weight gain may differ depending on this factor as recently described.54 
5.6 Conclusion 
To conclude, this is the first study evaluating extensively the association of w-GRS with 
BMI and the influence of clinical and genetic components on ≥10% weight gain over 
the first year post-Tx. The results obtained in the present study, showed the im-
portance of integrating genetic factors in the final model, since they contain predictive 
information on ≥10% weight gain. Genetics of obesity among Tx recipients remains an 
important issue and will definitely contribute towards treatment personalizing and pre-
diction improvement of weight gain in these populations by identifying at risk-
individuals. 
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6.1 Abstract 
Weight gain after liver transplantation (LTx) facilitates development of new-onset obesi-
ty; however, the risk factors and outcomes of post-LTx new-onset obesity are poorly 
understood. This study aimed to identify the impact of new-onset obesity on cardiovas-
cular events (CVEs) and patient survival, and to identify its risk factors. Using the pro-
spective Swiss Transplant Cohort Study’s sociodemographic, behavioral, biomedical, 
psychological and genetic data we tested possible risk factors for post-LTx new-onset 
obesity. Using multiple Cox regression models, we examined risk factors for CVEs, 
patient survival and new-onset obesity in 253 adults (mean age 52.2 ± 11.6 years, 
male gender 63.6%, mean follow up 5.7 ± 2.1years). During follow-up, cumulative inci-
dence of CVE was 28.1%; that of new-onset obesity was 21.3%. In multivariable anal-
ysis, regardless of CVE status at LTx, risk factors identified for post-LTx CVEs were 
new-onset obesity (Hazard Ratio (HR) 2.95; 95% confidence interval (CI), 1.47-5.95; p 
= 0.002) and higher age at LTx (HR, 1.05; 95% CI, 1.02-1.08; p < 0.001). In patients 
with no pre-transplantation CVEs (n = 214), risk factors for post-LTx CVEs included 
new-onset obesity (HR, 2.59; 95% CI, 1.21-5.53; p = 0.014) and higher age (HR, 1.04; 
95% CI, 1.02-1.07; p = 0.001). Survival was not associated with new-onset obesity 
(HR, 0.84; 95% CI, 0.34-2.04; p = 0.696). Independent predictors of new-onset obesity 
were male gender (HR, 0.39; 95% CI, 0.16-0.93; p=0.034) and alcoholic liver disease 
(HR, 3.37; 95% CI, 1.17-9.71; p = 0.025). In a subsample of patients with available 
genetic data, (n = 114), male gender (HR, 0.26; 95% CI, 0.076-0.889; p = 0.032) and 
genetic risk score (HR, 21.83; 95% CI, 1.50-317.64; p = 0.024) predicted new-onset 
obesity. In conclusion, as post-LTx new-onset obesity predicted CVEs, early introduc-
tion of post-LTx weight management programs may suggest a potential pathway to 
reduce CVE risk. 
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6.2 Background 
Following liver transplantation (LTx), weight gain is common. Studies from diverse ge-
ographical regions describe mean weight gain of 2–9 kg within the first year after 
transplantation.1-4 After one year post-LTx, weight gain slows, but typically continues, 
leading to a new-onset obesity incidence of 22% at 2 years1,2 and up to 38% at 3 years 
post-LTx.3,4 
Long-term post-LTx survival is affected by the development of metabolic and 
cardiovascular comorbidities,5-7 as they increase the risk of death due to cardiovascular 
events (CVEs).8,9 However, evidence regarding the impact of post-LTx obesity on CVE 
is scarce.10 Albeldawi et al. found patients with obesity at 1 year post-LTx more likely to 
experience CVEs compared to their non-obese counterparts (49% versus 35%, p = 
0.06).11 However, as the authors did not differentiate between patients who were con-
sistently obese over the course of LTx and those who became obese only after LTx, 
the impact of new-onset obesity on CVE remains unclear. Additionally, their cross-
sectional study design precluded causal inferences. As CVEs also develop over the 
long-term post-LTx trajectory,9,10,12,13 post-LTx body weight parameters should be con-
sidered as influencing factors. 
The complex mechanisms leading to weight gain and subsequent obesity are 
driven by an interplay of genetic, physiological, behavioral, and environmental 
factors.14,15 Still, despite frequent reports of weight gain and development of new-onset 
obesity after LTx, few studies have examined risk factors in this specific population. 
Multivariate analysis of independent factors shows that several, i.e., higher recipient 
and donor BMI at LTx, being married, and absence of post-LTx rejection, predicted 
new-onset obesity at 2 years post-LTx. Univariate analysis showed that factors associ-
ated with new-onset obesity were older age, former smoking, family history of over-
weight, pre-LTx diabetes, dialysis in the week before LTx, and higher Model for End-
Stage Liver Disease (MELD) scores at LTx.1,2,16 Another study, not differentiating be-
tween new-onset and continuing obesity, found that age, pre-LTx BMI, and post-LTx 
diabetes predicted obesity at 1 year post-LTx.12 Understanding factors contributing to 
new-onset obesity in LTx, building on current evidence and including new types of po-
tentially modifiable but unstudied factors would provide a much-needed evidence base 
to identify intervention leverage points. 
The open, nationwide Swiss Transplant Cohort Study (STCS) provides a re-
search framework to assess new-onset obesity, its consequences, and risk factors. Its 
prospective pre- and post-transplant data collection allows the capture and examina-
tion of time-dependent events such as CVE. It also includes a set of sociodemograph-
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ic, behavioral, biomedical, psychological, and genetic variables, allowing assessment 
of the broadest range of potential risk factors for new-onset obesity assessed to date. 
The aims of the current study were therefore to examine the impact of new-onset obe-
sity on CVE (primary outcome) and patient survival (secondary outcome) as well as to 
determine risk factors for the development of new-onset obesity after LTx. 
Materials and Methods 
Design, sample and setting 
Since May 2008, the STCS has enrolled LTx patients from 3 Swiss transplant centers. 
Data are collected at LTx, 6- and 12-months post-LTx, then yearly thereafter. Inclusion 
criteria for this analysis were: receiving a first and solitary LTx between May 5, 2008 
and May 31, 2012, age ≥18 years, and available data about weight and height at time 
of LTx. Patients who were obese at LTx but lost weight after LTx and were therefore 
categorized as non-obese in at least the first post-LTx measurement (at 6 months) 
were included. This procedure was chosen because weight at LTx could not be cor-
rected for possible fluid overload, e.g., ascites, which might have led to a false high 
assessment of obesity at LTx. Patients with obesity at LTx who remained continuously 
obese after LTx were excluded. Patients who did not have at least 1 post-LTx meas-
urement at 6 months because of death or re-transplantation were also excluded. 
Variables and Measurement 
The STCS dataset includes clinical and genetic data as well as sociodemographic, 
psychosocial, behavioral and quality of life variables. The latter factors are assessed 
via the STCS Psychosocial Questionnaire (PSQ). More information about the STCS 
methodology is provided elsewhere.17,18 The STCS was approved by all relevant Swiss 
cantonal ethics committees. 
Body weight parameters 
BMI was calculated as weight in kg divided by the square of height in meters and cate-
gorized as follows: underweight <18.5 kg/m2, normal weight 18.5-24.9 kg/m2, over-
weight 25-29.9 kg/m2, obesity ≥30 kg/m2, obesity class I 30-34.9 kg/m2, obesity class II 
34.9-40 kg/m2, and obesity class III ≥40 kg/m2.19 Weight changes over time were exam-
ined in relation to the measurement at LTx. New-onset obesity was defined at the first 
assessment of BMI ≥30 kg/m2 in the post-LTx follow up. Once categorized as new-
onset obese, patients remained in this group for further analysis. 
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Clinical outcomes 
The primary clinical outcome was any CVE during post-LTx follow-up. Consistent with 
the World Health Organization,20 the STCS defined CVE as including coronary heart 
disease, coronary heart disease event, cerebral vascular disease event, peripheral 
vascular disease, peripheral vascular disease event, left ventricular dysfunction, pul-
monary embolism or venous thrombosis, and others (e.g., myocardial infarction, circu-
latory failure). The first occurrence of post-LTx CVE was considered for analysis. The 
secondary outcome was patient survival. Patients without death were censored to the 
last known assessment date or the date of data extraction from the database (January 
17, 2017). 
Risk factors for new-onset obesity 
We assessed sociodemographic, behavioral biomedical, psychological, and genetic 
variables as potential risk factors for new-onset obesity. Variables were assigned to the 
categories of our theoretical framework (Figure 1), which was developed based on pre-
vious evidence.14,15 
 
 
 
 
 
 
 
 
 
 
 
 
 
LTx: liver transplantation, MELD: Model for End-Stage Liver Disease, STCS: Swiss Transplant 
Cohort Study 
Figure 1.  Framework of factors influencing post-LTx weight gain included in this study. 
Source: Own Illustration. 
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The baseline STCS PSQ is usually distributed at time of LTx listing. Given that the me-
dian waiting list time in Switzerland ranged from 204 to 319 days across the previous 5 
years,21 selected PSQ variables at 6 months post-LTx were considered more appropri-
ate for examination in relation to post-LTx body weight parameters. 
Sociodemographic factors were: age (years), gender (male/female), ethnicity 
(Caucasian/African/Asian/other), marital status (living alone/partnership), level of edu-
cation (<9 years, 10 – 13 years, >14 years), and monthly income in Swiss Francs at 
LTx (<4500, 4501 – 6000, >6001). Working capacity was assessed at 6 months post-
LTx (0%, 1 – 50%, >51%). 
The behavioral factor was smoking, evaluated at LTx with the question “Do you 
smoke?” with the answer options yes/no.22 
Biomedical factors were: type of organ donor (deceased/living), etiology of liver 
disease (viral hepatitis/alcoholic liver disease/hepatocellular carcinoma/nonalcoholic 
steatohepatitis/other), MELD score (calculated at LTx as raw laboratory MELD without 
exception points), presence of comorbidities (chronic kidney disease/diabetes mellitus) 
at LTx, and type of immunosuppressive medication at 6 months post-LTx (most com-
monly used drugs and combined regimen). Perceived health status at 6 months post-
LTx was assessed by the EQ-5D in view of mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression.23 For our analysis, we dichotomized each dimen-
sion’s answer categories as: no problem/problems (i.e., some problems or extreme 
problems). On the EQ-visual analogue scale, patients self-rated their health between 0 
(worst imaginable health state) and 100 (best imaginable health state), which was 
treated as continuous variable. 
The psychosocial variable assessed was depressive symptomatology at 6 
months post-LTx, measured via a 7-item subscale from the Hospital Anxiety and De-
pression Scale, a self-report non-diagnostic screening instrument integrated in the 
PSQ.24 Each of the 7 items was answered on a 4-point Likert scale from 0 (not at all) to 
3 (most of the time) and summed up (range 0 to 21). The presence of depressive 
symptomatology was noted if the calculated score was ≥8.25 
Genetic factor: Genetic data were available in 1100 STCS patients with Cauca-
sian origin. The generation of the genetic risk score was based on 97 single nucleotide 
polymorphisms (SNPs), associated with BMI in a recent genome-wide association 
study in the general population.26 For each SNP, genotypes in our sample were coded 
as 0, 1 or 2, depending on the number of specific BMI risk alleles. The additive number 
of alleles corresponds to an unweighted genetic score. But as the effect on BMI differs 
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among SNPs, each SNP was weighted for its relative effect size by the β-coefficient as 
mentioned in the genome-wide association study.26 The weighted genetic risk score 
has been used previously in an STCS sample; more detailed information on the calcu-
lation have been described elsewhere.27-29 
Data analysis 
Patient characteristics and weight changes were described using frequency and per-
centage, mean and standard deviation (SD) as appropriate for the data measurement 
level and distribution. The mean weight change over time in relation to LTx was shown 
graphically. 
Multiple Cox regression models examined the risk factors for new-onset obesity 
in 2 patient groupings: those who became obese and those who did not. Manual back-
ward elimination was used to purge the model to only its significant predictors. The 
same method was used to test new-onset obesity’s relationships with patient survival 
and CVE outcomes. 
In the model examining CVE, new-onset obesity was entered as a time-
dependent variable. The following covariates were included: age at LTx, gender, smok-
ing at LTx, diabetes at LTx, etiology, tacrolimus, cyclosporine and cortisone at 6 
months, income and CVE at time of LTx. As cardiovascular disease is a chronic and 
progressive process,30 some patients had already been assessed with CVE at LTx. We 
therefore performed two analyses to examine the link between new-onset obesity and 
CVE: First, we considered all patients irrespective of their CVE status at LTx. Second, 
we only considered patients without CVE at LTx. Statistical analyses were conducted 
using IBM SPSS Version 23 and SAS version 9.4 software. A two-tailed p-value <.05 
was considered statistically significant. 
5.3 Results 
Patient characteristics 
Of 3315 solid organ transplant recipients in the STCS dataset, 253 LTx patients met 
our inclusion criteria and were analyzed (Figure 2). Sample characteristics are pre-
sented in Table 1. 
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STCS, Swiss Transplant Cohort Study; Tx, transplantation; LTx, liver transplantation 
Figure 2.  Flowchart of the sample 
Source: Own Illustration. 
 
 
 
 
Variables valid 
n 
Total 
group 
valid 
n 
New-onset 
obesity 
valid 
n 
No 
new-onset 
obesity 
Body weight parameters       
New-onset obesity, n (%)	 	 	 54	 21.3%	 199	 78.7%	
Weight at LTx        
  mean ± SD 253 75.5 ± 15 54 84.3 ± 13.4 199 70.6 ±14 
Weight at 6 months       
  mean ± SD 225 68 ± 12.6 49 78 ± 11.1 176 65.4 ±11.7 
BMI at LTx       
  mean ± SD 253 24.9 ± 3.9 54 28.1 ± 3.6 199 24 ± 3.5 
BMI at 6 months       
  mean ± SD 225 23.1 ± 3.2 49 26 ± 2.5 176 22.3 ± 2.9 
BMI category at LTx*       
  Underweight; n (%) 253 9 (3.6) 54 0 (0) 199 9 (4.5) 
  Normal weight; n (%) 253 137 (54.2) 54 9 (16.7) 199 128 (64.3) 
  Overweight; n (%) 253 77 (30.4) 54 30 (55.6) 199 47 (23.6) 
  Obesity; n (%) 253 30 (11.9) 54 15 (27.8) 199 15 (7.5) 
Patients in STCS dataset n = 3315 
Exclusion because of: 
• Re-Tx: n = 437 
• Multiple Tx: n = 256 
• Age <18: n = 144 
• Not kidney, heart, liver or lung Tx: n = 12 
• No data on weight or height at Tx: n = 72 
• Tx after 01.06.2012: n = 1035 
• Kidney, heart or lung Tx: n = 1064 
 
 
LTx patients n = 295 
Exclusion because of: 
• No 6 month measurement because of 
death or re-LTx: n = 24 
• Obesity at pre-LTx and continuously after 
LTx: n = 18  
 
LTx patients n = 253 
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BMI category at 6 months*       
  Underweight; n (%) 225 18 (8.0) 49 0 (0) 176 18 (10.2) 
  Normal weight; n (%) 225 138 (61.3) 49 15 (30.6) 176 123 (69.9) 
  Overweight; n (%) 225 69 (30.7) 49 34 (69.4) 176 35 (19.9) 
Clinical outcomes       
  CVE at LTx; n (%) 253 39 (15.4) 54 8 (14.8) 199 31 (15.6) 
  CVE after LTx; n (%) 253 71 (28.1) 54 25 (46.3) 199 46 (23.1) 
  Death until end of follow up; n (%)  253 52 (20.6) 54 6 (11.1) 199 46 (23.1) 
  Re-LTx later than 6 months; n (%) 253 9 (3.6) 54 0 (0) 199 9 (4.5) 
  Rejection episode after LTx; n (%) 253 125 (49.4) 54 18 (33.3) 199 107 (53.8) 
  Follow up, mean ± SD 253 5.7 ± 2.1 54 6.4 ± 1.5 199 5.5 ± 2.2 
Sociodemographic risk factors       
Age in years at Tx       
  mean ± SD 253 52.2 ± 11.6 54 54.9 ± 9 199 51.5 ± 12.1 
Sex        
  Male; n (%) 253 161 (63.6) 54 44 (81.5) 199 117 (58.8) 
Ethnicity        
  Caucasian; n (%) 253 240 (94.9) 54 52 (96.3) 199 188 (94.5) 
  African; n (%) 253 7 (2.8) 54 1 (1.9) 199 6 (3) 
  Asian; n (%) 253 6 (2.4) 54 1 (1.9) 199 5 (2.5) 
Marital status at LTx       
  Living alone; n (%) 218 68 (31.2) 48 15 (31.3) 170 53 (31.2) 
  Living in a partnership; n (%) 218 150 (68.8) 48 33 (68.8) 170 117 (68.8) 
Level of education at LTx       
  ≤ 9 years; n (%) 243 66 (27.2) 53 15 (28.3) 190 51 (26.8) 
  10 to 13 years; n (%) 243 108 (44.4) 53 26 (49.1) 190 81 (43.2) 
  ≥ 14 years; n (%) 243 69 (28.4) 53 12 (22.6) 190 57 (30) 
Working capacity at 6 months       
  0%; n (%) 206 135 (65.5) 44 35 (79.5) 162 100 (61.7) 
  1 to 50%; n (%) 206 29 (14.1) 44 4 (9.1) 162 25 (15.4) 
  > 50%; n (%) 206 42 (20.4) 44 5 (11.4) 162 37 (22.8) 
Income at LTx       
  < 4500 CHF; n (%) 184 85 (46.2) 42 21 (50) 142 64 (45.1) 
  4501 - 6000 CHF; n (%) 184 45 (24.5) 42 14 (33.3) 142 31 (21.8) 
  > 6000 CHF; n (%) 184 54 (29.3) 42 7 (16.7) 142 47 (33.1) 
Behavioral risk factors       
Smoking at LTx       
  Smoker; n (%) 219 61 (27.9) 48 13 (27.1) 171 48 (28.1) 
  Non-Smoker; n (%) 219 158 (72.1) 48 35 (72.9) 171 123 (71.9) 
Biomedical risk factors       
Donor type       
  Deceased donor; n (%) 253 235 (92.9) 54 53 (98.1) 199 182 (91.5) 
Etiology       
  Viral hepatitis; n (%) 253 89 (35.2) 54 15 (27.8) 199 74 (37.2) 
  Alcoholic liver disease; n (%) 253 57 (22.5) 54 20 (37) 199 37 (18.6) 
  Hepatocellular carcinoma; n (%) 253 22 (8.7) 54 8 (14.8) 199 14 (7) 
  Nonalcoholic steatohepatitis; n (%) 253 7 (2.8) 54 3 (5.6) 199 4 (2) 
  Other; n (%)  253 78 (30.8) 54 8 (14.8) 199 70 (35.2) 
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Severity of disease - MELD       
 mean ± SD 253 18 ± 10.4 54 17.1 ± 8.8 199 18.4 ±10.8 
Comorbidities        
 Chronic Kidney Disease at LTx; n(%) 253 53 (20.9) 54 9 (16.7) 199 44 (22.1) 
 Diabetes Mellitus at LTx; n (%) 253 52 (20.6) 54 16 (29.6) 199 36 (18.1) 
Immunosuppressive drugs at 6 
months       
  Cyclosporine; n (%) 253 53 (20.9) 54 14 (25.9) 199 39 (19.6) 
  Tacrolimus; n (%) 253 140 (55.3) 54 29 (53.7) 199 111 (55.8) 
  Cortisone; n (%)  253 94 (37.2) 54 14 (25.9) 199 80 (40.2) 
  Cortisone and Cyclosporine; n (%) 253 21 (8.3) 54 3 (5.6) 199 18 (9.0) 
  Cortisone and Tacrolimus; n (%) 253 60 (23.7) 54 10 (18.5) 199 50 (25.1) 
Perceived Health Status at 6 
months       
  Mobility problems; n (%) 211 71(33.6) 48 13 (27.1) 163 58 (35.6) 
  Self-care problems; n (%) 212 17 (8.0) 48 5 (10.4) 164 12 (7.3) 
  Activity problems; n (%) 209 102 (48.8) 47 18 (38.3) 162 84 (51.9) 
  Pain problems; n (%) 208 130 (62.5) 47 29 (61.7) 161 101 (62.7) 
  Anxiety problems; n (%) 210 80 (38.1) 46 13 (28.3) 164 67 (40.9) 
  EQ-VAS; mean ± SD  209 69.6 ± 19.2 48 72.6 ± 18 161 68.7 ± 19.5 
Psychological risk factors        
  Depression at 6 months; n (%) 214 34 (15.9) 48 5 (10.4) 166 29 (17.5) 
Genetic risk factor       
 Genetic Risk Score, mean ± SD 114 2.15 ± 0.16 29 2.18 ± 0.14 85 2.14 ± 0.17 
LTx, liver transplantation; BMI, body mass index; SD, standard deviation; MELD, Model for End-
Stage Liver Disease; VAS, visual analogue scale 
Table 1. Clinical patient characteristics and risk factor variables. 
Source: Own Illustration. 
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New-onset obesity after LTx 
The cumulative incidence of new-onset obesity during post-LTx follow up was 21.3% (n 
= 54, Figure 3A). With one exception, all patients were categorized as obesity class I 
(BMI 30-34.9 kg/m2). Therefore, we did not distinguish between obesity classes. 
 
A B 
  
LTx: liver transplantation; CVE: cardiovascular event, mo: months, y: year 
Figure 3.  Cumulative incidence of new-onset obesity and CVE in LTx patients 
Source: Own Illustration. 
 
 
 
 
 
 
 
 
 
 
 
Numbers at risk 6 mo 1y 2y 3y 4y 5y 6y 7y 8y 
Patients, n 225 221 193 170 178 149 102 61 24 
New-onset obesity, n 0 12 25 35 42 49 54 54 54 
CVE after LTx, n 23 36 39 45 53 57 64 67 71 
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Overall, both groups, with and without new-onset obesity, lost weight from LTx to 6 
months post-LTx and gained weight afterwards (see Figure 4). Those who became 
obese had their highest proportional weight gain between 6 months and 2 years post-
LTx. 
 
 
6 mo 12 mo 24 mo 36 mo 48 mo 60 mo 72 mo 84 mo 96 mo 
Total, n  225 221 193 170 178 149 102 61 24 
New-onset 
obesity, valid n 49 51 50 43 43 39 29 16 7 
weight change 
(kg),  
mean ± SD 
-6.3 ± 
9.8 
-0.9 ± 
10.7 
3.2 ± 
10.6 
4.3 ± 
13.3 
6.3 ± 
13.2 
7.1 ± 
11.0 
9.6 ± 
12.3 
7.8 ± 
15.6 
15.1 ± 
17.3 
 No new-onset 
obesity, valid n 176 170 143 127 135 110 73 45 17 
weight change 
(kg),  
mean ± SD 
-5.2 ± 
7.9 
-3.9 ± 
8.9 
-3.1 ± 
9.1 
-1.8 ± 
9.8 
-1.0 ± 
9.3 
-0.4 ± 
9.6 
0.4 ± 
10.2 
-0.1 ± 
10.3 
-0.4 ± 
12.2 
LTx, liver transplantation; SD, standard deviation; mo, months 
Figure 4.  Mean weight change compared to LTx in patients with or without new-onset obesity. 
Mean weight changes in kg were calculated as difference between each measure-
ment point and the weight at LTx. 
Source: Own Illustration. 
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Of the 54 patients who developed new-onset obesity, 15 were obese at LTx. Those 
patients lost weight early after LTx and had fallen below the obesity threshold, shifting 
to overweight (n = 13) or normal weight (n = 2). The majority (n = 8) developed new-
onset obesity by 2 or 3 years post-LTx. The evolution of their BMI over time is shown in 
Figure 5. 
 
LTx, liver transplantation; BMI, body mass index 
Figure 5.  Evolution of the BMI in 15 patients, who were obese at LTx and developed new-
onset obesity after a period of being overweight or normal weight. The dashed hori-
zontal lines represent the cutoffs for overweight (BMI ≥25kg/m2) and obesity (≥30 
kg/m2). 
Source: Own Illustration. 
 
CVE and patient survival 
In the total cohort, 71 patients (28.1%) had a CVE during follow-up, mostly within the 
first year post-LTx (Figure 3B). Patients with new-onset obesity had a greater incidence 
of CVE than those without (46.3% versus 23.1%). Between 6 months and end of follow 
up, 52 patients (20.6%) died. The group of patients who did not become obese had a 
higher mortality compared to those who developed new-onset obesity (23.1% 
vs.11.1%). 
Impact of new-onset obesity on patient outcomes 
The multivariable analysis identified the following independent risk factors for CVE: 
new-onset obesity (Hazard Ratio (HR) 2.95; 95% Confidence Interval (CI) 1.47-5.95; p 
= 0.002) and higher age (HR 1.05; 95% CI 1.02-1.08; p < 0.001). In the sensitivity 
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analysis, using a sample of 214 patients without CVE at LTx, new-onset obesity (HR, 
2.59; 95% CI, 1.21-5.53; p = 0.014) and higher age (HR, 1.04; 95% CI, 1.02-1.07; p = 
0.001) remained predictors for CVE after LTx. However, new-onset obesity was not 
associated with increased mortality (HR, 0.84; 95% CI, 0.34-2.04; p = 0.696). 
Risk factors for new-onset obesity after LTx 
Given the complex mechanisms of weight gain and subsequent new-onset obesity, we 
intended to include risk factors from each of the framework’s categories in our analysis. 
As the low number of new-onset obesity events (n = 54) required a reduction of factors, 
the final selection of variables was based on evidence from the literature and availabil-
ity of relevant data in the STCS dataset: genetic risk score, age at LTx, gender, smok-
ing at LTx, etiology, use of tacrolimus, cyclosporine and cortisone at 6 months, and 
income at LTx. Independent risk factors for new onset obesity were male gender (HR, 
0.26; 95% CI, 0.076-0.889; p = 0.032) and genetic risk score (HR, 21.83; 95% CI, 1.50-
317.64; p = 0.024). Given the limited sample of 114 patients for whom the genetic risk 
score was available and the broad confidence intervals observed, we performed an-
other analysis excluding the genetic risk score. In this model, male gender (HR, 0.39; 
95% CI, 0.162-0.930; p = 0.034) and alcoholic liver disease were independent predic-
tors for new-onset obesity (HR, 3.37; 95% CI, 1.17-9.71; p = 0.025). 
6.4 Discussion 
Weight gain and obesity are well-known health issues in LTx recipients.31 This analysis 
of a nationwide prospective transplant cohort study contributes to our understanding of 
both, the impact of new-onset obesity on clinical outcomes and of new-onset obesity’s 
risk factors. After nearly 6 years of follow-up, the cumulative incidence of new-onset 
obesity was 21.3%, which is comparable to studies with shorter follow-up from the 
United States (21.6% at 2 years),2 Brazil (23.7% at 3 years),1 and the United Kingdom 
(26.3% at 3 years).3 Male gender, etiology of alcoholic liver disease and genetic risk 
score were independent predictors for new-onset obesity. From transplantation until 
end of follow up, CVE occurred in nearly one-third of recipients. Independent of the 
presence of CVE at LTx, patients with new-onset obesity had a nearly 3-fold higher risk 
for CVE. New-onset obesity was not associated with increased mortality. 
Impact of new-onset obesity on outcomes 
Our analyses revealed mixed results regarding the impact of new-onset obesity on the 
two examined patient outcomes. Our sample’s CVE incidence was within the range of 
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CVE later than 6 months after liver Tx reported by a systematic review (mean 11.8%; 
range 0% to 31.4%).10 To the best of our knowledge, this study was the first to show 
that new-onset obesity predicts CVE after LTx. Fussner et al.12 also studied post-LTx 
body weight parameters in a single center cohort of 455 LTx patients. In that study, 
nearly 30% of recipients experienced a CVE after 8–12 years of follow-up. Post-LTx 
BMI change, defined as a change of at least 1 BMI point in relation to the BMI at 4 
months post-LTx, was not associated with CVE. A recent systematic literature review 
aimed to identify risk factors for CVE after LTx (e.g., individual cardiac events or com-
bined outcomes, e.g., coronary artery disease, myocardial ischemia, heart failure, ar-
rhythmias).10 Of the 29 studies retrieved, only 3 examined post-LTx body weight pa-
rameters. Via multivariate analyses, none found any association between BMI at 1 year 
post-LTx and CVE. 
To date, very few studies have examined post-LTx body weight parameters (i.e., 
post-LTx BMI or BMI change) in relation to CVE after LTx. This is rather surprising as 
CVE is a common post-LTx complication, increasing the mortality risk.8,9 In light of the 
existing literature, which has showed no relationship between post-LTx body weight 
parameters and CVE, our finding in a prospective cohort is novel. We excluded pa-
tients who were continuously obese from pre- to post-LTx, meaning at least between 
LTx and the first measurement at 6 months post-LTx, all patients were under-, normal-, 
or overweight. The operationalization of new-onset obesity and the results of our anal-
yses emphasize the need of weight gain prevention to avoid new-onset obesity. If the 
prevention of new-onset obesity might also have the potential to lower the risk of CVE 
will require further investigation. 
In multivariable analysis, new-onset obesity did not predict mortality. Moreover, 
the descriptive results actually showed lower mortality in those who became obese 
compared to those who did not (11% versus 23%). Data published in 2016 show that 
weight gain and obesity may actually convey a survival benefit. Using data from 2968 
patients with initial BMI values between 16 and 25 kg/m2, Martinez-Camacho et al. ex-
amined weight gain at 2 years post-LTx.16 Recipients who had gained weight (increase 
of >1 BMI point) showed significantly increased 5-year patient and graft survival com-
pared to those whose weight decreased (decline of >1 BMI point) or remained stable. 
Additionally, patients who became obese by 2 years post-LTx (4.7%) had significantly 
longer patient and graft survival compared to those whose BMIs remained stable. Alt-
hough the findings of this study support our observation, the methodology differed be-
tween the two studies. First, in that study, new-onset obesity was examined at 1 year 
post-LTx, while we analyzed it as a time-dependent event; second, the sample was 
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limited to patients with BMIs between 16 and 25 kg/m2. This was probably why that 
study showed a lower incidence of new-onset obesity compared to our result (4.7% 
versus 21.3%). However, this issue requires further examination, especially as the re-
sults in LTx contradict studies in the kidney transplant population, where weight gain 
and obesity at 1 year after transplant are associated with increased risks of cardiovas-
cular and all-cause mortality32-34 as well as graft failure.32-35 
Risk factors for new-onset obesity 
It is well established that genes contribute to obesity in the general population;26 and in 
the present study, the genetic risk score predicted new-onset obesity. Unfortunately, as 
the genetic risk score was only available in a subsample of the patients, the power of 
our analysis was limited. However, another STCS study examined two samples of kid-
ney, liver, heart, lung and multi-organ transplant patients (total n = 1151), showing that 
the genetic risk score predicted 10% of weight gain in the first year after transplant.29 
The authors also found that the multivariable models with genetic variables better pre-
dicted weight gain compared to those with none. 
To date, evidence on the impact of genes on body weight parameters in the 
transplant population is scarce. Of the few studies to examine candidate genes or 
SNPs, though, all found significant associations between the genetic variables and 
increased risk for weight gain and obesity after liver36,37 and kidney transplant.38 
While the results from candidate gene studies can be used to identify patients at 
risk of weight gain after transplantation, the clinical interpretation of a genetic risk score 
is limited, as it is calculated as the mean of BMI risk alleles. However, given that weight 
gain is driven by a complex interplay of factors, these results highlight the importance 
of incorporating genes in studies examining weight gain and obesity. 
Another predictor for new-onset obesity indicated in our sample but not in previ-
ous research was male gender. Interestingly, in the general population, the global 
prevalence of obesity is higher in women than in men.39 Despite the multitude of factors 
contributing to weight gain, gender specific risk factors such as hormones, menopause, 
and pregnancy place women at higher risk of developing obesity.40 The reason why 
males were more likely than women to become obese following LTx remains unclear. 
However, the likelihood for males to gain rather than lose weight has also been shown 
in a large database study comparing male and female recipients with BMI changes 
after LTx.16 In that study, 65% of patients who gained weight, and 56% of those who 
lost weight by 2 years post-LTx were male. 
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Our indication that alcoholic liver disease is a risk factor for new-onset obesity is 
also novel. Previous research showed a nearly 4-fold higher risk for post-LTx metabolic 
syndrome in patients with pre-Tx alcohol disorder;41 however the mechanism driving 
this remains unclear. Brunault et al. hypothesized that LTx patients with previous alco-
hol use disorder switch from alcohol addiction to food addiction, leading to their higher 
post-Tx prevalence of obesity and metabolic syndrome.42 This issue however, warrants 
further investigation. 
While the present study showed meaningful and partly novel results, some limi-
tations should be mentioned. First, physical activity is an important variable regarding 
weight gain and obesity. However, as it has only been measured in the STCS since 
2012, too many data were missing to include it. Therefore, two EQ-5D dimensions–
mobility and usual activity–were considered as proxies for activity level at 6 months 
post-LTx, although these dimensions might not effectively reflect the behavior per-
formed. Second, we could not correct the weight and BMI at time of LTx for possible 
fluid overload (e.g., ascites). Therefore, we included patients with obesity at LTx only if 
they lost enough weight afterwards to shift them into a lower BMI category for at least 
the first measurement at 6 months post-LTx. It is likely that some of those patients did 
not have fluid overload at LTx but were obese because of increased fat mass. Third, 
we had no data on body weight parameters before liver disease was diagnosed. There-
fore, while an elevated BMI before liver disease has been shown to predict post-LTx 
weight gain,1 it could not be included as a covariate in our multivariate model. Finally, 
the risk factors included were measured at specific time points. As some risk factors 
(e.g., income, perceived health status) might be subject to change over the post-LTx 
course, future studies might consider them time-dependent variables. 
Future research is needed not only to better understand individual risk factors 
for weight gain and subsequent obesity, e.g., genetic factors, gender and alcoholic liver 
disease, but also to identify interrelationships and combined effects based on the inter-
play of those risk factors. Healthcare professionals in follow-up care should consider 
that new-onset obesity gradually increases over time. Therefore, to prevent the devel-
opment of new-onset obesity, patients who are normal weight or overweight after LTx, 
males and those transplanted because of alcoholic liver disease should be subject to 
long-term weight gain monitoring after LTx. Although older patients and those who be-
came obese were at higher risk for CVE, prevention of CVE should be considered in all 
LTx recipients as adherence to a healthy lifestyle (diet, physical activity and non-
smoking) has the potential to prevent 80% of CVE.30 
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Conclusion 
In conclusion, post-LTx new-onset obesity had an incidence of 21.3% in our sample, 
and was predicted by the genetic risk score, male gender and alcoholic liver disease. 
However, it was not associated with patient survival. Independent of a history of pre-
LTx CVE, both new-onset obesity and older age predicted CVE after LTx. Therefore, 
prevention of weight gain and new-onset obesity via a weight management program 
early after LTx might reduce the risk for CVE. 
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Weight gain is in itself a hugely complex issue that demands an appropriately creative 
solution.1 When it leads to obesity, the problem becomes what Finegood et al. labeled 
“wicked”: it is easily perceived as policy resistant and has no clearly described single 
true solution.1 While numerous approaches exist to tackle obesity, evidence suggests 
that interventions are most effective if they follow three basic guidelines: (a) target the 
individual instead of a larger population, because policy changes do not sufficiently 
support behavior change;2,3 (b) focus on the prevention of weight gain instead of weight 
loss, because weight loss maintenance is far more challenging;4-7 and (c) integrate 
multiple components, including physical activity, advice for healthy eating and promo-
tion of behavior change.8-10 Therefore, regarding intervention development, no one-
size-fits-all solution exists.4,5 A tailored approach, considering personal, behavioral and 
contextual factors, is recommended.8-10 
The results of the studies conducted under the BALANCE project increased our 
understanding of the target population and to some extent of energy balance-related 
behaviors. This is the crucial first step of behavioral intervention development following 
the COM-B model and the behavior change wheel. The following section provides a 
theoretical introduction about the COM-B model and the behavior change wheel, then 
follows the three stages of the behavior change wheel, leading finally to the suggestion 
of the BALANCE intervention in the liver Tx population. 
7.1 The COM-B model and the behavior change wheel 
Harmful behaviors such as unhealthy eating and physical inactivity are major drivers of 
weight gain and the development of obesity. However, behavior change is challenging 
and requires careful consideration not only of the individual but of the social, economic 
and political context in which the behavior occurs.11 Also, before behavior change can 
be tackled via interventions, a profound knowledge of the target behavior is crucial.11,12 
Therefore, the application of theoretical models is a key factor in the development of 
weight-reduction interventions. 
A variety of frameworks can be used to explain behavior and view it in the con-
text of variables such as beliefs, norms, attitudes, skills, preferences, experiences or 
barriers.13 One particularly useful framework is the COM-B model (Figure 1).14 “COM-
B” stands for Capability, Opportunity, Motivation, and Behavior. Each of these compo-
nents can be divided into two types: capability can be physical (strength/skills) or psy-
chological (knowledge/skills), motivation can be reflective (conscious planning) or au-
tomatic (desire/impulse), and opportunity can be physical (environmental re-
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sources/facilitators) or social (cues/norms). In Figure 1, which depicts the theoretical 
model, the double-ended arrows indicate interactions among the determinants and the 
behavior. 
 
Figure 1.  The COM-B model.  
Source: Illustration from: Michie S, Artkins L, West R. The behaviour change wheel. 
A guide to designing interventions. Great Britain: Silverback Publishing; 2014. 
 
The COM-B model is the core of the behavior change wheel, an intervention design 
tool derived from 19 behavior change frameworks identified in a systematic literature 
review (Figure 2).14 While the COM-B serves as an explanatory model by characteriz-
ing the sources of behavior, the behavior change wheel guides the systematic devel-
opment and evaluation of a behavioral intervention. It can be applied at any level from 
the individual to groups or populations; and, acknowledging the complexity of real 
world problems, its systematic step-by-step approach forces the intervention developer 
to think on multiple levels, e.g., from individual-, social- and system-level perspectives. 
In the behavior change wheel, the COM-B model is surrounded by 2 outer lay-
ers: intervention functions and policy categories.12,14 As behavior change tools, the 9 
intervention functions can be combined as appropriate, i.e., an intervention may in-
clude multiple functions. The 7 policy categories support the delivery of the chosen 
intervention functions. All three layers of the wheel are closely interlinked via empirical 
evidence from the literature.12,14 
Suggested by Michie et al., behavior change techniques are important additions 
to the behavior change wheel.15 Though not depicted in Figure 2, these are integral to 
the intervention functions.12 As the smallest active intervention components, behavior 
change techniques are by definition observable, replicable and irreducible, and are 
usable alone or in combination. The behavior change technique taxonomy currently 
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provides 93 distinct techniques, grouped into 16 clusters (e.g., goals and planning, 
feedback and monitoring, social support). 
Some techniques have been more effective compared to others in supporting 
behavior change. They are summarized in separate taxonomies for specific behaviors, 
e.g., physical activity and healthy eating,16,17 smoking cessation,18,19 reduction of ex-
cessive alcohol consumption,20 or medication adherence.21,22 
 
Figure 2.  The behavior change wheel. 
Source: Illustration from: Michie S, Artkins L, West R. The behaviour change wheel. 
A guide to designing interventions. Great Britain: Silverback Publishing; 2014. 
7.2 The three stages of intervention development 
Michie et al. suggested a 3-stage process of behavioral intervention design12,14 (Figure 
3). The first stage involves understanding the behavior itself and the target population 
via a behavioral diagnosis. The second requires identification of intervention functions 
and policy categories that will be effective in relation to the target behavior(s). For the 
third level, the intervention developers select optimal content (behavior change tech-
niques) and decide on the delivery mode that best facilitates implementation. 
For all 3 stages, evidence from diverse sources and multiple perspectives, using 
a variety of methods, is needed to inform decisions. And for each, patients’ preferences 
and needs are at the center of the decision-making process. As related studies in the 
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liver Tx population can be scarce, evidence from other Tx groups may also be consid-
ered. 
 
Figure 3.  Designing an intervention by applying the behavior change wheel.  
Source: Illustration adapted from: Michie S, Artkins L, West R. The behaviour 
change wheel. A guide to designing interventions. Great Britain: Silverback Publish-
ing; 2014. 
 
Understand the behavior 
a) Define the problem in behavioral terms 
The first step towards understanding the target problem is to examine and define its 
characteristics in behavioral terms within the target population. The evidence base for 
this step of intervention development has already been introduced and discussed in the 
previous sections of this dissertation. The following passage is an example of a prob-
lem statement: 
In conclusion, the definition of the problem in behavioral terms is as follows: 
Weight management behavior in liver Tx recipients who are normal weight or over-
weight at 6 months after liver Tx. 
b) Select the target behavior 
Target behaviors should be selected within the specific context in which they occur. 
Behaviors do not occur in isolation but they are part of interlinked systems. Depending 
on the importance of a target behavior, it might impact related behaviors via the so-
Stage 1: 
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called spillover effect (e.g., targeting healthy eating impacts shopping for fruits and 
vegetables, preparation of healthy food at home, and food choices in the workplace 
canteen). 
In the ongoing discussion of the obesity epidemic, reduced to its simplest pos-
sible form, the fundamental mechanism of weight change is an imbalance between 
calories consumed and calories expended.23 While it is important to acknowledge that 
increased intake of energy-dense foods and decreased physical activity are closely 
related to an obesogenic environment (e.g., easy access to high-fat, low-fiber foods, 
urban planning that discourages walking or cycling, workplace changes that minimize 
physical movement…),24 an understanding of relevant and modifiable behavioral fac-
tors is crucial to body weight management. This statement is supported by two studies 
in which liver Tx patients were asked about the reasons for their weight gain.25,26 
Among the most common causes mentioned were reduced physical activity (24% and 
36%), and increased food intake (48%). Energy balance related behaviors such as 
healthy eating and physical activity should therefore be considered core behaviors to 
prevent weight gain. 
Naturally, a healthy diet is recommended after liver Tx; however, for many graft 
recipients, current evidence suggests that adherence to dietary guidelines is a serious 
challenge. One longitudinal study found that the total energy intake (carbohydrates, fat 
and protein) at 3-, 6-, and 9 months after Tx was greater than pre-Tx.27 As an unfavor-
able development, the proportion of dietary fat increased from 35% to 40% after liver 
Tx–far more than the maximum of 10% recommended.28 However, at 9 months post-
Tx, fat intake was not associated with BMI.27 Unfortunately, the current European clini-
cal guidelines in liver Tx mention only dietary counseling to prevent weight gain and 
obesity, but recommend no specific content or other details.29 
Increased physical activity has been identified as an essential component of 
comprehensive lifestyle interventions to manage weight in the general population.3 
Physical activity can be differentiated according to the subject’s activity level and inten-
tion to perform the behavior. The American College of Sports provides the following 
definitions: “Physical activity refers to any bodily movement produced by skeletal mus-
cles that results in energy expenditure above resting levels. Physical activity broadly 
encompasses exercise, sports, and physical activities done as part of daily living, oc-
cupation, leisure, and active transportation. Exercise refers to physical activity that is 
planned, structured, and repetitive with the final or intermediate objective to improve or 
maintain physical fitness. Sedentary behavior is activity that involves little or no move-
ment or physical activity.”30 
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For healthy adults, national and international health organizations recommend 
performance of at least 30 minutes of moderate-intensity physical activity (working hard 
enough to break a sweat, but still able to carry on a conversation) five days per week, 
or 20 minutes of more vigorous activity three days per week.7,30,31 A combination of 
moderate- and vigorous- intensity activity is also possible. The same amount and in-
tensity of physical activity is recommended for older adults or people with chronic con-
ditions. However, the American College of Sports Medicine guidelines emphasize that 
if people “cannot perform 150 minutes of moderate-intensity aerobic activity per week 
because of chronic conditions, they should be as physically active as their abilities and 
conditions allow”.32 
In the liver Tx population, physical activity is linked to more health benefits than 
only weight gain prevention. For example, smaller studies have also found associations 
with increased muscle mass,33 increased functional capacity,34 decreased fat mass and 
blood lipids,33 fewer comorbidities and a higher quality of life.35 Moreover, lower exer-
cise intensity has been associated with the development of metabolic syndrome.36 A 
systematic review examined health outcomes of supervised exercise training programs 
reported in 15 randomized controlled trials in solid organ Tx recipients.37 In heart Tx 
patients, regular exercise improved exercise capacity compared to standard care. The 
authors were unable to examine long-term patient outcomes such as cardiovascular 
risk factors and survival because no included studies were adequately powered. 
Despite the beneficial effects of being active, physical inactivity is a serious is-
sue in the liver Tx population. Immediately following Tx, this might be related to the 
severity of disease, ongoing fatigue, and decreased functional capacity after hospital 
and intensive care stay.38-40 However, even in the long term, only 24% to 50% of liver 
Tx recipients engage in regular physical activity,41,42 with performance below recom-
mended levels.43,44 One study that measured activity levels among patients from differ-
ent BMI categories found that, compared to normal-weight patients, those who were 
overweight or obese were significantly less active.45 Within the BMI groups, most nota-
ble difference was found in vigorous activity, with the highest levels reported in normal 
weight and lowest levels in obese patients.45 Interestingly, though, total physical activity 
was associated with neither post-Tx obesity46 nor BMI.47 
Overall, research on physical activity and exercise in the Tx population lacks 
high quality studies.38 Although the European liver Tx guidelines recommend integrat-
ing physical activity into the therapeutic regimen, they provide no further specifications 
regarding activity levels or amounts of activity.29 This lack of specific recommendations 
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hinders evidence based decision-making in view of timing, frequency, duration and 
intensity of physical activity after Tx. 
In considering intervention development, selection of the target behavior is guided by 
the following questions: What is the expected impact of the behavior change? What is 
the likelihood of changing this behavior? Is a spillover effect expected? Can the behav-
ior be measured? Given the importance of physical activity regarding weight regula-
tion,48 its association with health benefits in the general30,32 and Tx populations,38 and 
the possibility to objectively measure physical activity, it might be the preferred target 
behavior over healthy eating. In addition, changes in physical activity might also pro-
voke a spillover effect by leading to healthy eating. The following is an example of a 
clear statement regarding the selection of a specific target behavior. 
In conclusion, the suggested target behavior is: physical activity (150 min/week 
with moderate-intensity OR 60 min/week with vigorous intensity). Depending on 
their physical condition, patients might start with a lower amount of activity and fol-
low a stepwise approach to increase that until the recommendations are achieved. 
c) Specify the target behavior 
A detailed specification of the selected target behavior includes details about who, 
what, when, how often, where, and with whom the behavior is to be performed. The 
previous behavioral analysis steps have already covered ‘who’ and ‘what’. As no de-
tailed recommendations are available for liver Tx patients, further decisions about 
specified target behavior need to be based on the best available evidence relating to 
the general and overall Tx populations.38 
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Specification Evidence 
Who • Patients who are normal weight or overweight at 6 months after liver Tx (Chapter 3 
and 6) 
What • Being physically active for 150 min/week with moderate-intensity OR 60 min/week 
with vigorous intensity (stepwise increase of activity is possible to reach the 
goal)7,30,31 
When • After 6 months post-Tx the immunosuppressive regimen is usually reduced to the 
minimum dose and the risk for opportunistic infection is decreased. Quality of life, 
mental and physical functioning, and satisfaction with life increase within the first 
year after Tx29 
• The most effective interventions start within 1 year after Tx37 
• The highest proportional weight gain in our liver Tx patients occurred between 6 
months and 1 year after Tx (Chapter 3) 
How often • Comprehensive weight loss interventions should cover at least 14 sessions over 6 
months6 Exercise training over 12 to 24 weeks increased oxygen consumption and 
exercise capacity in heart Tx37 
• Weight gain in our liver Tx patients leveled off after 2nd year post-Tx (Chapter 3) 
Where • Most effective interventions included supervision (not specified by whom)37 
• Kidney Tx patients’ intervention needs: support for help in lifestyle changes by 
various healthcare providers (dieticians, nurses, physicians)49 
à Expert supervision and coordination of diverse healthcare professionals can best 
   be provided or at least initiated in the Tx center setting  
With whom • Peer support and exercise partners are perceived as important49: 
• In Switzerland only 3 Tx centers perform liver Tx, covering a wide geographic re-
gion. For some patients, the effort and time needed to travel to the Tx center is an 
organizational and financial burden and should not be underestimated 
à Provision of a physical activity group at the Tx center and a home-based 
   training program 
 
In conclusion, the specified target behavior is as follows: 
Who: Liver Tx patients with normal or overweight at 6 months after Tx 
What: Being physically active for 150 min/week with moderate intensity OR 
60 min/week with vigorous intensity (stepwise increase of activity is 
possible to reach the goal) 
When: At 6 months after Tx (if the recipient is medically stable) 
How often: 12-week program with a follow up until 2 years post-Tx 
Where: Initiated in the Tx center 
With whom: Physical activity group at the Tx center and a home-based training 
program 
d) Identify what needs to change 
The fourth step is to identify the changes needed in the individual and/or the environ-
ment to accomplish behavior change. This step includes an analysis of the behavior in 
its context using the COM-B model. Behavior change is expected if one or more of the 
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3 behavior determinants change. The need for change is summarized in the following 
table: 
COM-B What needs to happen 
for the target behavior to 
occur? 
Is there 
a need 
for 
change? 
Evidence 
Capability - 
Physical 
• Having the physical skills 
to be active for 150 
min/week with moderate-
intensity OR 60 min/week 
with vigorous intensity 
(stepwise increase of ac-
tivity is possible to reach 
the goal) 
Yes 
 
Evidence from liver Tx: 
• Calcineurin inhibitors are associ-
ated with prolonged muscle re-
generation38 
• Risk for post-Tx comorbidity: 
metabolic, cardiovascular, renal 
and bone disease malignancy50 
• Ongoing fatigue post-Tx de-
creases functional capacity40 
 
Capability - 
Psychological 
• Knowing activities cate-
gorized as moderate or 
vigorous intensity 
• Knowing the benefits of 
physical activity and its 
impact on outcomes 
Yes 
• Kidney Tx: 29% believed they 
could lose weight by exercising 
and changing diet49 
• Heart Tx: recipients with ade-
quate health literacy had higher 
odds of engaging in suffi-
cient physical activity51 
Opportunity - 
Physical 
• Environment allows physi-
cal activity  No 
 
Opportunity - 
Social 
• Being physically active is 
socially accepted, culturally 
integrated, and enforced on 
a policy level in Switzerland 
No 
 
Motivation -   
Reflective  
• Belief that one’s physical 
capabilities are sufficient 
to be physically active 
• Belief that being physi-
cally activity helps to 
prevent weight gain 
• Intention to be more 
physically active 
• Setting goals to achieve 
the aim of being physical-
ly active  
Yes 
 
Evidence from kidney Tx: 
• Belief that the ability to be physi-
cally active was important facili-
tator (81%)52 
• Lack of motivation was most 
frequent barrier (62%) for physi-
cal activity52 
• Fear of injuring the new kidney49 
• Fear of movement associated 
with lower daily physical 
activity53  
Motivation - 
Automative 
• Have established the 
routine to integrate phys-
ical activity into daily life 
• Feeling satisfied after 
being physically active  
Yes 
 
Evidence from liver Tx: 
• Only 24% to 50% engaged in 
regular physical activity post-
Tx41,42 
• Physical activity associated with 
increased quality of life35  
 
In conclusion, via the COM-B, following needs to change: capability (physical 
and psychological), and motivation (reflective and automatic) 
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Identify intervention options 
a) Identify intervention functions 
The fifth step links the specific target behavior to one or more intervention functions 
likely to be effective to change behavior. Selection of the most appropriate intervention 
requires guidance from the existing evidence and a systematic rating against the 
APEASE criteria: affordability, practicability, (cost-)effectiveness, acceptability, side-
effects/safety, equity. The 9 intervention functions requiring modification are defined in 
the following table: 
Intervention 
function 
Definition Is there a 
need for 
change? 
Evidence 
Education 
 
Increase knowledge 
or understanding 
Yes 
Evidence from kidney Tx: 
• Patients want to receive written 
information on diet and physical 
activity49 
• 86% want personal contact for 
help in lifestyle changes49 
Persuasion 
 
Using communica-
tion to induce posi-
tive or negative feel-
ings or stimulate 
action 
Yes 
Evidence from kidney Tx: 
• Most important facilitators for 
physical activity: positive feel-
ings such as feeling healthy, 
wanting to improve health and 
increase energy52 
Incentivisation 
 
Creating an expecta-
tion of reward 
Not feasible 
because of 
limited re-
sources 
 
Coercion 
 
Creating an expecta-
tion of punishment or 
cost 
Not acceptable   
Training Imparting skills Possible, but 
being physically 
active can be 
covered with the 
‘enablement’ 
function in this 
context 
 
Restriction 
 
Using rules to reduce 
the opportunity to 
engage in the target 
behavior  
Not appropriate 
in this context 
 
Environmental 
restructuring 
Changing the physi-
cal or social context 
Yes 
Evidence from kidney Tx: 
• Implementation of a collaborative 
interprofessional chronic care 
team providing consultations and 
self-management support im-
proved outcomes54 
Modelling 
 
Providing an example 
for people to aspire 
to or imitate 
Yes 
• Kidney Tx patients perceived 
peer pressure as a positive moti-
vator for change49 
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• Peer support strengthened self-
management tasks55  
Enablement 
 
Increasing means or 
reducing barriers to 
increase capability 
(beyond education 
and training) or op-
portunity (beyond 
environmental re-
structuring) 
Yes 
Evidence from general population: 
• Increase capability and motiva-
tion by targeting the underlying 
subdomains such as self-
regulation, goals, beliefs and 
self-efficacy12 
• Interventions are more success-
ful if they include behavior 
change components8-10 
Based on the evidence from the literature, Michie et al. connected each of the 9 listed 
intervention functions to one or more components of the COM-B model (green cells), 
see table below.12 The ‘x’ indicates the intervention function requiring modification in 
relation to the previously chosen COM-B dimension (in bold). 
 Intervention functions 
COM-B E
du
ca
tio
n 
Pe
rs
ua
si
on
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n 
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io
n 
En
vi
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-
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g 
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g 
En
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en
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Capability - Physical         x 
Capability - Psychological x        x 
Opportunity - Physical          
Opportunity - Social          
Motivation - Reflective x x      x  
Motivation - Automatic  x     x x x 
 
Based on the international evidence, we identified the following intervention func-
tions as requiring change: education, persuasion, environmental restructuring, 
modeling, and enablement 
b) Identify policy change 
The sixth step is to determine which policy category would best support the delivery of 
the chosen intervention. The selection of the policy categories is again based on the 
best evidence available and evaluated against the APEASE criteria. The policy catego-
ries that require change are identified in the following table: 
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Policy category Definition Is there a need for change 
Communication/ 
marketing  
Using print, electronic, telephonic or 
broadcast media Yes 
Guidelines Creating documents that recommend or mandate practice Are already available 
Fiscal policy Using the tax system to reduce or in-crease the financial cost Not practicable in this context 
Regulation Establishing rules or principles of behav-ior or practice Not practicable in this context 
Legislation Making or changing laws Not practicable in this context 
Environmental/social 
planning 
Designing and/or controlling the 
physical or social environment Yes 
Service provision Delivering a service (e.g. counseling, training, other support…) Yes 
 
From a content and delivery perspective, the three chosen policy categories are closely 
interrelated and can be elegantly combined in the category of ‘service provision’. Given 
that the intervention should be initiated in the Tx center, service provision can be real-
ized with a care re-organization according to a chronic care model. This possibility will 
be elaborated in Chapter 12.4 (Implications for clinical practice). Again, each policy 
category is connected to one or more intervention functions (green cells), see table 
below.12 The ‘x’ indicates the policy chosen as needing change in relation to the previ-
ously chosen intervention function (in bold). 
 Policy category 
Intervention 
function C
om
m
un
ic
at
io
n 
/ 
m
ar
ke
tin
g 
G
ui
de
-li
ne
s 
Fi
sc
al
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ol
ic
y 
R
eg
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n 
Le
gi
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at
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n 
En
vi
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l/ 
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la
nn
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g 
Se
rv
ic
e 
pr
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io
n 
Education x      x 
Persuasion x      x 
Incentivisation        
Coercion        
Training        
Restriction        
Environmental 
restructuring      x  
Modelling x      x 
Enablement      x x 
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Based on international evidence, we identified the following policy categories as 
requiring change: communication /marketing, environmental/social planning, and 
service provision. 
Identify content and implementation options 
a) Identify behavior change techniques 
The seventh step is identification of the most appropriate behavior change techniques. 
Based on the chosen target behavior for the final intervention, the results of two meta-
analyses guided the preliminary selection of techniques effective as intervention com-
ponents to increase physical activity and healthy eating.16,17 The selection of the final 
technique is again based on the best available evidence and evaluated against the 
APEASE criteria. 
Intervention 
function 
Effective behavior change tech-
niques in meta-analyses 
Techniques meeting the APEASE 
criteria 
Education 
 
2.2 Feedback on behavior 
2.3 Self-monitoring of behavior 
2.4 Feedback on outcome(s) of the be-
havior 
5.1 Information about health conse-
quences 
7.1 Prompts/cues 
2.2 Feedback on behavior 
2.3 Self-monitoring of behavior 
2.4 Feedback on outcome(s) of the 
behavior 
5.1 Information about health conse-
quences 
Persuasion 
 
2.2 Feedback on behavior 
2.4 Feedback on outcome(s) of the be-
havior 
5.1 Information about health conse-
quences 
2.2 Feedback on behavior 
2.4 Feedback on outcome(s) of the 
behavior 
5.1 Information about health conse-
quences 
Environmental 
restructuring 
7.1 Prompts/cues 
12.1 Restructuring the physical environ-
ment 
7.1 Prompts/cues 
 
Modelling 6.1 Demonstration of the behavior 6.1 Demonstration of the behavior 
Enablement 
 
1.1 Goal setting (behavior) 
1.2 Problem solving 
1.3 Goal setting (outcome) 
1.4 Action planning 
1.5 Review behavior goal(s) 
1.7 Review outcome goal(s) 
2.3 Self-monitoring of behavior 
3.1 Social support (unspecified) 
3.2 Social support (practical) 
12.1 Restructuring the physical environ-
ment 
1.1 Goal setting (behavior) 
1.2 Problem solving 
1.4 Action planning 
1.5 Review behavior goal(s) 
1.7 Review outcome goal(s) 
2.3 Self-monitoring of behavior 
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Based on international evidence, we identified following behavior change tech-
niques: goal setting (behavior), problem solving, action planning, review behavior 
goal(s), review outcome goal(s), feedback on behavior, self-monitoring of behavior, 
feedback on outcome(s) of the behavior, information about health consequences, 
demonstration of the behavior, prompts/cues 
b) Identify mode of delivery 
The eighth step is the identification of the delivery mode for the intervention (Figure 4). 
Based on the decisions made in the previous steps, selection of the delivery mode is 
again evidence based and evaluated against the APEASE criteria. 
 
Figure 4.  Delivery modes for the intervention.  
Source: Illustration adapted from: Michie S, Artkins L, West R. The behaviour 
change wheel. A guide to designing interventions. Great Britain: Silverback Publish-
ing; 2014. 
Mode of delivery Evidence 
Face-to-face  Evidence from kidney Tx: 
• Face-to-face support was preferred to text or e-mail messages49 
Evidence from the general population: 
• Individual-level interventions should be favored to target obesity2,3 
• Comprehensive interventions delivered on-site lead to more weight loss com-
pared to those via internet or e-mail6 
• Groups who received personal contact in weight loss maintenance trials had 
less weight re-gain compared to the self-directed control group members during 
the study period56-58 
Distance • Some patients have to travel long distances to Tx center, which can be a finan-
cial burden or resource-intense 
• It is possible to connect via telephone or digital media to support a home-based 
training program 
Mode of 
delivery
Face-to-face
Individual
Group
Distance
Population
Broadcast 
media
TV
Radio
Digital media
Internet
App
Outdoor 
media
Billborad
Poster
Print media
Newspaper
Leaflet
Individual
Phone
Phone 
helpline
SMS
PC
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Based on international evidence, we identified following delivery mode: individual 
level interventions, using a face-to-face approach in a combination with eHealth 
technology. 
7.3 Summary of the intervention’s components 
Aim • Weight management behavior in liver Tx patients who are normal weight or 
overweight 
Target behavior • Being physically active for 150 min/week with moderate-intensity OR 60 
min/week with vigorous intensity 
• Patients might start with a lower activity and follow and increase stepwise to 
achieve recommendations  
Timeline of the 
intervention  
• Start of the 12-week program at 6 months after liver Tx (if clinically stable) 
• Follow up until 2 years post-Tx 
Setting • Outpatient clinic in the Tx center 
• Delivery of the intervention within a healthcare system structured according to 
a chronic care model 
Interprofessional 
Team 
• Nurse / Advanced Practice Nurse, Hepatologist, Surgeon, Physiotherapist, 
Nutritionist, Psychiatrist, Social worker 
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As in the general population, the health risks of weight gain and obesity have been 
recognized in the Tx populations. The introduction of this dissertation outlined post-Tx 
weight gain and obesity’s associations with morbidity and mortality, the complex sys-
tem of factors influencing weight gain, the importance of energy balance-related behav-
iors (i.e., healthy eating and physical activity), and arguments for favoring interventions 
to prevent weight gain over those focused on weight loss. Given the lack of interven-
tions targeting the liver Tx population, the aim of this thesis was to develop a behavior-
al intervention focusing on physical activity and diet to support effective weight man-
agement and a healthy lifestyle after liver Tx. 
This final section discusses the included studies’ key findings according to two 
clinical questions that helped conceive, drive and direct the BALANCE project’s re-
search aims; it suggests implications for future research and clinical practice; and final-
ly, acknowledges the project’s strengths and limitations. 
8.1 How important is the prevention of weight gain after 
transplantation? 
Our analysis of STCS data was the first simultaneous comparison of body weight pa-
rameters in all solid organ Tx recipients going beyond the first year after Tx. Although 
the evolution of obesity and weight gain varied among the organ groups, both issues 
are health concerns in all solid organ Tx recipients. First, the majority of patients who 
were obese at 6 months post-Tx remained obese at 3 years post-Tx. Second, post-Tx 
weight gain was common. Although our sample’s mean weight gain in the first year 
after Tx was less excessive than described in the international Tx literature,1-8 we 
showed that weight gain continues beyond the first year post-Tx, leading, in many cas-
es, to new-onset obesity. This finding should be considered in long-term follow-up care 
as, compared to the early post-Tx period, clinically stable Tx recipients are usually 
scheduled less often for Tx center follow-up appointments. Therefore, early post-Tx 
education should both include information on the risk for post-Tx weight gain and sup-
port patients to monitor their weight also long-term after Tx. 
The need to prevent weight gain after liver Tx was reinforced by the findings of 
our second STCS analysis, involving post-Tx new-onset obesity. Indeed, patients who 
developed new-onset obesity after liver Tx had a 3-fold higher risk for CVE. This result 
is novel as our study was the first to examine the impact of post-liver Tx new-onset 
obesity on CVE. 
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Following liver Tx, cardiovascular and metabolic comorbidities have been shown 
to increase the risk for CVEs and mortality compared to age and gender-matched gen-
eral populations.9,10 This is one reason why long-term post-liver Tx outcomes have not 
reflected improvements in short-term patient- and graft survival.11 Therefore, non-
obese liver Tx recipients should be supported to prevent weight gain. 
However, it is important to mention that in our research, over a follow-up of 
nearly 6 years, new-onset obesity had no negative impact on patient survival after liver 
Tx. While a recent study suggested that patients with new-onset obesity actually had a 
survival benefit compared to those who maintained a stable weight,12 this issue has not 
been examined by other studies in this population. 
Overall, another systematic review by our group showed a serious shortage of 
studies examining post-Tx weight gain and obesity in relation to outcomes in liver Tx. 
While we did not include the findings of this systematic review in this thesis as some 
sub-analyses were still pending at the time of submission, the lack of research, espe-
cially on post-Tx body weight parameters and outcomes, was substantiated in this re-
view by the limited available evidence that was usable for meta-analysis. More specifi-
cally, of 184 studies that met our inclusion criteria, 37 were eligible for inclusion in our 
meta-analysis, whereof only 6 examined one post-Tx body weight parameter (i.e., post-
Tx BMI). The reason so few were usable was the huge variation in outcome and body 
weight parameter definitions used among the studies. To extend the value of future 
studies, we recommend that prospective researchers intensify exploration of the link 
between post-Tx weight gain parameters (including new onset obesity) and patient 
outcomes. 
In summary, both in the short- and long-term periods following Tx, weight gain 
prevention is important to avoid the development of new-onset obesity. Intuitively, this 
is hardly surprising; however, our research showed that in liver Tx recipients, prevent-
ing weight gain leading to new-onset obesity is particularly important, as it might im-
prove cardiovascular outcomes. 
8.2 Which factors are related to weight gain and obesity after 
transplantation? 
Modifiable risk factors can make excellent targets for intervention development aiming 
to prevent weight gain and obesity. However, the current shortage of research guided 
by theoretical frameworks precludes a deeper understanding of factors influencing 
weight gain after liver Tx. 
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Through the use of our theoretical framework as a working model to guide the 
design of two BALANCE project studies, we were able to systematically map and bet-
ter understand a number of variables related to body weight parameters. We were the 
first to summarize the literature and examine pre- and post-Tx factors from multiple 
categories associated with body weight parameters after liver Tx. The framework was 
then adapted according to the evidence generated in this dissertation, Figure 1. Over-
all, our findings highlight that, as in the general population,13 weight gain in the Tx pop-
ulation is driven by a complex interplay of multiple factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Theoretical framework of factors influencing weight gain in the BALANCE project. 
The variables assigned to the categories are: evidence from meta-analysis (bold, 
crossed factors were non-significant), evidence from single studies in liver Tx (* from 
the BALANCE project), and selected variables in the general population (in grey col-
or and italics) 
Source: Own Illustration. 
 
Regarding suspected biomedical factors, our meta-analysis revealed that neither tacro-
limus nor cyclosporine was associated with obesity after liver Tx. This is an important 
finding, as the results from single studies remain conflictive regarding the impact of 
immunosuppressive drugs on post-Tx weight gain and obesity.14 Our synthesis of 6 
studies provides higher-level evidence that might also guide clinicians’ decision-
making, as most liver Tx recipients receive either cyclosporine or tacrolimus.15 It is no-
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table that, although neither tacrolimus nor cyclosporine were associated with obesity, 
the systematic review and meta-analysis provided no evidence regarding either their 
impact on weight gain per se or their potential interplay with factors with known rela-
tionships to weight gain and obesity. Therefore, independent of the immunosuppres-
sive drug used, prevention of weight gain should be included in routine follow-up care 
after liver Tx. 
Our analysis regarding new-onset obesity identified two distinct risk factors. Both male 
recipients and those who received liver Tx for alcoholic liver disease had a significantly 
higher risk of developing new-onset obesity. To our knowledge, no other study has 
specifically examined gender and the impact of etiology on weight gain and obesity 
after liver Tx. Therefore, both these factors and the specific underlying pathways lead-
ing to new-onset obesity warrant further investigation. However, our results support the 
theoretical assumption that factors from various categories drive post-liver Tx weight 
gain. 
Additionally, we examined genetic factors in combination with sociodemograph-
ic, behavioral, and biomedical factors derived with the guidance of our theoretical 
framework. In both of our relevant studies examining genetic risk scores, these scores 
were significantly associated with post-Tx body weight parameters. More specifically, 
over a mean follow-up period of nearly 6 years after liver Tx, the genetic risk score 
predicted new-onset obesity; and it predicted ≥10% weight gain at 1 year after Tx in a 
mixed sample of kidney, liver, heart, lung and multi-organ Tx recipients. Importantly, in 
the study sample of all four solid organ Tx groups, the models including genetic risk 
scores better predicted weight gain than models not including them. 
The clinical interpretation of this finding, as well as the identification of patients 
at risk for weight gain and obesity based on a genetic risk score are limited, as the ge-
netic risk score is based on the mean of BMI risk allele values. This means a genetic 
risk score does not facilitate the tailoring of interventions to specific genotypes. How-
ever, our results regarding the genetic risk score’s predictive value emphasize the im-
portance of including this and similar information in studies examining weight gain and 
obesity in Tx. 
To the best of our knowledge, no other studies to date have examined the im-
pact of genetic risk scores on body weight parameters in the Tx population, although 
they have been studied more frequently in the general population. Interestingly, in the 
general population, genetic risk scores were associated not only with BMI16 and weight 
gain,17 but also with gene-environment interactions such as socio-economic situation 
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(with larger BMI increases in people in the most deprived situations compared to their 
more affluent counterparts), self-reported physical activity (with larger BMI increases in 
physically inactive than active people),18 and dietary fat and energy intake.19 
Although we have examined the genetic risk score in combination with other 
factors from our theoretical framework, we were unable to study gene-environment 
interactions: to allow meaningful effects, a study design with such a focus would re-
quire much larger sample sizes, along with precise definitions of environmental con-
texts,16 neither of which was available in the STCS database. Therefore, interactions 
between genetic risk scores and the environment remain a topic for future research. 
Although we identified specific factors and categories impacting post-Tx weight 
gain, our systematic literature review also detected several areas that remain poorly 
understood. Despite retrieving 43 articles studying a total of 82 distinct factors related 
to post-liver Tx body weight parameters, we were unable to perform meta-analyses 
regarding gender, age or cortisone use, which are all common sociodemographic and 
biomedical factors and are often included in data collection as sample characteristics. 
The reason we could not use them was the variety of definitions and operationalization 
of variables among the studies (e.g., steroid use was defined as use of cortisone 
(yes/no), cumulative steroid dose, length of steroid use, or use of steroids combined 
with other immunosuppressive drugs). 
Furthermore, behavioral variables such as energy balance-related behaviors 
(i.e., eating and physical activity) are key factors in relation to weight gain and subse-
quent obesity.20,21 However, our literature search identified no studies examining either 
eating or physical activity in relation to post-Tx weight gain and obesity. This could be 
because of the methods applied, as our research questions were not specifically for-
mulated to examine this relationship. Still, even our broad search strategy returned no 
results regarding energy balance-related behaviors in relation to body weight parame-
ters after liver Tx. Finally, very few articles retrieved covered psychological or environ-
mental factors, leading to the conclusion that these factors are generally understudied. 
8.3 Implications for future research 
While the findings of the studies included in this dissertation contributed to the evi-
dence base on evolution of body weight parameters in Tx, as well as weight gain and 
new-onset obesity after liver Tx, they also identified the following implications for future 
research: First, risk factors and outcomes related to post-Tx weight gain and obesity 
should be determined via theoretical frameworks and defined outcome measures using 
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standardized operational definitions; second, patients’ perspectives should be explored 
concerning weight management and weight gain; and third, weight management inter-
ventions should be developed, implemented, and evaluated in the Tx populations. 
Given that post-Tx weight gain and obesity have been issues for more than 2 
decades in the liver Tx population, the shortage of studies examining risk factors for 
weight gain and obesity or their impacts on morbidity and mortality calls for immediate 
action. From a methodological perspective, longitudinal data collection, including re-
peated measurements over the full course of Tx, as well as the assessment of diverse 
risk factor and patient outcome categories would provide an optimal basis for further 
research. Yet, while we strongly suggest conducting more studies, the value of such 
studies will be greatly enhanced via the application of the quality criteria suggested in 
the following paragraphs. 
In view of studies examining risk factors for weight gain and obesity, any future 
research should use a theoretical framework to guide study design. Theoretical guid-
ance has been proved beneficial in other research contexts examining multifaceted 
issues. For example, a theoretical model can be a basis for the development of evi-
dence-based behavioral interventions;22 a comprehensive framework can be used to 
guide the evaluation of interventions in implementation science;23 and the effectiveness 
of a dietary or physical activity intervention can be assessed based on a theoretical 
model.24 
A theory driven approach would not only facilitate a systematic research proce-
dure, but would allow researchers to name and highlight research gaps regarding 
weight gain risk factors. The BALANCE project, for example, identified the need for 
more research in view of energy balance-related behaviors, as well as psychological, 
environmental and even genetic factors. Although we examined the genetic risk score 
in relation to weight gain and obesity, evidence on the impact of candidates’ genes is 
still scarce. The few studies examining genetic impact found significant associations 
between 4 genes (CPE, LEP, NPY1R, and NPY5R) and weight gain at 6 months post-
kidney Tx,25 an ACE polymorphism and weight gain at 1 year post-liver Tx,25,26 and 
between the PNPLA-3 genotype and obesity at 1 and 3 years post-liver Tx.27 These 
results suggest that body weight parameters are impacted not only by genetic risk 
scores, but by specific genes or their polymorphisms. Expanding research in this area 
might provide information as to whether genes important for obesity in the general 
population, e.g., FTO and MC4R,28 influence weight gain and obesity after Tx. 
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Finally, as with the genetic risk score, single genes should be examined in 
gene-environment and gene-behavior interactions, as they play a significant role in the 
etiology of obesity.29-31 For example, strong evidence supports a gene-behavior interac-
tion between the FTO gene (an important obesity-linked gene) and physical activity.32,33 
Meaning, the association of the FTO risk allele with weight gain and obesity is attenu-
ated by approximately 30% in individuals who are physically active compared to those 
who are inactive. Gene-interactions may also account for why some people tend to 
gain weight faster and sooner than others in times of ongoing high energy intake. 
Likewise, they might account for outcome variability in randomized controlled trials us-
ing standardized dietary and physical activity interventions.34 Research on gene-
interactions related to weight gain and obesity in the general population has grown rap-
idly35 and should also be pursued in Tx patients. 
The research infrastructure in single center studies and registries might not al-
ways support the collection of measures beyond baseline clinical and sociodemograph-
ic data. However, in the era of big data, the opportunities to merge clinical and scien-
tific databases and collaborate with other research groups might allow the inclusion of 
genetic, behavioral, psychological, and environmental data to study body weight pa-
rameters in the Tx population. In combination with a more systematic and theory driven 
approach, this is expected to enhance our understanding of post-Tx weight gain and 
obesity. 
In view of relevant patient outcome measures, clear identification and standard-
ized definition of terms is crucial. In our ongoing systematic review, the variety in out-
comes measured was a major limitation, hindering both the comparison of studies and 
the performance of meta-analyses. Konerman et al. faced a similar challenge in their 
systematic review on risk factors for CVE after liver Tx.36 The authors reported sub-
stantial heterogeneity among their final selection of 29 studies (i.e., definition of out-
comes, inclusion and exclusion criteria), which hampered their meta-analysis. 
While we acknowledge that measures need to be operationalized to serve the 
aims and methods of the study employing them, the Tx research community would 
benefit from a consensus to harmonize outcome research in relation to body weight 
parameters. Two recent applications of this principle have been reported in nephrology, 
concerning the development of standardized core outcomes to be considered in trials 
in hemodialysis 37 and in kidney Tx.38 The standardization of outcomes (i.e., classifica-
tion of outcomes relevant to researchers, clinicians and patients; identification of spe-
cific assessment instruments; definition of thresholds) is expected to improve both the 
quality of reporting and the relevance of trials in nephrology patients. 
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While recommendations for core outcomes in relation to body weight parame-
ters are missing in the Tx population, one initiative guiding the movement in this direc-
tion could be the 2017 consensus statement about the management of modifiable risk 
factors in kidney and liver Tx.39 An international interprofessional expert panel devel-
oped specific practical recommendations to manage risk factors for decreased graft 
and patient survival beyond the first year post-Tx. After summarizing causes for graft 
loss, their statement provided information on cardiovascular and metabolic comorbidi-
ties, which would also be relevant for examination in relation to body weight parame-
ters. Reaching consensus in view of outcome measures is expected to improve re-
search quality across all Tx populations. The resulting improvement of evidence quality 
would facilitate the performance of systematic reviews and meta-analyses. 
The second implication for future research is related to the patients’ perspective, i.e., 
how liver recipients perceive their post-Tx weight gain and its potential causes, as such 
reports inform intervention development. When two quantitative studies asked recipi-
ents about the causes of their post-liver Tx weight gain, their most commonly reported 
answers included constant hunger–leading to increased food intake–and reduced daily 
physical activity.40,41 However, further in-depth insights into these patients’ perceptions 
with weight gain need to be explored through qualitative methodology. 
The BALANCE project has already picked up this issue and is currently con-
ducting a qualitative study to explore patients’ perceptions regarding weight gain after 
liver Tx. Unfortunately, we were not able to finalize the qualitative study and include the 
results in this dissertation; however, the data will be available in the coming months. 
This study of patients’ perceptions is expected to improve our understanding of how 
liver recipients perceive post-Tx weight management and weight gain. 
A deeper understanding of patients’ engagement in physical activity and healthy 
eating also has the potential to lower barriers and enhance facilitators of energy bal-
ance-related behaviors. As the COM-B model was used to guide our research (i.e., 
development of the interview questions, analysis guidelines), the results are expected 
to contribute significantly to the suggested BALANCE intervention. Integrating partici-
pants’ preferences should enhance their adherence to and acceptance of a weight 
management program, which is essential for success.42 
Finally, more research is needed to implement and evaluate behavioral weight 
management interventions. These will include both preventive interventions, which 
should be favored because of the physiological mechanisms of weight re-gain, and 
weight loss interventions in obese recipients, which might require a longer follow-up to 
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support participants to maintain weight loss.43-45 In our analysis of the Swiss cohort, two 
patient groups qualified for behavioral weight management interventions. 
Kidney Tx patients had continuously high prevalence rates of obesity over the 
course of Tx (19% to 22%). Given that 81.4% of these patients remained obese after 
Tx, this group might benefit from a weight loss intervention. Before kidney Tx, inten-
tional weight loss in patients with chronic kidney disease is debated as a survival bene-
fit in high-BMI patients requiring hemodialysis has been reported.46,47 However, regard-
ing a nonrandomized 12-month weight loss program in 169 obese patients with chronic 
kidney disease,48 MacLaughlin et al. reported that after 1 year, their intervention group 
lost significantly more weight than their control group (-4.3 ± 5.5 kg versus -1.9 ± 6.6 
kg, p = 0.001). During the median follow-up of 32 months, although weight loss had no 
impact on the likelihood of being waitlisted for kidney Tx, the intervention group had 
fewer combined events (i.e., death, myocardial infarction, stroke, hospitalization for 
congestive heart failure) compared to the control group (12% versus 20%, p = 0.055). 
The authors concluded that participation in this weight loss program might be beneficial 
for patients with chronic kidney disease, independent of kidney function or need for 
hemodialysis. In the post-Tx course, however, there have been no studies published 
on weight loss interventions after kidney Tx.49,50 This lack of evidence is rather surpris-
ing, as both weight gain and obesity are known to increase the risk for graft loss and 
mortality.4,8,51 
The second group from the Swiss STCS cohort to qualify for a weight loss inter-
vention consisted of liver Tx recipients. By 3 years post-Tx, this group had the greatest 
weight gain of any organ group (mean 4.8 kg), the highest incidence of obesity 
(38.1%), and normal- or overweight patients who gained weight and became obese 
had increased CVE risk. These patients would benefit from an intervention to prevent 
weight gain after liver Tx. However, to the best of our knowledge, no post-liver Tx 
weight management intervention study–either to prevent weight gain or to promote 
weight loss–has been published to date. 
In summary, although increasing rates of post-Tx weight gain and obesity have 
long been reported in both kidney and liver Tx patients, published studies on post-Tx 
weight management interventions targeting either remain scarce. The development of 
programs to support weight management and a healthy lifestyle in both populations is 
urgently needed, as would likely improve long-term morbidity and mortality. 
For the implementation and evaluation of a behavioral intervention, the study 
design should take into account several methodological aspects: to use a conceptual 
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framework guiding implementation in clinical practice (e.g., Consolidated Framework 
for Advancing Implementation Research),52 to assess additional measures of body 
weight parameters (e.g., body composition), to measure low levels of physical activity 
(e.g., sedentary behavior), to combine various research methods (e.g., mixed method 
design to examine clinical outcomes and acceptance of the behavioral intervention), to 
consider study designs other than randomized controlled trials (e.g., realist randomized 
controlled trials, which acknowledge the dynamic structures, mechanisms and contexts 
influencing the research setting),53 and to integrate e-Health technology that facilitates 
data collection (e.g., smart phones, step trackers). 
8.4 Implications for the clinical practice 
Although evidence on the impact of post-Tx body weight parameters on patient out-
comes remains scarce, interventions to prevent post-Tx weight gain and obesity should 
be considered based on the best available information. Prevention of excessive weight 
gain has also been suggested by clinical guidelines in the liver, kidney and heart Tx 
populations; however, these guidelines made no recommendations specifying interven-
tion content.54-56 
The BALANCE project’s findings support the organization of post-Tx follow-up 
care based on a chronic disease model supported by eHealth technology.57 Structuring 
the healthcare system according to a chronic disease model shifts the focus from tradi-
tional symptom-driven management of acute conditions to an approach that addresses 
the needs of chronically ill people and empowers patients to take an active part in the 
management of their illness.58 A proactive, evidence-based, patient-centered approach 
is a key component to increasing the quality of care and improving outcomes.59-61 
Wagner et al.’s Chronic Care Model (CCM)58,62 is one of the most studied chron-
ic disease models.63 It will be used to describe and elaborate on 6 components, all of 
which the healthcare system needs to address to support effective weight management 
after Tx: self-management support, delivery system design, decision support, clinical 
information systems, organization of health care, and community. 
1. Self-management support: This element highlights the patients’ roles in 
managing their own health issues. To be optimally prepared to manage daily life with a 
chronic condition, patients need information on their conditions, assistance in skill 
building, and support from their social and professional surroundings. 
Regarding weight management, a behavioral intervention would mainly target 
this CCM element. As outlined in Chapter 7, service provision (i.e., delivering special-
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ized services or offering specific consultations) is the policy category best suited to the 
delivery of intervention functions (i.e., the component expected to support behavior 
change, e.g., education, persuasion, environmental restructuring, modeling, or ena-
blement). In a weight management program, self-management support may cover a 
broad range of aspects; however, the amount of support, i.e., the intervention dosage, 
should follow a step-wise approach tailored to the Tx patients’ specific needs. 
As indicated above, all Tx recipients should receive information regarding the 
potential impacts of weight gain and obesity on their health and the value of post-Tx 
energy balance-related behaviors. This information should be supplemented by weight 
measurement and review during each Tx center follow-up consultation. Moreover, over 
the long-term post-Tx period, all solid organ Tx recipients are encouraged to regularly 
monitor and log their weight at home. 
Patients with increasing weight and especially those at risk of becoming obese 
need additional self-management support. This should cover building skills to self-
monitor their physical activity, setting goals to increase activity levels, solving problems 
to reduce barriers for activity, and obtaining support both from the interprofessional 
healthcare team and from their peers. 
Supporting patients in self-monitoring is particularly important. Self-monitoring 
includes, for example, recording body weight, dietary intake and physical activity. This 
increases individuals’ awareness of their current behaviors.64 Conclusive evidence has 
showed that self-monitoring is crucial to successful weight management and mainte-
nance of a healthy lifestyle.65 
2. Delivery system design: This component covers the structures necessary 
within the organization to deliver all necessary care. It includes the definition of roles 
within the organization, clarity regarding the amount and intensity of care appropriate 
for specific patients, and the implementation of healthcare innovations. 
Regarding weight management, the importance of a multidisciplinary healthcare 
team has already been outlined.39,54 On a regular basis, this team evaluates whether 
an intervention needs to be adapted, e.g., if a patient is unable to increase physical 
activity. 
Another important component in this element is the use of new technologies 
such as eHealth to facilitate intervention delivery. eHealth has been defined as “the use 
of information and communication technologies for health”.66 Due to rapid recent tech-
nical developments, eHealth has become an effective, accessible and common deliv-
ery mode for behavioral interventions focusing on weight management.67,68 Additional-
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ly, eHealth tools can be used to enhance self-management in people living with chronic 
conditions.57 
The application of eHealth technology is also increasing in the Tx population, 
and has recently been reviewed by Fleming et al.69 The authors found potential bene-
fits of eHealth applications both pre- and post-Tx. The greatest success was noted in 
multicomponent interventions (i.e., use of electronic devices with multiple applications, 
reminders and alert functions), which were effective in view of increased self-
monitoring, increased adherence to medication taking and blood monitoring, as well as 
decreased blood pressure levels. However, no study has yet found a beneficial effect 
regarding graft outcomes, few have aimed to control post-Tx chronic conditions such 
as hypertension or diabetes and none have focused on weight management or post-Tx 
energy balance-related behaviors.69 
Although patients’ overall acceptance and willingness to use eHealth devices af-
ter Tx appears high,69 the sustained use of eHealth technology remains challenging. It 
could be argued that eHealth applications embedded in a chronic care model and sup-
ported by a healthcare team might improve eHealth tools’ sustainability. 
In this regard, a recent randomized controlled trial in 46 kidney Tx recipients reported 
interesting results. Schmidt et al. combined telemedical technology (i.e., remote tele-
monitoring, real-time video consultations) with a case management approach in the 
first year of post-Tx follow up care.70 Compared to the usual care group, the interven-
tion group had higher adherence rates with immunosuppressive medication, fewer un-
planned hospital admissions, better disease-specific quality of life, and higher post-Tx 
employment rates. Additionally, the authors reported high patient engagement with the 
telemedical intervention. 
3. Decision support: Treatment decisions should be rooted in evidence-based 
guidelines. Regarding weight management, specific treatment guidelines in the Tx 
population (e.g., diet and physical activity, management of cardiovascular risk factors) 
have yet to be developed. Until they become available, healthcare professionals are 
advised to follow guidelines for the general population.39 
4. Clinical information systems: Electronic information systems facilitate rapid 
information exchange both between healthcare professionals and between the care 
team and the patient. Regarding weight management, the inclusion of eHealth technol-
ogy would provide a stable platform for information access and data sharing (e.g., elec-
tronic patient records, use of a website with secured log in, data transfer via 
smartphone applications). 
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5. Organization of health care: Teamwork and leadership within the organiza-
tion both drive and guide the implementation of the CCM. 
Regarding weight management, the interprofessional healthcare team could be 
led by an advanced practice nurse, which has been successfully tested in kidney Tx.71 
Advanced practice nurses have at least a master degree in nursing science and are 
prepared to care for complex patient populations. The integration of specialized nurses 
into Tx teams is highly recommended. They provide expert care and guidance in pre- 
and post-Tx settings, especially in supporting patient self-management.72,73 
6. Community: Community-based resources and programs can expand the 
services offered by clinics. Regarding weight management, a broad variety of external 
programs are available, many of which support healthy post-Tx lifestyle choices. This 
can include offers from sport clubs, cooking classes, peer groups, or weight loss pro-
grams. Given that some patients have to travel longer distances to their Tx centers, 
attending programs in their areas or neighborhoods might be more feasible for them. 
The rationale for suggesting the CCM to support effective weight management in Tx 
recipients is 2-fold. First, as a chronically ill population, Tx patients need complex med-
ical and therapeutic regimens to manage the risk of Tx-related, metabolic or cardiovas-
cular comorbidities.54-56 This involves lifelong self-management in view of following a 
healthy lifestyle (e.g., weight management, physical activity, healthy eating), adherence 
to medication taking, and symptom management.73 Implementation of chronic illness 
management (in place of the current acute care model) is expected to improve long-
term outcomes and has been postulated by Tx experts.74 The benefits of restructuring 
the healthcare system according to a chronic disease model go well beyond facilitating 
follow-up care and improving clinical patient outcomes,60,61,71 it is also an optimal struc-
ture to provide behavioral interventions to prevent weight gain and obesity. 
Second, obesity belongs to the chronic diseases. The World Obesity Federation 
labeled obesity as a chronic, relapsing, progressive disease process, and emphasized 
the need to prevent and control the global epidemic.75 And as with other chronic dis-
eases, acute-care treatments do nothing to change its driving mechanisms. Therefore, 
targeting weight gain and subsequent obesity requires a shift from the existing acute-
care paradigm to a comprehensive patient-centered approach based on the target 
population’s long-term needs and incorporating coordinated care from multidisciplinary 
teams.76,77 The implementation of a chronic disease model was also recommended by 
the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in 
Adults.78 
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Assessing the effectiveness of chronic disease models, two recent literature re-
views63,79 found promising results in view of improved clinical outcomes (e.g., meas-
urements of blood pressure, lipid or blood sugar, adherence to treatment) and process 
outcomes (e.g., adherence to guidelines for the performance of routine tests) in various 
patient groups with chronic conditions (e.g., diabetes, cardiovascular disease or chron-
ic obstructive pulmonary disease). The most commonly studied and applied chronic 
disease model elements were self-management support and delivery system design. 
Those two elements have been suggested as the effective key components of chronic 
disease models.59 However, in the literature review the variability of studies examining 
such models (e.g., study design, implementation of specific elements) limited direct 
comparison of the components. Davy et al. therefore concluded that it remains unclear 
which element of the chronic disease model most effectively improves outcomes.60,61,79 
In kidney Tx, Bissonnette et al.’s 2013 study elegantly described the successful 
application of a chronic disease model.71 The authors re-organized their follow-up care 
and tested the effectiveness of a nurse-led interprofessional collaborative chronic care 
clinic. The team intervention was designed to support disease self-management, 
shared decision making and adherence-enhancing behavior. 
Over the 3.5-year period, intervention patients had significantly fewer emergen-
cy room visits and hospital admissions compared to the control group. Clinical outcome 
parameters including systolic and diastolic blood pressure, carbon dioxide, hemoglo-
bin, or phosphate parameters did not differ between the groups. Although this interven-
tion did not focus on post-Tx body weight parameters, the implementation of a chronic 
disease model is also expected to improve post-Tx weight management outcomes. 
The organization of the healthcare system according to the CCM is expected to 
support patients not only to effectively self-manage the Tx-related recommendations, 
but to augment that care with post-Tx weight management. However, experts have 
argued that comprehensive programs supporting lifestyle changes might be beyond the 
resources of some Tx centers.80 If the implementation of a CCM is not feasible, or if it 
takes some time to realize, the interprofessional healthcare team should at least ad-
dress the following issues in regular follow-up appointments: 
– Measurement of body weight parameters: weight, BMI, and body composition (if 
available) 
– Review and feedback on the evolution of the patient’s body weight parameters 
– Normal weight, overweight and obese patients should be advised not to gain weight 
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– Normal weight and overweight liver Tx patients (especially males and those with 
alcoholic liver disease) should be informed about the relationship between new-
onset obesity and CVE 
– Physical activity: note the amount, intensity and duration of daily physical activity, 
advise on beneficial effect of physical activity and national recommendations (150 
min/week with moderate-intensity OR 60 min/week with vigorous intensity). In cases 
where the patient does not meet the recommendations, encourage goal-setting to 
increase daily physical activity, refer to local training groups 
– Diet: advise on healthy eating, encourage recipients to favor healthy food 
8.4 Strengths and Limitations of the BALANCE project 
One strength of this dissertation was the inclusion of various methods and study de-
signs to comprehensively examine body weight parameters in the Tx populations. Not 
only did the meta-analyses provide important evidence by summarizing the current 
literature, the accompanying systematic literature review allowed a mapping of the re-
maining gaps, which imply recommendations for future research. 
Additionally, three studies used data from the prospective nationwide STCS, in-
cluding genetic, sociodemographic, behavioral, biomedical, and psychological varia-
bles. This comprehensive dataset allowed us to take into consideration the complexity 
of weight gain and obesity. Additionally, we used a theoretical framework to examine 
many individual factors and their interrelationships. This was novel, as previous studies 
lacked theoretical guidance, hampering their research quality. Our framework guided 
the design and realization of 2 studies. Regarding our findings on obesity, which is 
characterized by complex mechanisms, the results of our theory-driven approach not 
only add to the body of evidence, but potentially will advance the field of obesity re-
search. 
Besides its strengths, this thesis has also several methodological limitations. 
Several variables important to the examination of body weight were not available for 
analysis in the BALANCE project. For example, we were unable to integrate data on 
energy balance-related behaviors including physical activity and eating–which Tx recip-
ients themselves consider key factors of weight gain and obesity.40,41 While the meas-
ure of eating behavior was not included in the STCS dataset, a measure of activity was 
added to the regular STCS data collection in 2012. However, a preliminary data analy-
sis in an early phase of the dissertation revealed questionable results in view of that 
item’s validity in relation to the concept of physical activity. It was therefore not possible 
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to include this variable in our analyses. Instead, the item was revised for the benefit of 
future STCS data studies examining body weight parameters. 
Another component which could not be captured was body composition, as it al-
so was not included in STCS data collection. This variable would have been useful to 
verify and differentiate post-Tx weight gain in view of possible miscalculation of BMI 
due to unusual levels of fluids, muscle or fat mass. Finally, we were unable to include 
information about body weight parameters previous to end-stage organ disease. Given 
the action of physiological mechanisms that compensate for energy shortages–i.e., that 
drive weight re-gain after weight loss–43-45 it is possible that some of those physiologi-
cal mechanisms contributed to post-Tx weight gain. However, we could not distinguish 
this aspect in our analysis. 
Another limitation is the short follow-up period in our studies using data from the 
STCS database. The STCS was established in 2008 as an open cohort, i.e., a cohort 
which not only follows participants included since the beginning, but also adds every 
Swiss Tx patient willing to sign an informed consent form. In practical terms, this meant 
that while some of our participants had a follow-up period of 8 years, many had been 
followed up over much shorter periods. A longer follow-up time would have provided an 
opportunity to examine whether weight gain eventually levels off. Additionally, a longer 
follow-up would also have been favorable to better examine outcomes such as CVE 
and survival. 
Although we performed a systematic literature search in all 4 solid organ 
groups, we only had the time and resources for data extraction in the liver Tx popula-
tion. Since the BALANCE project commenced, five systematic reviews examining the 
impact of pre-Tx body weight parameters on patient survival have been published (kid-
ney n = 3,81-83 liver n = 1,84 and lung n = 185). This emphasizes first how timely the topic 
itself is, second, that our ongoing review will be the first to also look explicitly at post-Tx 
body weight parameters, and third, that a systematic review is still missing in heart Tx. 
8.5 Conclusion 
In conclusion, the BALANCE project contributed to the evidence base regarding the 
evolution of body weight parameters in kidney, liver, heart and lung Tx, as data on the-
se groups were compared concurrently for the first time, thereby highlighting how their 
trajectories differ up to 3 years post-Tx. Additionally, the thesis increased the limited 
evidence on the impact of new-onset obesity on morbidity and mortality following liver 
Tx. Finally, its findings provided new insights regarding the broad examination of ge-
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netic, biomedical, behavioral, sociodemographic, and psychological risk factors related 
to post-Tx weight gain, obesity and new onset obesity. 
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